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ABSTRACT
REDUCING ADVERSE OUTCOMES IN HEPATOCELLULAR CARCINOMA
PATIENTS UNDERGOING HEPATECTOMIES
Yongyue Qi, M.S.
University of Nebraska, 2020
Supervisor: Paraskevi A. Farazi, PhD
The incidence and mortality of liver cancers are increasing in the United States. In
addition to the classic risk factors of hepatic viral infection and high alcohol consumption,
non-alcoholic Fatty Liver Disease (NAFLD), has emerged as a risk factor for hepatocellular
carcinoma (HCC). The most effective curative treatment for HCC is liver resection
(hepatectomy), however, hepatectomy is a major operation with potential risks of mortality,
hospital readmission and other adverse outcomes such as postoperative complications
and longer hospital stay. The reported 90-day mortality and 30-day readmission rates
following a hepatectomy vary widely across studies, most of which have limitations due to
small sample size, localized study sites and lack of use of national representative samples.
Furthermore, very few studies have focused on the impact of NAFLD on postoperative
outcomes in HCC patients undergoing hepatectomies. The long-term goal of this proposal
was to improve 90-day mortality, unplanned 30-day readmission and other adverse
outcomes among HCC patients undergoing hepatectomies. The specific aims of this work
were to: (1) develop and test the discriminatory ability of a risk score model to group
patients into low, medium, high and excessive risks groups for 90-day mortality following
hepatectomy based on the weighting of identified demographic and hospital related risk
factors; (2) investigate risk factors associated with 30-day unplanned readmission and
address its impact on conditional 90-day mortality; (3) describe 10-year (2005-2014)
national trends and patterns of NAFLD prevalence among all hospitalized HCC patients
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and compare the impact of NAFLD on adverse outcomes (increased occurrence of
postoperative complications, in-hospital mortality and longer hospital stay) in HCC patients
who underwent hepatectomy. To address the first aim, a retrospective, cross-sectional
study was conducted using one of the largest clinical cancer database in the world – the
National Cancer Database (NCDB) to investigate the rate of 90-day mortality and
associated risk factors and to build a risk score model based on the weighting of identified
risk factors to predict 90-day mortality. For the second aim, a cross-sectional study design
was used to identify risk factors associated with 30-day unplanned readmission and
assess how a history of 30-day unplanned readmission would affect patients’ conditional
90-day mortality using NCDB. For aim 3, another national representative database Nationwide Inpatient Sample (NIS) was used for a retrospective study to describe the
national trend and pattern of NAFLD prevalence among hospitalized HCC patients from
2005 to 2014 and to address the impact of NAFLD on adverse outcomes including
postoperative complications, in-hospital mortality and hospital length of stay (LOS) in HCC
patients undergoing hepatectomies. Our results indicated that an integer-valued risk score
can be developed based on 10 identified risk factors to predict 90-day mortality. The
discriminatory ability of this risk score, measured by AUC of 0.69, was comparable with
other risk models of prior studies. Our study also showed that patients with a history of 30day unplanned readmission carried higher risk of conditional 90-day mortality. Interestingly,
NAFLD did not seem to increase the risk of postoperative adverse outcomes. Future
studies are needed to further improve the risk model by linking NCDB to Midwest CoC
accredited hospital databases to add detailed information on comorbidity and
complications, by addressing the roles of family care and medication compliance between
discharge and readmission, and by repeating study 3 in multi-institutional setting with more
accurate and complete diagnosis of NAFLD cases.
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CHAPTER 1
INTRODUCTION

HEPATOCELLULAR CARCINOMA
Hepatocellular carcinoma (HCC) is a primary liver cancer arising from liver cells
(hepatocytes). It is the most common histological type of liver cancers accounting for
approximately 80-90% of all liver malignancies (Chacko & Samanta, 2016). Some of the
risk factors for HCC include infection with hepatitis B or C viruses, heavy alcohol
consumption, aflatoxin B1 exposure, and non-alcoholic fatty liver disease (NAFLD).
Approximately 80% of HCC develop in the background of liver cirrhosis, which is an
independent cause of death (Couto, Dvorchik, & Carr, 2007). HCC is often diagnosed late
due to the absence of symptoms and lack of effective surveillance strategies for high risk
patients (Simmons et al., 2019; Kansagara et al., 2014).

Epidemiology of HCC
HCC is the fifth most common cancer and the second leading cause of cancer
deaths worldwide (Akinyemiju et al., 2017). Asian countries including China, Mongolia,
Southeast Asia, and Sub-Saharan Western and Eastern African have the highest
incidence rates in the world (WHO, 2012). The age-adjusted incidence rates of liver cancer
ranked seventh highest among all cancers in the world with approximately 15.1 (male)
and 5.6 (female) cases per million people diagnosed for the year of 2017. There were
around 819,000 liver cancer-related deaths accounting for 8.6% of all cancer deaths in
2017 globally (Global Burden of Disease Cancer Collaboration, 2019). The incidence and
mortality of liver cancers have been increasing for more than three decades from 1975 to
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2009 in the United States (Siegel, Naishadham, & Jemal, 2013). However, a recent study
using the US Cancer Statistics Registry showed that the incidence of HCC increased 4.5%
annually between 2000 and 2009 while it decreased slightly by 0.7% annually from 2010
through 2012 indicating the increase in the incidence of HCC might have slowed or
plateaued (White et al., 2017). Most recent cancer statistics projected that 42,030 new
cases would occur, and 31,780 patients would die from liver cancer in 2019 (Siegel at al.,
2019).
HCC largely affects men with incidence two to four times than the incidence in
women (Bosch et al., 2004). However, hazard ratios of risk factors such as viral hepatitis
and cirrhosis are similar in male and female stratum (Yi et al., 2018) and this protective
effects against the development of HCC in women may come from the role of estrogen,
which is strongly evidenced in young women (Davis et al., 2010). Racial disparities in the
incidence of HCC are also evident in the US. One research conducted by Yang and
colleagues reported that the incidence of HCC was highest among Asian and Pacific
Islanders followed by Hispanics and black, with the lowest rates among whites (Yang et
al., 2018). The study also discovered that Hispanics and blacks were less likely to be
diagnosed with early stage HCC compared with whites. Regardless of whether they were
diagnosed at an early stage, Hispanics were less likely to receive curative treatment for
HCC than their white counterparts. Blacks demonstrated significantly worse survival than
whites before and after adjusting for other important factors including insurance coverage,
Child-Pugh class, BCLC tumor stage, and receipt of HCC treatment. These disparities
may reflect behavioral differences with regards to other HCC risk factors such as alcohol
consumption and unhealthy diet.

Risk Factors of HCC
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There are a number of well-established HCC risk factors including cirrhosis, infection
with Hepatitis B virus (HBV) or Hepatitis C virus (HCV), alcoholic liver diseases, nonalcoholic fatty liver disease (NAFLD), and aflatoxins. Tobacco smoking, androgenic
steroids, and diabetes mellitus are suspected risk factors (Ledda et al., 2017). HCC occurs
overwhelmingly in the presence of cirrhosis or advanced fibrosis, though among a small
portion of patients, HCC is developed without a background of cirrhosis (Adams & Lindor,
2007).

Hepatitis infections
Chronic infections with HBV and HCV are the most commonly recognized risk factors
of HCC worldwide (Stuver et al., 2008; Boffetta et al., 2014). It is estimated that 54% of all
liver cancers in the world can be attributed to HBV infection (Parkin, 2002). In the United
States, approximately 45% to 55% of new HCC cases are contributed to HCV, 10% to 15%
to HBV, and 5% are co-infected with HBV and HCV, and 30% to 35% show no association
with either HBV or HCV (Mittal & El-Serag, 2013). Individuals with chronic HBV infection
have 15- to 20-fold higher odds of developing HCC and the odds are doubled in the case
of HBV and HCV co-infection (Mittal & El-Serag, 2013; Shi, Zhu, Liu, & Xie, 2005). HCV
infection alone is believed to be associated with approximately 17-fold increased odds of
developing HCC (Shi, Zhu, Liu, & Xie, 2005). It is postulated that chronic liver inflammation
due to HCV infection leads to the injury of liver parenchyma with subsequent development
of fibrosis (Lok et al., 2011). The progression from cirrhosis to HCC in actively HCVinfected patients occurs at an annual rate of 1% to 4% (El-Serag, 2012).
Other etiologic factors that coexist with HBV-infected individuals may further
increase the risk of developing HCC. For example, male patients, HBV infection at
younger age, Asian and Pacific Islanders, and individuals with heavy alcohol consumption
and/or tobacco use have been shown to have increased risk of HCC (El-Serag, 2012). In
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addition to these risk factors, HCV genotype also modifies individual’s risk of HCC. A metaanalysis has reported that genotype 1b was associated with 78% increased risk of HCC
compared to all other genotypes (Kanwal et al., 2014; Kattakuzhy et al., 2016) and
genotype 3 is associated with highest risk of cirrhosis (Raimondi et al., 2009).

Alcohol drinking
Approximately 13% to 23% of HCC cases are attributable to alcohol drinking and the
effect varies based on patients’ race and sex (Makarova‐Rusher et al., 2016; Welzel et al.,
2013). Most case-control studies have indicated that heavy alcohol drinking is associated
with increased risk of primary liver cancer (Bagnardi et al., 2001; IARC Working Group on
the Evaluation of Carcinogenic Risks to Humans, 2010). A case-control study in Italy
enrolled 464 cases with primary diagnosis of HCC and 824 controls. Researchers found
the odds of HCC were 7 times higher in individuals with alcohol intake of > 60 g/day
compared to those with an intake of ≤60 g/day (Donato et al., 2002). In the National
Institutes of Health (NIH) – AARP Diet and Health Study, drinkers with three levels of
alcohol consumption were compared. It was found that drinkers of > 3 drinks per day had
nearly 2-fold increased odds of developing HCC compared to drinkers of <1 drink per day
(Persson et al., 2013). It is believed that alcohol may play a crucial role in initiating cancers
through enhancing certain oncogene expression or the impairment of cell’s ability to mend
their DNA resulting in the increase of oncogenic mutation (Testino, Leone, & Borro, 2014).

Non-Alcoholic Fatty Liver Disease (NAFLD)
Over the last decade, there has been an increase in the proportion of NAFLDassociated cirrhosis and HCC (White, Kanwal, & El–Serag, 2012). Research has reported
that between 4% and 22% of HCC cases in Western countries are attributed to NAFLD
(Yang et al., 2012; Hucke et al., 2011; Ertle et al., 2011). From 2002 to 2012, the number
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of patients with NASH-HCC undergoing a liver transplant increased by 4-fold, almost twice
as many as those with HCV-HCC (Wong, Cheung, & Ahmed, 2014). The association
between NAFLD and increased risk of HCC was confirmed in a large prospective cohort
study involving 130 facilities in the Veteran Health Administration from January 1, 2004 to
December 31, 2008. During 2,382,289 person-year of follow-up, NAFLD patients
demonstrated a 7.6-fold increased risk of developing HCC than non-NAFLD patients. In
addition, approximately 20% of NAFLD patients with HCC had no evidence of cirrhosis
(Kanwal et al., 2018). Fatty liver may also increase the risk of HCC in other types of liver
disease. Two studies have indicated that in patients with chronic hepatitis C infection, the
risk of HCC will increase by 2-3-fold if patients also have a coexisting steatosis compared
to those without steatosis (Pekow et al., 2007; Tanaka et al., 2007).
Type 2 diabetes and obesity
Type 2 diabetes is associated with HCC. Literature began to describe the existence
of an association between Type 2 diabetes and HCC more than 30 years ago where a
case-control study matched 105 HCC patients with 105 patients with either colorectal
cancer or femoral bone fracture by age and gender. The study found a 4-fold risk of
prevalent type 2 diabetes among patients with HCC compared to those with colorectal
cancer or femoral bone fracture (Lawson et al., 1986). In a meta-analysis that included 32
cohort studies and 17 case-control studies, researchers found a 2.3-fold increased risk of
HCC prevalence in individuals with type 2 diabetes. In addition, an increased risk of HCC
mortality was also noted in diabetic individuals (Wang et al., 2012). A recent cohort study
prospectively followed up two cohorts of U.S. men and women. The Nurses’ Health Study
(NHS) enrolled 120, 826 women in 1980 and followed them through 2012. The Health
Professionals Follow-up Study (HPFS) enrolled 50,284 men in 1986 and followed them
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through 2012. The study found type 2 diabetes was associated with 4.6-fold increase in
the risk of HCC (Simon et al., 2018).

Aflatoxin B1
Aflatoxin B1 (AFB1) is a mycotoxin produced by fungus Aspergillus flavus and
Aspergillus parasiticus which are common and widely distributed in nature (Kew, 2013).
Foodstuffs including corn, rice oil seeds, dried fruits and peanuts can be contaminated
with AFB1 if they are improperly stored in environment with high temperature and humidity
(Baydar et al., 2005). Farm produce such as milk, meat and eggs would also be
contaminated if farm animals were fed with aflatoxin-contaminated food (Bennett, 2003;
Fink-Gremmels, 1999). AFB1 has been classified as ‘group A’ carcinogen by World Health
Organization (WHO) because evidence showed that exposure to AFB1 significantly
increased the risks for HCC (Lopez et al., 2002). Several studies proposed that AFB1
affects liver and increase the risk of HCC via p53 gene mutation (Egal et al., 2005; Bressac,
Kew, Wands, & Ozturk, 1991). Aflatoxins are the most common non-infectious food-borne
risk factor that threats 4.5 to 5.5 billion people worldwide (Williams et al., 2004; Strosnider
et al., 2006). It has reported that the risk of liver cancer in individuals exposed to both HBV
and ALB1 is 30 times higher than the risk in those exposed to aflatoxin alone (Groopman,
Kensler, & Wild, 2008; Liu & Wu, 2010).

Staging of HCC
Multiple staging systems are used to direct clinical treatment modalities and to
determine prognosis. The Barcelona Clinic Liver Cancer (BCLC) model (Figure 1.1) is a
widely endorsed staging system assisting treatment decisions. BCLC classifies patients
into 5 stages (0, A, B, C, and D) incorporating patients’ tumor characteristics and
underlying liver functions (measured as Child-Pugh stage). Other commonly used staging
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systems include the Cancer of the Liver Italian Program (CLIP), and two main pathologybased staging systems: the American Joint Committee on Cancer (AJCC)/ Union for

Figure 1. 1: Barcelona Clinic Liver Cancer (BCLC) staging and treatment strategy
The BCLC system establishes a prognosis in accordance with the five stages that are linked to first-line treatment recommendation. The
expected outcome is expressed as median survival of each tumour stage according to the available scientific evidence. Note that liver
function should be evaluated beyond the conventional Child-Pugh classification or the Model of End-stage Liver Disease (MELD) score.
None of them serves to properly gauge the liver function status, and this evaluation should take into account biochemistry parameters as
well as the compensated or decompensated status of the patient. Preserved liver function includes a group of patients with different
degrees of liver function reserve that has to be carefully evaluated. For most treatment options, compensated liver disease (Child-Pugh
stage A without ascites) is required to obtain optimal outcomes. The sole option that could be applied irrespective of liver function is liver
transplantation. ECOG PS=Eastern Cooperative Oncology Group Performance Status. *Patients with end-stage cirrhosis due to heavily
impaired liver function (Child-Pugh stage C or earlier stages with predictors of poor prognosis or high a MELD score) should be considered
for liver transplantation. In these patients, hepatocellular carcinoma might become a contraindication if it exceeds enlistment criteria.
†Currently, sorafenib followed by regorafenib has been shown to be effective. Lenvatinib has been shown to be non-inferior to sorafenib,
but no second-line option after lenvatinib has been explored. (Adapted from Forner, Reig, & Bruix. 2018)

International Cancer Control (UICC) staging system and the Japan Integrated Staging (JIS)
score (Edge & Compton, 2010; Nanashima et al., 2006). CLIP score takes Child-Pugh
grade, tumor morphology, alpha-fetoprotein (AFP) and portal vein thrombosis into account
and generates a score ranging from 0 to 6. Rather than make a treatment recommendation,
the CLIP system determines prognosis in terms of the number of months that patients will
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survive (Cancer of the Liver Italian Program (CLIP) Investigators, 1998). For HCC patients
who will undergo either a liver resection or liver transplant, a staging system that includes
pathologic assessment of the tumor is recommended. AJCC/UICC and JIS are used for
this purpose and both include TNM staging, which assesses tumor size, regional lymph
node involvement and metastasis (Edge & Compton, 2010). These staging systems along
with other considerations of personal factors such as race/ethnicity are very helpful in
directing therapies.

Treatment of HCC
Surgical resection, transplantation, ablation, transarterial chemoembolization and
the tyrosine-kinase inhibitors sorafenib, lenvatinib, and regorafenib are treatments with
proven survival benefit (Llovet & Bruix, 2003; Llovet et al., 2008; Kudo et al., 2008; Bruix
et al., 2017). Other treatment modalities including arterial embolization without
chemotherapy, external radiotherapy, and radioembolization have not been definitively
shown to have survival benefit (Llovet et al., 2002; Kalogeridi et al., 2015; Sangro et al.,
2011).

Surgical resection
A liver resection refers to the surgical removal of all or a portion of the liver. Resection
is the most effective, curative treatment, and generally performed in patients without
cirrhosis. However, HCC without cirrhosis is rare in Western countries whereas only 5%
of HCC developed in a non-cirrhotic liver (Schwartz, Roayaie, & Konstadoulakis, 2007).
The evaluation of hepatic reserve is important when a liver resection is considered. Partial
hepatectomy may be performed on patients with a localized single tumor without cirrhosis
or Child class A cirrhosis with adequate liver parenchyma (Delis & Dervenis, 2008). The
overall long-term survivals after liver resection are favorable. Greater than 70% of 5-year
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survivals after liver resection were reported in patients with tumor<5cm, no vascular
invasion and a negative surgical margin of at least 1 cm (Shi et al., 2007).
In patients with cirrhosis, possible pre-existing liver damage and tumor multifocality
may complicate treatment and a preoperative risk evaluation is necessary to achieve longterm survival. A minimum of 40% well-perfused liver volume must remain in situ after liver
resection (Vauthey et al., 2000). Studies have shown that resection can be performed in
cirrhotic patients without (Eguchi et al., 2011) and even with portal hypertension
presenting acceptable mortality rates and oncological benefits (Ishizawa et al., 2008;
Verloh et al., 2013). Good 5-year survival of 57% and 38% were achieved among patients
whose liver was resected on the basis of BCLC stages of B and C respectively in centers
specialized in complex liver surgery (Torzilli et al., 2013).

Liver transplantation
Liver transplantation is the most effective treatment option to prevent intrahepatic
recurrence. Milan criteria has been accepted in the US and Europe as the selection
standard for eligible patients (Sapisochin & Bruix, 2017). Milan criteria restrict
transplantation in patients with HCC as follows: 1) single tumor less than 5 cm in diameter;
2) up to three modules less or equal to 3 cm in diameter; 3) no angioinvasion and 4) no
extrahepatic involvement (Mazzaferro et al., 1996). For patients who had liver surgery
within Milan criteria, 5-year survival of 50% to 70% can be achieved so the benchmark for
liver transplantation is set at 70% overall survival at 5 years (Poon et al., 2002; Giuliante
et al., 2012; Clavien et al., 2012). The expanded criteria were proposed in 2001 by Yao
and colleagues because they considered Milan criteria were too restrictive. The expanded
criteria made transplantation possible for patients with single tumor <6.5 cm or <3 nodules
with the largest lesion <4.5 cm and total tumor diameter <8 cm (Yao et al., 2001). Patients
with tumors within the expanded criteria had 1-year survival rate of 90%, significantly
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higher than the 50% among patients with tumors exceeding these limits (Yao et al., 2001).
Liver transplantation can treat HCC and pre-existing cirrhosis or other chronic liver disease
simultaneously, however, donor availability is a challenge and patients may wait for a long
time during which tumor may progress and impede transplantation.

Surgical Outcomes of HCC
Several adverse outcomes related to liver resection in patients with HCC include
perioperative mortality, readmission, postoperative complications and prolonged hospital
length of stay.

Perioperative mortality
Prior studies have reported that perioperative mortalities associated with liver
resection have improved from 10%-20% to less than 5% (Nagasue & Yukaya, 1989;
Thompson, Tompkins & Longmire, 1983; Fan et al., 1995). A meta-analysis that included
a large number of studies evaluated the postoperative mortality rates for the sample that
comprised more than 35,000 patients with primary and metastatic tumors and found that
3.15% patients died after the hepatectomy (Ramacciato et al., 2012). The mortality rate of
4.01% in HCC patients was significantly higher than the rate of 2.34% in non-HCC cases.
In another population-based study, Mayo et al. (2011) used the SEER database to define
postoperative mortality. The study included 2,597 patients who underwent hepatic
resection during 1991-2006 and found that the 30, 60 and 90-day postoperative mortalities
were 5.7%, 8.3% and 10.1% respectively (Mayo et al., 2011). The study also discovered
that HCC patients had a higher mortality rate than those with colorectal liver metastasis
(15.0% versus 8.4% respectively for 90-day mortality). Dimick et al. (2003) identified 2097
patients (16% with HCC, 52% with secondary metastases) who underwent liver resection
between 1996 and 1997 and reported an overall postoperative mortality rate of 5.8%. The
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study also found that low hospital volume, older than 65 years, hepatic lobectomy (vs.
wedge resection), primary liver tumors (vs. metastases) and liver disease severity were
risk factors associated with higher risk of 90-day mortality (Dimick et al., 2003). In a
population-based study from Taiwan, researchers reported that the 90-day mortality after
hepatectomy was 3.9% and preexisting renal and cirrhosis-related complications were
found to be the strongest risk factors of mortality (Chang et al., 2014). Another hospitalbased study investigated 774 early stage HCC patients who underwent liver resection and
found a lower postoperative mortality of 1.3% (Margonis et al., 2017). An analysis of 1803
consecutive patients who underwent hepatic resection at Memorial Sloan-Kettering
Cancer Center from 1991 to 2001 reported an overall mortality after hepatectomy of 3.1%
(Jarnagin et al., 2002). Risk factors associated with mortality were the number of hepatic
segments resected and the blood loss during the operation. A study with more
representative samples from five hepatobiliary centers located in France, China, and USA
was performed aiming to examine long-term survival trend for HCC patients experiencing
major hepatectomy. The study found the overall 90-day postoperative mortality rate was
4% and there were no differences in patients underwent right hepatectomy and those who
received extended hepatectomy (Andreou et al., 2013). In summary, hepatectomy related
mortality decreased dramatically from as high as 20% to less than 5% during last 30 years.
The postoperative mortality rates are higher in patients with HCC than those with
metastasis liver tumors. Risk factors associated with early mortality after hepatectomy
include demographic factors (gender and age), clinical factors (surgical procedures,
complications, blood loss during operation, postoperative liver function and comorbidities),
hospital related factors (hospital type and annual volume), and biochemical factors
(bilirubin and serum phosphorus level).

Early readmission after liver resection
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In addition to perioperative mortality, early readmission after liver resection is
another adverse outcome related to the surgery and associated with substantial burdens
in health care spending. Several studies examined the 30- or 90-day readmissions after
hepatectomy. An analysis of early readmission and its characteristics, patterns and risk
factors reviewed 1,281 patients who underwent hepatic resection from 1996 to 2009 at
Duke University Medical Center. The study indicated that 90-day readmission rate was
14.4%.

Contributing factors included major

hepatectomy,

major

postoperative

complications and index hospitalization>7 days (Barbas et al., 2013). However, indications
from this study were contradicted with a research led by Kulaylat that concluded neither
index hospitalization>7 days nor postoperative hepatobiliary complications played a
significant role for the readmission (Brudvik et al., 2015). Another study conducted at
Johns Hopkins Hospital identified 338 patients undergoing hepatectomy from 2008 to
2012. The overall 30-day readmission was 14.2% and, like previous study, postoperative
complication was found to be the strongest risk factor for the readmission (Spolverato et
al., 2014). Two publications reported higher 90-day readmission rates. In a study that
reviewed a prospectively maintained hepatobiliary database for 245 HCC patients
undergoing hepatectomy from 2000 to 2012, Kimbrough and colleagues found that the
90-day readmission rate was 18.7% (Kimbrough et al., 2014). A slightly lower 90-day
readmission rate of 17.3% was reported in another study that analyzed 1,184 patients who
underwent major hepatectomy from three institutions (Emory University, the University of
Louisville and the University of Wisconsin) from 2000 through 2012 (Egger et al., 2014).
Insurance status is often used as a demographic variable in many studies. A retrospective
medical record review for examining risk factors of unplanned hospital readmission
compared demographics, severity of illness, family support, symptoms and comorbidities
of 78 readmitted cancer patients with those (78 patients) without a readmission. The study
found that patients with financial and insurance concerns were more likely to be readmitted
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to hospital (Weaver et al., 2006). A more recent study explored risk factors for 30-day
unplanned readmissions in patients with parotid cancer who underwent surgery from 2003
to 2012 recorded in NCDB. The study indicated that the odds of readmission were 2.3
times higher for uninsured patients when compared with those privately insured (Zhan et
al., 2016). As two of the postoperative outcomes, perioperative mortality and early
readmission after surgery are believed to be associated with each other. Studies have
found that early readmission is associated with increased postoperative mortality. A crosssectional study investigated the relationship between time to readmission and mortality in
Medicare patients undergoing high-risk surgery from 2005 to 2009. The study found that
the odds of postoperative mortality were 4.9, 4.2 and 3.8 times higher for patients
readmitted between 1-5 days, 6-10 day and 11-15 days respectively than those not
readmitted (Gonzalez et al., 2015). In another population-based study, Hu and colleagues
evaluated the impact of 30-day readmission on 90-day postoperative mortality for patients
who underwent lung cancer resection. The study used SEER-Medicare linked database
and identified 11,432 patients from 2006 to 2011. Researchers reported that the overall
30-day readmission rate was 12.8% and 30-day readmission was associated with 6-fold
increased odds of 90-day mortality (Hu et al., 2014). The study also indicated that patient
age, preoperative morbidities, and type of operation were associated with 30-day
readmission.

Postoperative outcomes in patients with NAFLD-HCC
Though early postoperative mortality and readmission are the two main adverse
outcomes following a hepatectomy, there are other outcomes such as postoperative
complications and longer hospital stay as well. As mentioned earlier, NAFLD has emerged
as playing increasing roles in the development of HCC and affecting its prognosis. Several
studies have investigated surgical outcomes for NAFLD-HCC versus HCC with other
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etiologies such as HBV or HCV infection. In a study that used consecutive patient data
from a multicenter database between 2003 and 2012, researchers noted the similar
perioperative outcomes perioperative mortality and morbidity, and comparable overall
survival and recurrence-free survival (Yang et al., 2020). To examine the impact of
steatosis on the outcomes following hepatic resection in cancer patients, Kooby and
colleagues quantified steatosis for 325 patients with fatty liver. Patients with steatosis <30%
were classified as having mild steatosis while the rest were classified as having marked
steatosis. The study did not observe the differences in complications requiring major
medical intervention, hospitalization, or admission to the intensive care unit between mild
and marked steatosis groups in univariate analysis. However, in multivariable analysis,
steatosis was found to be an independent predictor of complications but did not impact on
60-day mortality (Kooby et al., 2003). NAFDL is believed to be closed related to metabolic
syndrome (MS) which include clinicopathological manifestations of hypertension,
dyslipidemia, obesity, and diabetes (Starley, Calcano, & Harrison, 2010; El-Serag, Tran,
& Everhart, 2004). In a study that compared the outcomes following liver resection
between patients with MS-HCC and HCV-HCC, patients with MS-HCC were matched oneto-one with patients with HCV-HCC without metabolic syndrome. The study indicated that
patients with MS-HCC had similar lower mortality and higher morbidity rates to patients
with HCV-HCC and MS-HCC was associated with much better long-term outcomes
(Viganò et al., 2015). Another retrospective, hospital-based study enrolled 147 HCV-HCC
patients, 61 HBV-HCC patients and 17 NAFLD-HCC patients aimed to investigate the
surgical outcomes of NAFLD-HCC patients. Univariate analyses of the study indicated that
postoperative morbidity and 30-day mortality rates were significantly higher in NAFLDHCC patients. However, these patients showed better disease-free survival on both
univariate and multivariable analyses (Wakai et al., 2011). Similar long-term survival
outcomes in NAFLD-HCC patients were also reported in another hospital-based study
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with a larger sample size. After comparing outcomes of curative treatment between
NAFLD-HCC and non-NAFLD-HCC patients, the study concluded that NAFLD-HCC was
associated with a higher surgical mortality and postoperative liver failure but a favorable
5-year overall survival. Prospect research revealed that NAFLD-HCC is more often found
at a later tumor stage than HCV-HCC resulting in overall worse prognosis. However, if
NAFLD-HCC patients are matched with HCV-HCC patients for tumor stage, prognosis for
both NAFLD-HCC and HCV-HCC patients are statistically same, which may indicate the
natural history is unrelated to the background etiology of liver disease (Piscaglia et al.,
2016).

KNOWLEDGE GAPS

Hepatectomy is a major operation with potential risks of mortality and hospital
readmission (Kim et al., 2015). Typically, 90-day mortality and 30-day readmission are
important quality measures of perioperative care and associated risks. The reported 90day mortality rates following a hepatectomy vary widely across studies from 2.0% to 10.1%
(Hyder et al., 2013; Etra et al., 2014; Bachellier et al., 2011; Margonis et al., 2017; Al-Alem
et al., 2016; Chang et al., 2014) and factors such as complications, amount of blood loss,
surgical procedures, and liver function were found to affect 90-day mortality (Al-Alem et
al., 2016; Jarnagin et al., 2002; Andreou et al., 2012). A handful of studies had proposed
some risk score models predicting 90-day mortality after hepatectomies, which generated
3 to 4 risk groups with corresponding 90-day mortality from 0.25% to 35.9%. However,
these studies have limited generalizability given the small sample size and localized study
sites. None of these studies have examined if these risk scores could be developed and
applied to a broader HCC population in the US.
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Of the few studies that examined 30-day readmission, most were either US hospitalbased or non-US population-based or are outdated. Among these studies, 30-day
readmission rates ranged from 10%-20% and postoperative complications were identified
as the main risk factors of 30-day readmission. These studies often include HCC and other
primary or secondary liver malignancies as well as benign tumors and cannot measures
HCC-specific readmission rates and associated risk factors. In addition, no prior studies
have investigated the impact of unplanned 30-day readmission on subsequent conditional
90-day mortality in a nationally representative sample that captures 70% of all newly
diagnosed cancer cases.
Though early postoperative mortality and readmission are the two main adverse
outcomes following a hepatectomy, there are other outcomes such as postoperative
complications and longer hospital stay as well. As obesity became pandemic, the
prevalence of NAFLD has increased significantly and emerged as playing increasing roles
in the development of HCC and affecting the prognosis. However, reports on the
prevalence and temporal trend of NAFLD in hospitalized patients with HCC are limited.
Furthermore, the impact of NAFLD on surgical outcomes including postoperative
complications, in-hospital mortality, and hospital length of stay in HCC patients with
NAFLD who underwent liver resection is not well addressed.

SPECIFIC AIMS AND HYPOTHESIS
Aim 1: To develop and test discriminatory ability of a risk score model to group patients
with low, medium, high, and excessive risks of 90-day mortality following a hepatectomy
based on the weighting of identified demographic and hospital related risk factors.
Hypothesis: As indicated by previous literature, factors such as age, gender, comorbidities,
hospital type and volume may affect 90-day mortality and these factors could be weighted
and used to develop a risk score model.
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Aim 2: To investigate risk factors associated with 30-day unplanned readmission and
address its impact on conditional 90-day mortality after hepatectomy.
Hypothesis: Patients’ age, gender, insurance program, comorbidity scores, tumor size and
surgical procedures may affect unplanned 30-day readmission as suggested by previous
literature. Furthermore, patients with a history of 30-DR would have a higher risk of
conditional 90-day mortality.
Aim 3: To describe the 10-year (2005-2014) national trends and patterns of NAFLD
prevalence among all hospitalized HCC patients and compare the impact of NAFLD on
adverse outcomes post-hepatectomy (occurrence of postoperative complications, inhospital morbidity and longer hospital stay) in HCC patients with and without NAFLD.
Hypothesis: NAFLD may be an independent factor affecting in-hospital outcomes among
HCC patients undergoing liver resection.

DATA SOURCES

National Cancer Database (NCDB)
Aim 1 and aim 2 used existing data from the largest cancer database in the United
States. NCDB, a clinical oncology database, is jointly sponsored by the American College
of Surgeons and the American Cancer Society. More than 1,500 Commission on Cancer
(CoC) accredited hospitals contribute to the cancer registry data, which represents 70%
of newly diagnosed cancer cases nationwide. The NCDB contains approximately 34
million records and includes variables associated with patients’ sociodemographic
characteristics, overall health, treatment, and survival (Boffa et al., 2016).

Nationwide Inpatient Sample (NIS)
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Aim 3 used another national representative sample of NIS, which is the largest,
publicly accessible all-payer inpatient database created and operated by the Agency for
Health Research and Quality (AHRQ). The database comprises of discharge data that
represent approximately 20% of the United States hospitals. NIS database contains
clinical variables on source and type of admissions, diagnosis related groups (DRGs), 25
diagnosis codes from the International Classification of Disease, 9th Revision, Clinical
Modification (ICD-9-CM), 15 ICD-9CM procedure codes, procedure days from admission,
length of stay (LOS) and discharge status. Demographic characteristics (gender, age,
race/ethnicity) and nonclinical variables including median household income in the
patients’ zip code area and rural/urban residence and expected payment source are also
included. NIS is widely considered the most valid and reliable source of epidemiological
data on inpatient care and outcomes in the United States.

19
CHAPTER 2
DEVELOPMENT OF AN INTEGER-BASED RISK SCORE TO PREDICT 90-DAY
MORTALITY AFTER HEPATECTOMY IN PATIENTS WITH HEPATOCELLULAR
CARCINOMA

ABSTRACT
Background: The incidence of liver cancer has more than tripled since 1980.
Hepatectomy represents the major curative treatment for liver cancer. The risk factors
associated with 90-day mortality after hepatectomy are not well understood and there are
currently no good prediction models for this outcome. The objectives of the current study
were to identify risk factors of 90-day mortality after hepatectomy in patients with
hepatocellular carcinoma (HCC) and to develop an integer-based risk score using the
National Cancer Database (NCDB).
Methods: Hepatectomies recorded in the NCDB during 2004-2012 were reviewed for 90day mortality. Risk factors were identified by multivariate logistic regression models. An
integer-based risk score was developed using the β coefficients derived from the logistic
regression model and tested for discriminatory ability. According to the total risk score,
patients were grouped into four risk groups.
Results: The overall 90-day mortality was 10.2%. Ten risk factors were identified, which
included sex, age, race/ethnicity, insurance status, education, annual hospital volume,
stage, tumor grade, Charlson-Deyo score and surgical procedure. The risk of 90-day
mortality was stratified into four groups. The calculated 90-day mortality rates were 2.47%,
5.88%, 12.58% and 24.67% for low, medium, high and excessive risk groups, respectively.
An area under curve (AUC) of 0.69 was obtained for model discrimination.
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Conclusions: The integer-based risk score we developed could easily quantify each
patient’s risk level and predict 90-day mortality after hepatectomy. The stratified risk score
could be a useful addition to the perioperative risk management and a tool to improve 90day mortality after hepatectomy.
Key Words: hepatocellular carcinoma, hepatectomy, 90-day mortality, risk factors

Introduction
The incidence and mortality of liver cancer is increasing in the United States (Davila
et al., 2012; Siegel, Miller, & Jemal, 2019). The high mortality associated with liver cancer
renders it a significant public health problem worldwide. In 2018, the mortality of liver
cancer was over three quarters of a million (781,631) accounting for 8.2% of all cancerrelated deaths globally (Bray et al., 2018). Hepatocellular carcinoma (HCC) accounts for
approximately 80-90% of all primary liver cancers (Chacko & Samanta, 2016). Despite the
advances in other modalities of treatments of HCC, hepatectomy (or liver resection), the
only potentially curative treatment option (Schiergens et al., 2015), remains the gold
standard for patients with resectable HCC (Maluccio & Covey, 2015) and is currently
performed more often than in the previous decades (Dimick et al., 2004).
Traditionally, death within 30 days after surgery was reported as operative mortality
(Virani et al., 2007; Kamiyama et al., 2010). However, researchers argued that 30-day
mortality after hepatectomy may underestimate the mortality associated with liver
resection, suggesting 90-day mortality should be reported for better mortality estimation
(Schiergens et al., 2015; Mayo et al., 2011).
Ninety-day mortality rates after hepatectomy reported from previous studies have
demonstrated a consistent trend but varied from 2.0% to 10.1% depending on the type of
study, study population, disease severity and surgical procedures (Hyder et al., 2013; Etra
et al., 2014; Bachellier et al., 2011; Margonis et al., 2017; Al-Alem et al., 2016; Chang et
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al., 2014). Several predictive models have been developed to help with risk stratification
for determining the ideal treatment approach for patients undergoing liver resection (Hyder
et al., 2013; Chang et al., 2014; Lee et al., 2016; Balzan et al., 2005; Simons et al., 2009;
Simons et al., 2010). Balzan et al. (2005) recommended the “50-50 criteria” on
postoperative day 5 as a simple, early and accurate predictor of mortality after
hepatectomy (Balzan et al., 2005). Simons and colleagues (2009) developed an integerbased risk score model that included age, sex, Charlson comorbidity scores, procedure
type, hospital type and type of neoplasm to predict in-hospital mortality after liver resection.
The mortality rates for five risk groups ranged from 0.9% to 35.9% (Simons et al., 2009).
In a population-based study conducted in Taiwan, Chang et al. (2014) proposed an
integer-based, weighted point system to stratify 90-day mortality risk and divided the
13,159 patients undergoing liver resection into four risk groups. The lowest risk group had
a 90-day mortality rate of 1.1%, while the rate for the highest risk group was 15% (Chang
et al., 2014).
Even though these previous studies have provided important risk stratification
methods for patients undergoing hepatectomy by developing integer-based risk score
systems, they are constrained by limited sample size. Most studies were based on single
center or multi-hospital data or from population-based data outside of the U.S. No previous
research has examined if these risk scores could be developed and applied to broader
HCC population in the U.S. Evaluation of the risk for each individual patient undergoing
liver resection is valuable for perioperative evaluation and management and patient
counseling. To address the aforementioned gaps, the objectives of this study were to 1)
estimate the 90-day mortality rate for patients with HCC after hepatectomy using the
NCDB, 2) investigate risk factors associated with 90-day mortality after hepatectomy, and
3) develop and test discriminatory ability of an integer-based risk score derived from the
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logistic regression model to group patients into four risk groups according to their total risk
scores and calculate mortality rates for each of the risk groups.

Methods

Study Design
This is a retrospective, cross-sectional study utilizing existing data from the largest
clinical cancer registry in the world (Boffa et al., 2017), NCDB.
NCDB contains approximately 34 million records from cancer registries of more than
1,500 Commission on Cancer (CoC) accredited hospitals across the U.S. It covers
approximately 70% of all newly diagnosed cancer cases at the institutional level and
includes variables associated with patients’ sociodemographic characteristics, overall
health, treatment, and survival (Boffa et al., 2017).

Study Population
The study population included patients 18 years and older who were diagnosed with
HCC between January 1st, 2004 and December 31st, 2012 and underwent liver resection
in the U.S. Patients were identified based on the International Classification of Disease for
Oncology, third edition (ICD-O-3) code C220 and histology codes 8170 through 8175.
Patients were excluded if they did not have surgery, had a total hepatectomy and
transplant, or received only loco-regional treatment. Patients who underwent extrahepatic
bile duct resection, had missing information on surgery type, or had unknown 90-day
mortality status were also excluded.

Outcome Measure
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The primary outcome was 90-day mortality after hepatectomy. This was identified
by the database variable named ‘PUF_90_DAY_MORT_CD’, which recorded mortality
within 90 days after the most definitive primary site surgery. This was determined by the
documented date of the most definitive (most extensive) surgical procedure of the primary
site that was performed as part of the first course of treatment, if known, otherwise, this
was based on the earliest date on which any first-course surgical procedure was
performed.

Predictor Variables
Predictor variables included age, sex, race/ethnicity, insurance status, annual
household income, education, urban or rural residence, Charlson/Deyo comorbidity score,
American Joint Committee on Cancer (AJCC) analytic stage group, tumor grade, tumor
size, surgical procedure, facility type, and annual hospital volume.
Age was grouped as 18-49, 50-64, 65-74 and 75+ years. Race/ethnicity was
classified as White, non-Hispanic; Black, non-Hispanic; Hispanic, and Other, non-Hispanic.
Insurance status at the time of initial diagnosis and/or treatment was categorized as not
insured, privately insured, insured with Medicaid, insured with Medicare and other
government insurance program, and unknown status. Income was estimated by the
median household income derived from 2000 U.S. Census data by matching patients’
documented zip code of residence. Income was grouped into four categories: less than
$30,000, $30,000-$34,999, $35,000- $45,999, and $46,000 and more. The percentage of
adults who had not graduated from high school in patients’ documented zip code of
residence was used as a proxy measure of education; this was categorized as less than
14%, 14-19.9%, 20-28.9%, 29% or more, and information not available. Federal
Information Processing Standard (FIPS) code recorded at time of diagnosis for patients’
state and county was matched to United States Department of Agriculture (USDA)
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Economic Research Service data (2003) to determine patients’ metro/urban/rural status
of residence.
The Charlson/Deyo value is a weighted score derived from the sum of the scores for
all comorbid conditions (American College of Surgeons, 2017). Each of the following
reported ICD-9-CM secondary diagnoses was assigned a score of 1: a) myocardial
infarction, b) congestive heart failure, c) peripheral vascular disease, d) cerebrovascular
disease, e) dementia, f) chronic pulmonary disease, g) rheumatologic disease, h) peptic
ulcer disease, i) mild liver disease and j) diabetes. Patients with diabetes and chronic
complications, hemiplegia or paraplegia, or renal disease were given a score of 2. Patients
diagnosed with AIDS were given a score of 6. Charlson/Deyo score was reported for
patients diagnosed in 2003 and later and categorized as 0, 1 and 2 or more. Tumor grade
was coded as 1 if well differentiated, 2 if moderately differentiated, 3 if poorly differentiated
and 4 if undifferentiated, the latter representing the most aggressive grade.29 Tumor size,
the largest dimension of the diameter of the primary tumor in millimeter (mm), was
categorized as ≤30mm, > 30mm and ≤50mm, and >50mm. Surgical procedures were
grouped as wedge or segmental resection, lobectomy, extended lobectomy, and unknown
type.
Facility type was categorized as 1) Community Cancer Program, 2) Comprehensive
Community Cancer Program, 3) Academic Comprehensive Cancer Program and NCIDesignated Network Cancer Program, 4) Integrated Network Cancer Program, and 5)
other or unknown type of cancer program (American College of Surgeons, 2016). Each
individual facility was assigned a unique random identifier, regardless of cancer site. This
unique identifier was used to calculate the total number of hepatectomies performed
annually in each facility (annual hospital volume) which were then grouped into low (<
4/year), medium (4-15/year), and high (>15/year) hospital volume.
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Statistical Analysis
All statistical analyses were performed using SAS version 9.4 software (SAS Institute,
Cary, North Carolina) and SPSS version 25.0 software (IBM Corp., Armonk, N.Y.). For
descriptive statistics, numerical variables were summarized as mean with standard
deviation, while categorical variables, count with percentage. Patient’s characteristics
were summarized and compared between those who died within 90 days after liver
resection and those who survived beyond 90 days using Pearson Chi-Square/Fisher’s
exact test or independent t test. Predictor variables with a p value 0.1 or less were included
in a multivariate logistic regression model to predict the 90-day mortality. The final model
was determined by the stepwise model selection method. The β coefficients derived from
the logistic regression model were used to develop an integer-based score model to
stratify the risk for 90-day mortality. Risk factors were assigned risk scores at each level
of the factor. First, the reference group for each of the factors was assigned a score of 0.
Second, among all the β coefficients, the smallest (here the number was 0.00853 from
Black, non-Hispanic) was assigned a risk score of 1. Third, all other β coefficients were
divided by 0.00853 and the quotients were rounded to the nearest integers. These integers
would be the risk score for each level of the risk factors. Finally, a total risk score for each
patient was calculated by summing all the risk scores from each of the factors. Patients
were then stratified into four risk groups based on their total risk scores. Patients with total
risk scores <105, 105-199, 200-305, and >305 were considered having low, medium, high
and excessive risk of 90-day mortality respectively. The cutoffs of risk scores were set to
reflect the corresponding mortality rates that were approximately 24%, 58%, 123%, and
242% of the overall 90-day mortality rates. The predictability of the risk score was tested
using the area under the receiver operating characteristic (ROC) curve. All p-values less
than 0.05 for all statistical two-sided tests were considered statistically significant.
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RESULTS

Patient characteristics
The NCDB database for liver diseases included 135,800 patients diagnosed
between January 1st, 2004 and December 31st, 2012. After applying exclusion criteria,
8,598 patients who underwent hepatectomy and met inclusion criteria were identified.
Patient characteristics are summarized in Table 1. Patient mean age was 61.9±12.9
years old, with 42.7% aged 55 to 64 years. The majority of patients were male and White,
non-Hispanic (69.6% and 57.8%) respectively. Most patients lived in metro areas (85.0%)
and had private insurance (41.1%) or were insured by Medicare and other government
sponsored insurance programs (42.2%). More than two-thirds of patients (67.8%) were
diagnosed or treated in academic or research-type facilities.
Over half of patients (54.7%) had a Charlson-Deyo score of 0 indicating no major
comorbidities before hepatectomy. Approximately two-thirds of patients (65.3%) were
either stage I or stage II and most (54.6%) had a tumor size greater than 50mm.
Approximately one-third of patients (33.2%) underwent hepatectomies in facilities where
more than 15 liver resections were performed annually.

Association between demographic and clinical factors with 90-day mortality
Table 2.1 (Table 2.1a and 2.1b) shows the univariate analysis results of the
association between demographic as well as clinical variables and 90-day mortality after
hepatectomy. The overall 90-day mortality rate after hepatectomy was 10.2%. Potential
demographic risk factors for 90-day mortality included age group, sex, race/ethnicity,
insurance status, annual household income, education, distance to facility, rurality, facility
type, and hospital volume. Clinical factors included Charlson/Deyo score, AJCC stage,
tumor grade, tumor size, and surgical procedures. The results indicated that older age,
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male sex, Hispanic race, lack of private insurance, living in communities with lower
education and less annual household income, treatment at facility types other than
academic or research, and lower annual hospital volume were significantly associated
with higher 90-day mortality after hepatectomy. For clinical predictors, higher CharlsonDeyo score, advanced NCDB analytic stage group, tumor grade III, larger tumor in size,
and surgical procedures other than wedge or segmental resection were also significantly
associated with increased 90-day mortality. Distance to treating facility and place of
residence (urban or rural) were found not to be significantly associated with 90-day
mortality.
The final model using multivariable logistic regression identified 10 risk factors of 90day mortality. Odds ratios and 95% confidence intervals are shown in Table 2.2. Patients
of male gender, older age, Hispanic origin, with insurance other than private or without
insurance, residing in communities with higher percentage of residents not graduated from
high school, higher Charlson-Deyo score, higher NCDB analytic stage group, advanced
tumor grade, lower hospital volume, and undergoing lobectomy and extended lobectomy
were associated with increased odds of 90-day mortality after hepatectomy.

Development of a risk score model for prediction of 90-day mortality post hepatectomy
This multivariate logistic regression model was then used to develop an integerbased risk model as detailed in the methods section. The β coefficients and calculated
risk scores for each of the factors are shown in Table 2.3. Patients were grouped into four
risk groups based on their total risk scores. The 90-day mortality rate for the first two
groups of patients were 2.47% and 5.88%, respectively, which were lower than the overall
mortality rate of 10.2%. The 90-day mortality rate for the last two risk groups of patients
were 12.58% and 24.67%, respectively, which were higher than the overall mortality rate.
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Integer-based risk groups and their levels of mortality are illustrated in Figure2.1. The area
under the curve of the risk score model was calculated as 0.69 (Figure 2.2).

DISCUSSION
This study identified 8,598 hepatectomies between 2004 and 2012 from NCDB and
is, so far, the first and largest analysis of 90-day mortality in patients with HCC after
hepatectomy within the U.S. With this U.S.-based NCDB data, we developed an integerbased risk score to predict 90-day mortality after hepatectomy for patients with HCC. We
defined four risk groups and found approximately 10-fold difference between the lowest
risk and highest risk groups. The overall 90-day mortality rate was 10.2%, whereas the
mortality rates based on our defined risk groups ranged from 2.47% to 24.67%. Factors
that were most significantly associated with higher risk of 90-day mortality after
hepatectomy included patients with stage III or IV disease, being uninsured or insured by
Medicaid, and having a Charlson-Deyo score of 2.
The 90-day mortality rate in our study was 10.2%, which was higher than the 3.15%
in a meta-analysis that included 35,000 hepatic resections (Ramacciato et al., 2012). In
our study, we only selected patients diagnosed with primary HCC, and the rate calculation
excluded patients with unknown 90-day mortality status, who were followed up for less
than 90 days or who had missing information on date of surgery/last contact. The above
meta-analysis included tumors that did not originate from the liver but had spread to the
liver from other organs of the body, in which the resection was found to have relatively
lower post-operative mortality. The 90-day mortality rates reported from several studies
ranged from as low as 2.0% to as high as 10.1% (Mayo et al., 2011; Margonis et al., 2017;
Al-Alem et al., 2016; Chang et al., 2014; Simons et al., 2009; Resende et al., 2011; Mullen
et al., 2007). This variation may be partially due to the factor differences in each individual
study in terms of age, gender, extent of hepatectomy and presence of cirrhosis. Moreover,
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population-based studies tend to reveal higher mortality following hepatectomy compared
to single hospital-based studies. More specifically, Mayo et al (2011) demonstrated that
mortality rate was 1.5 times higher in a study using the National Inpatient Sample than
mortality rate calculated from single hospital-based studies. This difference may be
partially due to reporting bias, in which institution-specific data tend to report favorable
outcomes (Asiyanbola et al., 2008). Despite these variations in mortality rates across
studies, the perioperative mortality associated with liver resection have greatly improved
from 10 - 20% (Nagasue et al., 1993; Thompson et al., 1983, Fan et al., 1995) to 5 - 7%
(Ramacciato et al., 2012; Dhir et al., 2016).
Many studies have been performed to examine the factors associated with early
mortality after hepatectomy. Some researchers noted that specific, early, postoperative
laboratory tests were indicative of post-hepatectomy mortality while others found factors
of patient demographics and clinical parameters had significant impact on posthepatectomy mortality. The “50-50 criteria” proposed by Balzan and colleagues (2005)
suggested that the combination of prothrombin time <50% and serum bilirubin >50 µmol/L
on postoperative day 5 was a strong predictor of mortality after hepatectomy .18 However,
this rule was criticized for lacking reliability (Mullen et al., 2007). In another study based
on a single institution database for patients undergoing major hepatectomy, Etra et al.
(2014) found that the total bilirubin ≥3 mg/dl at postoperative day 3 was associated with
increased risk of 90-day mortality. To increase the predictability of models from previous
studies, Hyder et al. (2013) proposed a composite weighted score model that included
variables of Clavien-Dindo complication classification, laboratory values of creatinine, and
bilirubin and international normalized ratio (INR) at postoperative day 3. This additive
model was weighted by the coefficients derived from multivariate logistic regression model
(Hyder et al., 2013). The model discriminated well and achieved higher area under the

30
ROC curve of 0.89. These studies used variables such as laboratory tests, which are not
available for over 60% of the cases in NCDB.
A handful of previous studies have attempted to develop integer-based risk models
to better predict early mortality after liver resection. Those studies were either based on
administrative data (Asiyanbola et al., 2008; Nagasue et al., 1993), individual hospital data
(Hyder et al., 2013), or population-based data from outside of the U.S. (Chang et al., 2014;
Lee et al., 2016). In an effort to develop and validate a risk score model based on available
preoperative parameters to predict 90-day mortality after hepatectomy, Chang et al. (2014)
established a weighted composite score using the parameters available before surgery.
Four risk groups were stratified by the composite score, and the 90-day mortality rates
ranged from 1.1% to 15.0% (Chang et al., 2014). This study was population-based,
focusing more on preexisting comorbidity information (such as heart failure and renal
disease) using Taiwan’s National Health Insurance Research Database. Our study used
a similar score development strategy to generate the composite risk scores. Compared to
our study in which the c-statistic was 0.69, the aforementioned research had a slightly
better predictability with a c-statistic of 0.75. However, this study was conducted in a single
race population with liver tumors that included HCC, cholangiocarcinoma, metastatic
malignancy as well as benign tumors. This risk score would not be representative of HCC
patients within the ethnically diverse US population . There is evidence in the literature
that the discriminatory ability of commonly used risk scores is not consistent in different
cohorts of patients undergoing hepatectomy. For example, the AUC for Model of EndStage Liver Disease (MELD) score in predicting postoperative mortality was 0.71 (Fromer
et al., 2016) in a study using retrospective administrative database while the AUC dropped
to 0.69 (Ghamarnejad et al., 2020) in another prospective study based on consecutive
patient data. Portsmouth-Physiological and Operative Severity for the enumeration of
Mortality and Morbidity (P-POSSUM) is currently widely used as a predictive scoring
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system for perioperative care. When this score was applied to a sample of 529 patients
undergoing liver resection in University Hospital Heidelberg (Knoblich et al., 2020), it
showed similar discriminatory ability (AUC=0.68) with our model (AUC=0.69).
Since detailed preexisting comorbidity information was not available in the NCDB,
the variables that were used in our study were those available before or immediately after
the hepatectomy. Compared to studies that rely on laboratory test values for creating risk
scores, our study selected 10 readily available variables comprised of four clinical
parameters (stage, tumor grade, Charlson-Deyo score, and surgical procedure) and six
non-clinical characteristics (gender, age, race/ethnicity, insurance status, education, and
annual hospital volume). Among these 10 variables, eight are available before the surgery
and two (stage, tumor grade) are available either before the surgery if a biopsy has been
conducted or immediately after the surgery.
The incidence of HCC has been increasing and is expected to continue increasing
in the future. Despite improved surgical techniques, patient selection for treatment, and
perioperative care (Kamiyama et al., 2010), hepatectomy is still associated with
perioperative mortality and high morbidity (Balzan et al., 2005; Mullen et al., 2006;
Asiyanbola et al., 2008). This study developed an integer-based risk model on a national
level to assess the risks of 90-day mortality after hepatectomy for patients with HCC only.
Even though the NCDB is not population based, it does cover approximately 70% of all
newly diagnosed cancer cases at the institutional level, which could be considered
nationally representative. Therefore, compared to studies that were hospital-based and
conducted in single or multiple institutions, our risk model may have improved
generalizability. Furthermore, our model did not use any information of laboratory tests
and therefore may be applied to databases where laboratory test results are not available.
The current study has some limitations as well. First, the NCDB does not provide
information on causes of death, making further investigation of cause of death impossible.
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Second, other than the Charlson-Deyo score, no detailed preoperative comorbidity and
postoperative complication information is available, therefore we were unable to relate 90day mortality to postoperative complications. Lastly, the widely used measures of ChildPugh and the MELD scores for the assessment of liver cirrhosis are not available in NCDB.
These indicators are important in predicting post-operative prognosis. However, in clinical
practice, Child-Pugh class A (which represents the least severe liver disease) is dominant
in patients with HCC who are eligible for liver resection (Zou et al., 2017), and MELD score
is used in determining the priority of liver transplant candidates (Peng, Qi, & Guo, 2016).
Therefore, we do not expect that lack of availability of Child-Pugh score had a significant
impact on our results.
Despite these limitations, the developed risk model can generate risk scores for each
patient in three easy steps, which included assigning 0 to reference groups, rounding the
quotient of factor β coefficients and the smallest β to the nearest integer, and summing up
risk scores of all significant factors. By completing the three steps, the risk level and
probability of 90-day mortality at that level can be quantified. Since the study used the
largest clinical cancer registry of NCDB, this score may well be representative and could
be generalized to all patients with HCC who undergo hepatectomy. The model could also
be applied to HCC-related research where secondary databases are used and detailed
laboratory tests are not available. The model may provide additional risk assessment of
90-day mortality in patients with HCC undergoing hepatectomy and assist informative
conversation between patients and clinicians regarding perioperative management of
potential adverse outcomes after hepatectomy.

Conclusion
In this study, we demonstrated a simple, integer-based risk score that could be used
to predict risk of 90-day mortality after hepatectomy in patients with HCC even without
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information on detailed postoperative complications and laboratory test values. We believe
that this risk score may be a useful tool in improving 90-day mortality after hepatectomy.
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Table 2. 1a. Univariate analysis of the demographics for patients undergoing hepatectomy, 2004-2012
Variable
Total
Alive*
Dead*
p-value
n (%)
n (%)
n (%)
Total
8598
7721 (89.8)
877 (10.2)
Age at diagnosis
<0.001
18-49
1174 (13.7)
1092 (14.1)
82 (9.4)
50-64
3673 (42.7)
3327 (43.1)
346 (39.5)
65-74
2307 (26.8)
2069 (26.8)
238 (27.1)
>74
1444 (16.8)
1233 (16.0)
211 (24.1)
Gender
<0.001
Male
5986 (69.6)
5325 (69.0)
661 (75.4)
Female
2612 (30.4)
2396 (31.0)
216 (24.6)
Race/Ethnicity
<0.001
White, non-Hispanic
4973 (57.8)
4470 (57.9)
503 (57.4)
Black, non-Hispanic
1158 (13.5)
1040 (13.5)
118 (13.5)
Hispanic
1112 (12.9)
964 (12.5)
148 (16.9)
Others, non-Hispanic
1355 (15.8)
1247 (16.2)
108 (12.3)
Insurance Status
<0.001
Not insured
292 (3.4)
249 (3.2)
43 (4.9)
Private insurance
3537 (41.1)
3275 (42.4)
262 (29.9)
Medicaid
813 (9.5)
710 (9.2)
103 (11.7)
Medicare or other
3618 (42.1)
3183 (41.2)
435 (49.6)
Unknown
338 (3.9)
304 (3.9)
34 (3.9)
Distance to facility
0.657
Less than 12.5 miles
3834 (45.6)
3435 (45.4)
399 (47.1)
12.5 to 49.9 miles
2598 (30.9)
2341 (31.0)
257 (30.3)
50 miles or more
1976 (23.5)
1784 (23.6)
192 (22.6)
Missing
190
Percentage of resident not
<0.001
graduated from high school
29% or more
1748 (21.2)
1566 (21.2)
182 (21.8)
20%-28.9%
1947 (23.7)
1710 (23.1)
237 (28.4)
14%-19.9%
1823 (22.2)
1634 (22.1)
189 (22.7)
Less than 14%
2712 (33.3)
2486 (33.6)
226 (27.1)
Missing
368
Annual median household income
<0.001
Less than $30,000
1326 (16.1)
1158 (15.7)
168 (20.1)
$30,000-$34,999
1442 (17.5)
1277 (17.3)
165 (19.8)
$35,000-$45,999
2253 (27.4)
2036 (27.5)
217 (26.0)
$46,000 or more
3211 (39.0)
2927 (39.6)
284 (34.1)
Missing
366
Urban or rural residence
0.051
Metro
7010 (85.0)
6322 (85.3)
688 (82.3)
Urban
1111 (13.5)
981 (13.2)
130 (15.6)
Rural
128 (1.6)
110 (1.5)
18 (2.2)
Missing
349
Facility type
<0.001
Community
282 (3.5)
239 (3.3)
43 (5.0)
Comprehensive
1857 (22.8)
1616 (22.2)
241 (28.1)
Academic/research
5515 (67.8)
5000 (68.7)
515 (60.0)
Other
478 (5.9)
419 (5.8)
59 (6.9)
Missing
466
Annual hospital hepatectomy volume
<0.001
<4/year
3132 (36.4)
2714 (35.2)
418 (47.7)
4-15/year
2613 (30.4)
2362 (30.6)
251 (28.6)
>15/year
2853 (33.2)
2645 (34.3)
208 (27.7)
*at 90 days post hepatectomy
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Table 2. 1b. Univariate analysis of clinical characteristics for patients undergoing hepatectomy, 2004-2012
Variable
Total
Alive*
Dead*
p-value
n (%)
n (%)
n (%)
Total
8598
7721
877
Charlson-Deyo score
<0.001
0
4702 (54.7)
4292 (55.6)
410 (46.8)
1
2449 (28.5)
2195 (28.4)
254 (29.0)
2
1447 (16.8)
1234 (16.0)
213 (24.3)
NCDB analytic stage group
<0.001
I
3560 (41.4)
3320 (43.0)
240 (27.4)
II
2054 (23.9)
1874 (24.3)
180 (20.5)
III
1788 (20.8)
1518 (19.7)
270 (30.8)
IV
334 (3.9)
269 (3.5)
65 (7.4)
Unknown
862 (10.0)
740 (9.6)
122 (13.9)
Tumor grade
<0.001
I
1715 (19.9)
1583 (20.5)
132 (15.1)
II
3759 (43.7)
3397 (44.0)
362 (41.3)
III
1595 (18.6)
1372 (17.8)
223 (25.4)
IV
265 (3.1)
240 (3.1)
25 (2.9)
Not determined
1264 (14.7)
1129 (14.6)
135 (15.4)
Tumor size
<0.001
≤30 mm
1566 (18.2)
1450 (18.8)
116 (13.2)
>30mm and ≤50 mm
1990 (23.1)
1819 (23.6)
171 (19.5)
>50 mm
4694 (54.6)
4189 (54.3)
505 (57.6)
Unknown
348 (4.0)
263 (3.4)
85 (9.7)
Surgical procedure
<0.001
Wedge or segmental resection 4533 (52.7)
4129 (53.5)
404 (46.1)
Lobectomy
2741 (31.9)
2423 (31.4)
318 (36.3)
Extended lobectomy
608 (7.1)
539 (7.0)
69 (7.9)
Unknown type
716 (8.3)
630 (8.2)
86 (9.8)
*at 90 days post hepatectomy
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Table 2. 2. Multivariate logistic regression analysis of the risk factors of 90-day mortality after hepatectomy
Predictor variables
Total
Mortality n (%)
Adjusted OR (95% CI)
p-value
Age group
18-49
1174
82 (7.0)
Reference
50-64
3673
346 (9.4)
1.062 (0.777-1.479)
0.714
65-74
2307
238 (10.3)
1.122 (0.790-1.618)
0.528
>74
1444
211 (14.6)
1.577 (1.093-2.305)
0.017
Sex
Female
2612
216 (8.3)
Reference
Male
5986
661 (11.0)
1.284 (1.073-1.542)
0.007
Race/Ethnicity
White, non-Hispanic
4973
503 (10.1)
Reference
Black, non-Hispanic
1158
118 (10.2)
0.992 (0.769-1.268)
0.947
Hispanic
1112
148 (13.3)
1.332 (1.060-1.663)
0.013
Others, non-Hispanic
1355
108 (8.0)
0.814 (0.630-1.040)
0.107
Insurance status
Private
3537
262 (7.4)
Reference
Not insured
292
43 (14.7)
1.967 (1.279-2.941)
0.001
Medicaid
813
103 (12.7)
1.927 (1.458-2.529)
<0.001
Medicare or other
3618
435 (12.0)
1.360 (1.089-1.703)
0.007
Unknown
338
34 (10.1)
1.200 (0.694-1.983)
0.495
Percentage of resident not graduated
from high school
Less than 14%
2712
226 (8.3)
Reference
29% or more
1748
182 (10.4)
1.185 (0.939-1.494)
0.152
20%-28.9%
1947
237 (12.2)
1.370 (1.104-1.701)
0.004
14%-19.9%
1823
189 (10.4)
1.262 (1.011-1.574)
0.039
Charlson-Deyo score
0
4702
410 (8.7)
Reference
1
2449
254 (10.4)
1.111 (0.921-1.338)
0.269
2
1447
213 (14.7)
1.691 (1.380-2.068)
<0.001
NCDB analytic stage group
I
3560
240 (6.7)
Reference
II
2054
180 (8.8)
1.348 (1.084-1.674)
0.007
III
1788
270 (15.1)
2.251 (1.829-2.770)
<0.001
IV
334
65 (19.5)
3.086 (2.078-4.494)
<0.001
Unknown
862
122 (14.2)
1.861 (1.409-2.438)
<0.001
Tumor grade
I
1715
132 (7.7)
Reference
II
3759
362 (9.6)
1.170 (0.931-1.480)
0.183
III
1595
223 (14.0)
1.525 (1.180-1.979)
0.001
IV
265
25 (9.4)
1.199 (0.656-2.098)
0.539
Not determined
1264
135 (10.7)
1.225 (0.912-1.642)
0.177
Annual hospital hepatectomy volume
>15/year
2853
208 (7.3)
Reference
<4/year
3132
418 (13.3)
1.636 (1.343-1.997)
<0.001
4-15/year
2613
251 (9.6)
1.187 (0.958-1.473)
0.118
Surgical procedure
Wedge or segmental resection
4533
404 (8.9)
Reference
Lobectomy
2741
318 (11.6)
1.437 (1.204-1.714)
<0.001
Extended lobectomy
608
69 (11.3)
1.370 (1.007-1.838)
0.040
Unknown type
716
86 (12.0)
1.230 (0.901-1.654)
0.181
OR = odds ratio, CI = confidence interval
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Table 2. 3. Predictor score development based on multivariate logistic regression model
Predictor variables
β Coefficient
Score Assigned
Age group
18-49
Reference
0
50-64
0.0601
7
65-74
0.1152
14
>74
0.4553
54
Sex
Female
Reference
0
Male
0.2497
29
Race/Ethnicity
White, non-Hispanic
Reference
0
Black, non-Hispanic
-0.00853
-1
Hispanic
0.2863
34
Others, non-Hispanic
-0.2062
-24
Insurance status
Private
Reference
0
Not insured
0.6766
80
Medicaid
0.6557
77
Medicare or other
0.3078
36
Unknown
0.1819
21
Percentage of resident not graduated
from high school
Less than 14%
Reference
0
29% or more
0.1696
20
20%-28.9%
0.3152
37
14%-19.9%
0.2327
27
Charlson-Deyo score
0
Reference
0
1
0.1053
12
2
0.5256
62
NCDB analytic stage group
I
Reference
0
II
0.2984
35
III
0.8112
95
IV
1.1268
133
Unknown
0.6211
73
Grade
I
Reference
0
II
0.1571
18
III
0.4222
50
IV
0.1813
21
Unknown
0.2027
24
Annual hospital volume
>15/year
Reference
0
<4/year
0.4920
58
4-15/year
0.1714
20
Surgical procedure
Wedge or segmental resection
Reference
0
Lobectomy
0.3624
43
Extended lobectomy
0.3145
37
Unknown type
0.2070
24
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Table 2. 4. Stratified risk score group and corresponding mortality rate observed
Risk group
Risk score range
Observed Mortality Rate (%)
Low risk group
<105
2.47
Medium risk group
105-199
5.88
High risk group
200-305
12.58
Excessive risk group
306+
24.67
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Figure 2. 1. Observed 90-day mortality rates (%) after hepatectomy based on stratified risk score groups
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Figure 2. 2. Area under the curve based on risk scores
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CHAPTER 3
THIRTY-DAY UNPLANNED READMISSION AND ITS EFFECT ON 90-DAY
MORTALITY IN HEPATOCELLULAR CARCINOMA PATIENTS UNDERGOING
PARTIAL HEPATECTOMY

ABSTRACT
Background: Despite advances of surgical techniques, hepatectomy continues to be
potentially dangerous and is associated with postoperative mortality, morbidity and
readmission. The objective of this study was to determine the effect of 30-day unplanned
readmission on ‘conditional’ 90-day mortality among hepatocellular carcinoma (HCC)
patients who underwent partial hepatectomy.
Methods: National Cancer Database (NCDB) was queried from 2004 to 2012 for patients
with hepatocellular carcinoma (HCC) who underwent partial hepatectomy. Thirty-day
unplanned readmission rate, and associated risk factors, was determined for 7,696
patients. The association between 30-day unplanned readmission and conditional 90-day
mortality was further addressed.
Results: The 30-day unplanned readmission rate for patients with HCC that underwent
partial hepatectomy was 5.2%. Risk factors associated with 30-day unplanned
readmission were sex, race/ethnicity, Charlson-Deyo score, and annual hospital
hepatectomy volume. An overall adjusted odds ratio of having conditional 90-day mortality
was 2.325 times higher (95% CI 1.643 – 3.219) among patients with a history of 30-day
unplanned readmission than those without. This association was dependent on age, sex,
race/ethnicity, insurance status, alpha-fetoprotein (AFP), liver fibrosis, Charlson-Deyo
comorbidity score and annual hospital hepatectomy volume.
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Conclusion: Efforts in patient care should be taken to reduce 30-day unplanned
readmission after partial hepatectomy for patients with HCC to reduce conditional 90-day
mortality.

INTRODUCTION
The reported cost of unplanned hospital readmissions is approximately $44 billion of
healthcare spending annually (Ostrovsky et al., 2016), yet a substantial proportion of these
readmissions could be avoidable. The Medicare Payment Advisory Commission
estimated that reducing potentially preventable readmissions could save up to $12 billion
every year (Montero et al., 2016). In 2019, the Hospital Readmissions Reduction Program
(HRRP) evaluated 3,129 general hospitals and penalized 83% of these hospitals for
excess 30-day readmissions with estimated fines of $563 million (Rau, 2019). Among
patients with private insurance, the average cost for readmission after hepatectomy was
approximately $34,100/person (Narula et al., 2018), much higher than the average
hospital readmission cost of $14,400 for 18 main diagnosis categories (Becker's
Healthcare, 2019).
Despite advances of surgical techniques, hepatectomy continues to be potentially
dangerous and is associated with postoperative mortality, morbidity and readmission.
Readmission rates after hepatectomy vary depending on the study population. Three
hospital-based studies reported 90-day readmission rates after hepatectomy for any
etiology ranging from 14.4% to 18.7% (Barbas et al., 2013; Egger et al., 2015; Kimbrough
et al., 2014), which were higher than the 30-day readmission rates of 13.0% and 14.2%
from two other hospital-based studies (Tamandl et al., 2015; Spolverato et al., 2014). A
relatively lower 30-day readmission rate of 10.5% was noted in a study using the American
College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP)
database (Kim et al.,2015).
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Contributing factors affecting readmission after hepatectomies include major
hepatectomies (≥4 segments resected), major postoperative complications and index
hospitalization of >7 days (Barbas et al., 2013). However, another study found that neither
index hospitalization nor postoperative hepatobiliary complications played a significant
role in 45-day readmission (Brudvik et al., 2015). Other risk factors include extensive blood
loss, postoperative pulmonary embolism, red blood cell transfusion, surgical infection, and
peak postoperative total bilirubin (Egger et al., 2014). Among these, postoperative
complications were identified as the strongest and dominant risk factor affecting
readmission (Spolverato et al., 2014; Kimbrough et al., 2014).
Significant correlations between 30-day readmission and subsequent 90-day
mortality have been reported, but results are inconsistent. Evidence suggests that a
history of readmission increases the risk of postoperative mortality (Berman et al., 2011).
Though not studied in patients with HCC, a 6-fold increase in 90-day mortality was found
among lung cancer patients with a history of 30-day readmission compared to those
without a 30-day readmission (Hu et al., 2014).
Most previous studies were based on single or 2-3 centers with limited sample size
where the readmission rate could easily be influenced by small changes in hospital
readmission. Furthermore, research on readmission after hepatectomy often include HCC
and other primary and secondary liver malignancies as well as benign tumors to increase
sample size. These studies cannot measure HCC-specific readmission rate and
associated risk factors. Moreover, no studies have evaluated the impact of 30-day
unplanned readmission on conditional 90-day mortality in a nationally representative
sample in patients with HCC who underwent hepatectomies.
The objective of this study was to determine the effect of 30-day unplanned
readmission on conditional 90-day mortality among hepatocellular carcinoma (HCC)
patients that underwent partial hepatectomy.
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METHODS

Data source
We used the National Cancer Database (NCDB) for all analyses. NCDB, a clinical
oncology database, is jointly sponsored by the American College of Surgeons and the
American Cancer Society. More than 1,500 Commission on Cancer (CoC) accredited
hospitals contribute to the cancer registry data, which represents 70% of newly diagnosed
cancer cases nationwide at the institutional level.

Study Population
NCDB was queried for all patients with HCC using International Classification of
Disease for Oncology, third edition (ICD-O-3) code C220 with histology codes 8170, 8171,
8172, 8173, 8174 and 8175. Only patients who were 18 years or older, diagnosed from
2004 to 2012 and underwent partial hepatectomy were included in the study. Patients
were excluded if they developed more than two cancers following HCC diagnosis or had
total hepatectomy and transplant. Patients who survived less than 30 days after
hepatectomy or had missing information on surgery procedures, 30-day readmission
status, and 90-day mortality status were also excluded.

Dependent measure
The first outcome measure was 30-day unplanned readmission. In NCDB, this
variable became available from 2003 onward. It describes patients’ readmission status
and is coded as: 0, 1, 2, 3 and 9. A value of 0 indicates that no surgical procedure of the
primary site was performed or the patient was not readmitted to the same hospital within
30 days of discharge; value of 1 means a 30-day unplanned readmission to the same
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hospital after a surgical procedure; value of 2 represents a 30-day planned readmission
to the same hospital; value of 3 denotes a patient having both 30-day planned and
unplanned readmission after a surgical procedure to the same hospital. For this study, we
only used the data for patients with known 30-day unplanned readmission status
(status=1). The second outcome measure was conditional 90 days after a hepatectomy.

Independent measures
Independent variables included age, sex, race/ethnicity, insurance status, annual
household income, education, urban or rural residence, distance to treatment facility,
annual hospital volume, facility type, alpha fetoprotein tumor marker (AFP), liver fibrosis,
Charlson/Deyo score, NCDB pathologic/clinical stage, tumor grade, tumor size, and
surgical procedure.
Age was grouped as 18-49, 50-64, 65-74 and 75+ years. A new variable
“race/ethnicity” was generated based on NCDB variables race and Hispanic origin and
classified as 1) White non-Hispanic, 2) Black non-Hispanic, 3) Hispanic, and 4) other nonHispanic. Insurance status refers to the patient’s primary insurance carrier at the time of
initial diagnosis and/or treatment and was categorized as not insured, privately insured,
Medicaid, Medicare and other government insurance plans, and unknown status. Income
is the estimation of median household income derived from 2000 US Census data by
matching patients’ zip code of residence. It was grouped into four levels: less than
$30,000, $30,000-$34,999, $35,000- $45,999 and $46,000 and above. The percentage of
adults not graduated from high school in patients’ zip code of residence was used as a
measure of education and was categorized as 29% or more, 20%-28.9%, 14%-19.9%,
less than 14%. In NCDB, patient state and county of Federal Information Processing
Standard (FIPS) code recorded at diagnosis is matched against 2003 files published by
the USDA Economic Research Service to determine patient metro/urban/rural status of
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residence. NCDB defines metro counties as counties in metro areas with a population
ranging from fewer than 250,000 to 1 million or more. Urban counties refer to areas with
a population ranging from 2,500 to 20,000 or more either adjacent or not adjacent to a
metro area. Rural counties include completely rural or less than 2,500 urban population
either adjacent or not adjacent to a metro area.
AFP was grouped into two levels of negative/normal and positive/elevated while liver
fibrosis was categorized as none to moderate and severe to cirrhosis based on Ishak
score of 0-4 and 5-6, respectively (Ishak et al., 1995). The Charlson/Deyo value is a
weighted score derived from the sum of scores for all comorbid conditions. Each of the
ten reported ICD-9-CM secondary diagnoses below has a score of 1 for each condition:
1) myocardial infarction, 2) congestive heart failure, 3) peripheral vascular disease, 4)
cerebrovascular disease, 5) dementia, 6) chronic pulmonary disease, 7) rheumatologic
disease, 8) peptic ulcer disease, 9) mild liver disease and 10) diabetes. In addition, a
patient is given a score of 2 if the patient has diabetes with chronic complications,
hemiplegia or paraplegia, or renal disease. A score of 6 is given to patients with AIDS.
Charlson/Deyo score is reported in the NCDB for patients diagnosed in 2003 and later
and categorized as 0, 1 and 2 or more. Tumor grade describes the resemblance of tumor
cells to the normal cells and is grouped as well differentiated, moderately differentiated,
poorly differentiated and undifferentiated which represents the most aggressive grade that
grows and spreads faster than tumors with lower grades. NCDB analytic stage group was
categorized as I, II, III, IV and unknown. Its value reflects reported pathologic stage group,
or clinical stage group if the former is not available. Tumor size describes the largest
diameter of the primary tumor in millimeter (mm). The variable tumor size was categorized
as ≤ 30mm, >30 and ≤50, >50. Surgical procedures were grouped as wedge or segmental
resection, lobectomy, extended lobectomy and unknown type.
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Facility type was categorized as 1) Community Cancer Program, 2) Comprehensive
Community Cancer Program, 3) Academic Comprehensive Cancer Program and NCIDesignated Network Cancer Program, 4) Integrated Network Cancer Program, and 5)
other or unknown type of cancer program. In the NCDB, the name of the facility is replaced
with a unique random identifier, which can be used to calculate the total number of
hepatectomies performed annually in each facility (annual hospital volume). Annual
hospital volume was then grouped into low (< 4/year), medium (4-15/year), and high
(>15/year) categories.

Statistical analysis
We first calculated overall 30-day unplanned readmission rate among patients with
HCC and underwent hepatectomies and then compared patients’ demographic, clinical
and facility characteristics between patients with and without 30-day unplanned
readmission using Pearson Chi-Square test for categorical variables. Independent t-test
was used to compare mean difference between the two groups. A multivariate logistic
regression model was performed, which included all variables with a p value less than or
equal to 0.1 in the univariate analysis. Adjusted odds ratios, 95% confidence intervals and
p values were reported. To evaluate the effect of 30-day unplanned readmission on
conditional 90-day mortality, we fit univariate and multivariate logistic regression models
using 30-day unplanned readmission as an independent variable and conditional 90-day
mortality as the dependent variable. Selected subgroup analysis was conducted to further
investigate how the association between 30-day unplanned readmission and conditional
90-day mortality varied between subgroups.

RESULTS
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A total of 18,751 patients who were 18 years or older, diagnosed with HCC between
2004 to 2012, had no more than one other cancer diagnosis during this time period, and
underwent partial hepatectomy were identified in the database. We excluded 8,696
patients who underwent total hepatectomy and transplant, leaving 10,055 patients for
calculating overall unplanned readmission rate. Of the 10,055 patients, 522 patients
experienced 30-day unplanned readmission, 152 patients experienced 30-day planned
readmission, 8 patients experienced both planned and unplanned readmission, and 322
patients whose readmission status was unknown. The overall 30-day unplanned
readmission rate was 5.2%. After further excluding patients who had planned readmission,
had both planned and unplanned readmission, survived fewer than 30 days, had missing
90-day mortality status, and had missing surgery date, we identified 7,696 patients to be
included in the study (Figure3.1). The average age of patients was 61.7±12.9 and 5,329
were male (69.2%). Approximately 42.7% of patients were aged 50-64, 58.1% were white,
non-Hispanic, 83.6% had private insurance, Medicare or other, 39.2% had median annual
household income of $46,000 or more, and 68.6% were treated in academic or research
type facilities (Table3.1a). Additionally, over half (55.0%) of patients had a Charlson-Deyo
score of 0, 42.5% belonged to stage I, and 43.9% were diagnosed with grade II tumor
(Table3.1b). The major surgery procedures these patients underwent were wedge or
segmental resection, which accounted for 53.3%.

Comparison of patients experiencing 30-day unplanned readmission vs. those without
readmission
Univariate analysis demonstrated differences of patient demographics, hospital and
clinical characteristics between patients with 30-day unplanned readmission and patients
without readmission (Tables3.1a and 3.1b). Patients with 30-day unplanned readmission
were slightly younger compared to those without a readmission (60.2 years vs. 61.8 years,
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p=0.01), more likely to be male (74.4% vs. 68.9%, p=0.02), Hispanic (17.9% vs. 12.3%,
p<0.01), and to have private insurance (45.7% vs. 41.6%, p<0.01). In addition, patients
with 30-day unplanned readmission were more likely to have a Charlson -Deyo score of ≥
1 (53.6% vs. 44.4%, p<0.01), and to be diagnosed with grade II tumor vs. all other grade
tumor (48.6% vs. 43.6%, p=0.028). Although a higher proportion of readmitted patients
had severe fibrosis/cirrhosis (12.2% vs. 9.0%, p=0.011), over three quarters (76.5%) of
patients did not have fibrosis scores available. Annual household income, education,
distance to treating facility, urban or rural residence, AFP tumor marker, NCDB analytic
stage group, tumor size and surgical procedures did not differ by 30-day unplanned
readmission status (Tables 3.1a and 3.1b).

Risk factors of 30-day unplanned readmission
Table 3.2 shows the odds ratios and 95% confidence intervals from multivariate
logistic regression investigating risk factors associated with 30-day unplanned
readmission. After adjusting for age, sex, race/ethnicity, insurance status, annual median
household income, facility type, hospital hepatectomy volume, Charlson-Deyo score, and
tumor grade, males had 29% increased odds of experiencing a 30-day unplanned
readmission than females. Hispanics had 39% increased odds of 30-day unplanned
readmission compared to non-Hispanic white. Patients with Charlson-Deyo scores of 1
and 2 had 31% and 55% increased odds experiencing 30-day unplanned readmission
compared to patients with Charlson-Deyo score of 0, respectively. In addition, patients
treated in hospitals where annual hospital hepatectomy volume was 4-15/year had 38%
lower odds experiencing 30-day unplanned readmission compared to those treated in
hospitals performing more than 15 hepatectomies annually.

Effect of 30-day unplanned readmission on conditional 90-day mortality
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The conditional 90-day mortality refers to those patients who died between 31 and
90 days after partial hepatectomy. The conditional 90-day mortality rate for patients with
an unplanned readmission was 10.0% while the rate for those not readmitted was only
4.5%. The crude odds of conditional 90-day mortality was 2.342 (95% CI: 1.663 - 3.225,
p<0.001) times higher in patients with a 30-day unplanned readmission than in patients
without a readmission (Table 3.3). After adjusting for sex, age group, race/ethnicity,
insurance status, Charlson -Deyo score and annual hospital hepatectomy volume, the
odds of conditional 90-day mortality was similar to the crude odds, 2.325 (95% CI: 1.643
- 3.219, p<0.001) (Table 3.3).

Association between 30-day unplanned readmission and conditional 90-day mortality in
select subgroups (Table 3.4)

Age and sex
Patients 75 years and older that experienced 30-day unplanned readmission had
the highest odds of conditional 90-day mortality (OR 3.081, 95% CI 1.453-6.044, p=0.002)
followed by age 50-64 (OR 2.846, 95% CI 1.626-4.728, p<0.001). Female patients who
had 30-day unplanned readmission, had twice the odds of 90-day mortality (OR 3.809,
95% CI 1.909-7.114, p<0.001) compared to male patients (OR 1.985 95% CI 1.314-2.903,
p<0.001).

Race/Ethnicity and insurance type
The association between 30-day unplanned readmission and conditional 90-day
mortality was only significant among white, non-Hispanic patients (OR 3.287, 95% CI
2.164-4.862, p<0.001). Thirty-day unplanned readmission was also associated with a 11fold (OR 11.247, 95% CI 1.666-77.316, p=0.01) increased odds of conditional 90-day
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mortality among uninsured patients, 2.4 fold (OR 2.391, 95% CI 1.347-4.012, p<0.01)
increased odds in privately insured patients and twice the odds (OR 2.140, 95% CI 1.2523.472, p<0.01) in patients enrolled in Medicare or other government insurance programs.

AFP tumor marker and cirrhosis score
AFP tumor marker was reported for 5,229 (out of 7,696) patients, of whom, more
than one-third (n=1,914, 36.6%) had negative/normal AFP values and the rest (n=3,315,
63.4%) had positive/elevated values. Among patients with an elevated AFP, the adjusted
odds of conditional 90-day mortality after partial hepatectomy were 2.1 times higher for
those with a 30-day unplanned readmission than those without. No significant association
between 30-day unplanned readmission and conditional 90-day mortality was noted in
patients with a normal AFP. In addition to AFP, NCDB also provides liver fibrosis
information based on Ishak score (Ishak et al., 1995) starting in 2004. For our dataset,
only 1,805 (out of 7,696) patients had complete fibrosis information where 1,099 patients
were reported as having none-moderate fibrosis and 706 having severe fibrosis to
cirrhosis. Significant impact of 30-day unplanned readmission on conditional 90-day
mortality was identified only in patients with Ishak score of 5-6 (adjusted OR 3.768, 95%
CI 1.478-8.815, p=0.003).
A significant impact of 30-day unplanned readmission on conditional 90-day
mortality was observed across all subgroups of Charlson-Deyo Score and showed a linear
trend with increasing score. Specifically, 30-day unplanned readmission was associated
with 2.0 (OR 2.002, 95% CI 1.139-3.312, p=0.01), 2.4 (OR 2.435, 95% CI 1.257-4.383,
p<0.01) and 2.7 (OR 2.741, 95% CI 1.410-5.029, p<0.01) fold increased odds of having
90-day mortality in patients with Charlson-Deyo scores of 0, 1 and 2, respectively. In
patients treated in facilities that performed more than 15 hepatectomies annually, 30-day
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unplanned readmission increased the odds of 90-day mortality by approximately 4 fold
(OR 3.969, 95% CI 2.312-6.561, p<0.01).

DISCUSSION
In this study, we used one of the largest cancer databases in the world to investigate
the rate and associated risk factors of 30-day unplanned readmission after partial
hepatectomy and evaluated how this readmission impacted conditional 90-day mortality
in patients with HCC. The study found that the overall 30-day unplanned readmission rate
following partial hepatectomy was 5.2%, which was much lower than previously reported
rates of 10.2% for partial hepatectomy from the American College of Surgeons National
Surgical Quality Improvement Program (ACS-NSQIP) dataset (Kim et al., 2015), 14.2%
from a hospital-based study (Spolverato et al., 2014) and 15.5% from a population-based
study using Surveillance, Epidemiology, and End Results (SEER) database (Schneider et
al., 2012). Studies on readmission after partial hepatectomy have been very limited and
the definition of readmission varied largely across studies. Readmission at 30-day, 90-day
and 1 year after discharge following a surgical procedure has been reported (Lucas et al.,
2014; Kimbrough et al., 2014; Egger et al., 2015; Tamandl et al., 2015; Brudvik et al.,
2015). To our knowledge, this study was the first to describe the 30-day unplanned
readmission rates after partial hepatectomy in patients with HCC using a national
database that captures 70% of newly diagnosed cancer cases. The NCDB collects
information only on 30-day readmission, which includes unplanned readmission, planned
readmission and both planned and unplanned readmission; therefore, we were unable to
compare 90-day or 1-year readmission with other studies. The lower rate of 30-day
unplanned readmission for the current study may partially reflect the fact that NCDB only
captures patients readmitted to the same treating facility. In another words, if a patient
was discharged from hospital A, but readmitted to hospital B due to postoperative
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complications, then the patient was not considered having an unplanned readmission in
NCDB. In our study, patients with an unplanned 30-day readmission resided in zip code
areas that were significantly closer to their treating facility than those without readmission
(37.6 miles vs 56.1 miles, p<0.001). Saunders and colleagues also found that patients
living far away from treating hospitals would go to a closer hospital for readmission either
because of convenience or patients being too sick to return to the original hospital
(Saunders et al., 2014). In a study that used States Inpatient Database of 5 states,
researchers reported that almost 1 of 4 readmissions were to a different hospital than the
original facility (Tapper, Halbert, & Mellinger, 2016).
Risk factors independently associated with 30-day unplanned readmission were sex,
race/ethnicity, Charlson-Deyo score, and annual hospital hepatectomy volume.
Consistent with other studies (Spolverato et al., 2014; Brudvik et al., 2015), our results did
not indicate a significant association between age and 30-day unplanned readmission.
However, we found that male gender was associated with a 29% increased odds of 30day unplanned readmission. One explanation may be the negative role of liver
fibrosis/cirrhosis in readmission (Chirapongsathorn et al., 2020). Our study showed that
41.9% of males had severe fibrosis or cirrhosis compared to 32.6% of females who had
the same condition (p<0.001). The other explanation is the lack of social support which is
not directly measured in NCDB. Previous studies have reported that men are less likely to
seek help and more likely to be socially isolated than women, which contributes to worse
health outcomes (Woz et al., 2012; Tang & Maselli, 2014). Our study also indicated a
racial disparity on 30-day unplanned readmission. Hispanics had a 39% increased odds
of 30-day unplanned readmission than Caucasians. The risk of 30-day readmission after
partial hepatectomy in Hispanics had not been reported and the comparison was often
made between white and non-white races in past studies, especially hospital-based
studies. Even though individual comorbidity cannot be identified in NCDB, research has
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reported higher prevalence of obesity, diabetes, hypertension and metabolic syndrome
among Hispanic patients (Guzman, 2012). These chronic conditions along with language
barriers and lower overall health literacy (Mochari-Greenberger et al., 2015), have
adversely impacted Hispanics’ health behavior and clinical outcomes including
readmission.
The current study found that the Charlson-Deyo score was significantly associated
with 30-day unplanned readmission. Males and Hispanics had higher proportion of index
score>0. The overall odds of 30-day unplanned readmission were 1.3 and 1.6 times higher
in patients with an index score of 1 and ≥2, respectively when compared to the index score
of 0. This finding was consistent with a study that reported 30-day unplanned readmission
among general medicine patients at six academic medical centers (Hasan et al., 2010).
They used self-reported Charlson comorbidity index of 0-9 and found the odds of
readmission increased 9% with each one-unit increase in the index. A second study that
used the NCDB for parotid cancer research discovered 57% and 108% increased odds of
readmission for the index scores of 1 and >1, respectively (Zhan et al., 2016). For major
abdominal procedures, an index score ≥3 was associated with a 77% increase in the odds
of 90-day readmission among patients recorded in the Truven Health MarketScan
Commercial Claims and Encounters Database (Kim et al., 2016). We believe a higher
Charlson-Deyo index has a negative impact on 30-day unplanned readmission. The
impaired physiological system and depleted physiological reserve at discharge puts
patients in a vulnerable situation (Krumholz, 2013) where comorbidities might be
exacerbated and lead to new acute conditions that increase the risk of readmission (Donzé
et al., 2013).
The major goal of this study was to evaluate the impact of 30-day unplanned
readmission on conditional 90-day mortality. Patients who died between 30 and 90 days
were considered as having conditional 90-day mortality. The conditional 90-day mortality
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rate was 10.0% in patients who experienced a 30-day unplanned readmission and was
4.5% among those without readmission. This translated to an unadjusted 86% higher rate
of conditional 90-day mortality in patients with a 30-day unplanned readmission than those
without. After adjusting for covariates, a higher odds of 2.3 for conditional 90-day mortality
was noted among patients readmitted within 30 days. This is the first time that the effect
of 30-day unplanned readmission in future conditional 90-day mortality following a partial
hepatectomy among patients with HCC is reported using a national cancer database. This
association is likely reflective of the impact of comorbidities and perioperative
complications on mortality. We have shown that Charlson-Deyo score was a strong,
independent predictor of 30-day unplanned readmission. Comorbidity has been reported
as an independent risk factor of postoperative complications (Inokuchi et al., 2014), and
postoperative complication was also significantly associated with 90-day mortality (Tzeng
et al., 2014). This finding is in concordance with outcomes derived from 2006-2010 SEERMedicare database showing a 6-fold increase in odds of 90-day mortality among lung
cancer patients with a 30-day readmission history (Hu et al., 2014). One earlier study using
the 1992-2002 SEER-Medicare database found that among patients undergoing
colectomy, 1-year postoperative mortality was 16% in those readmitted within 30 days of
discharge compared to 7% in those not readmitted (Greenblatt et al., 2010). Awareness
of patient 30-day readmission status may assist further monitoring and managing
postoperative care that aims to reduce 90-day mortality.
The finding that 30-day unplanned readmission affects 90-day mortality is especially
obvious in certain subgroups of patients. More specifically, among patients 75 years and
older, 30-day unplanned readmission was associated with a 3.1-fold increase in
subsequent conditional 90-day mortality. The significant association between 30-day
readmission and 90-day mortality was observed in both sexes, but the odds were higher
in female than male patients (OR: 3.809 and 1.985, respectively). This indicated that
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despite the overall lower odds of short-term readmission and mortality for females, the
odds of 90-day mortality was higher than males once female patients were readmitted
within 30 days of discharge. One important finding of this study was that the impact of 30day readmission on conditional 90-day mortality was only significant among the white,
non-Hispanic group. This may be related to the relatively older age of patients in this group
compared to other race groups. Patients aged 65 years and above accounted for 20% in
the white, non-Hispanic group, while they accounted for only 11.4% in all other groups
combined.
Variations in the risk of 90-day mortality were also found among patients enrolled in
different insurance programs. In the subgroup of uninsured patients, the odds of 90-day
mortality were 21 times higher for those with a 30-day readmission history compared to
those without. On the other hand, among patients with private insurance, the odds was
only 1.9 times higher. Previous studies have demonstrated that uninsured patients had
poorer survival than privately insured patients and this may be related to poorer overall
health with more comorbidities (Kwok et al., 2010) and no or inadequate management of
chronic conditions prior to cancer diagnosis (Slatore et al., 2010).
The association between 30-day unplanned readmission and conditional 90-day
mortality was significant in patients with an elevated AFP tumor marker and in patients
with severe liver fibrosis. However, this significant association was not noted in patients
with a negative AFP tumor marker and in patients with none-moderate liver fibrosis. No
studies have compared the impact of AFP and cirrhosis on 30-day unplanned readmission
and conditional 90-day mortality. However, previous studies have indicated that markedly
elevated serum AFP was an indicator of poor prognosis (Peng et al., 2004.). Decreased
survival among HCC resection patients was not associated with progressive increase in
fibrosis stage until complete cirrhosis is established (Wang et al., 2013). Severe
fibrosis/cirrhosis may diminish liver coagulability (Amitrano, Guardascione, Brancaccio, &
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Balzano, 2002) and increase susceptibility to infection (Thalheimer et al., 2005), which
may then lead to the rise of postoperative complications and the risk of mortality.
Our study has several limitations. Given the retrospective nature of the NCDB, we
were able to demonstrate associations and not causative relationships between predictors
and outcomes. NCDB only records readmissions to the same hospital, consequently the
recorded 30-day unplanned readmission may underestimate the true readmission rate due
to not tracking patients readmitted to a different hospital. The causes of 30-day unplanned
readmission are not collected in NCDB making the analysis for the most common causes
for early readmission unfeasible. Although NCDB included liver fibrosis information, data
were not available for more than three quarters of patients; therefore, we were unable to
verify the conclusion from one study that claimed neither cirrhosis nor fibrosis is
associated with readmission (Kimbrough et al.,2014). Instead, we addressed the
association between 30-day unplanned readmission and conditional 90-day mortality by
fibrosis score.
Despite these limitations, NCDB provides national level readmission and mortality
information with a large sample size for HCC patients undergoing partial hepatectomies,
which enables us to explore the relationship between 30-day unplanned readmission and
conditional 90-day mortality among subgroups. This is the first study based on NCDB to
identify multiple predictors of 30-day unplanned readmission for HCC patients following
partial hepatectomies. Most importantly, this was the first time to report that 30-day
unplanned readmission was significantly associated with conditional 90-day mortality after
partial hepatectomy. The study also detailed how this association varied among different
subgroups.

CONCLUSION
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In this study, we demonstrated that male sex, Hispanic ethnicity, higher CharlsonDeyo score, and higher annual hospital hepatectomy volume were significant predictors
of 30-day unplanned readmission. We further demonstrated that 30-day unplanned
readmission had a significant impact on conditional 90-day mortality among patients with
HCC who underwent partial hepatectomies. The study documented more than 3-fold
increases in the odds of 90-day-mortality in subgroups of patients 75 years and older,
female sex, white, non-Hispanic race, uninsured, with severe fibrosis/cirrhosis and treated
in hospitals with more than 15 hepatectomies annually.
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Patients 18 years and older, with only HCC
or HCC and one later cancer diagnosis who
underwent liver surgery
(n=18,751)
Excluded (n=8,696)
-

Total hepatectomy and
transplant (n=8,696)

Patients underwent partial hepatectomy
(n=10,055)

Patients
without 30-day
readmission
(n=9,051)

Patients with 30day unplanned
readmission
(n=522, 5.2%)

Patients with other
types of 30-day
readmission
(n=160)

Patients with
unknown 30-day
readmission status
(n=322)

Excluded (n=482)
-

-

Patients with / without
30-day unplanned
readmission
(n=9,573)

30-day planned readmission
(n=152)
Both 30-day planned and
unplanned readmission
(n=8)
Unknown 30-day
readmission (n=322)

Excluded (n=1,877)
-

Study population
(n=7,696)

Figure 3. 1. Flow chart of study population

Unknown 90-day mortality
(n=1,405)
Survived less than 30 days
or surgery date missing
(n=472)
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Table 3. 1a. Demographic and facility characteristics of patients undergoing partial hepatectomy (20042012), stratified by 30-day unplanned readmission
Variable
All, n (%)
30-Day Unplanned Readmission, n (%)
p-value
No
Yes
Total
7696
7254
442
Age (mean years± SDa)
61.7 ± 12.9
61.8 ± 12.9
60.2 ± 13.5
0.010
18-49
1074 (14.0)
994 (13.7)
80 (18.1)
0.059
50-64
3283 (42.7)
3096 (42.7)
187 (42.3)
65-74
2080 (27.0)
1969 (27.1)
111 (25.1)
>74
1259 (16.4)
1195 (16.5)
64 (14.5)
Gender
0.015
Male
5329 (69.2)
5000 (68.9)
329 (74.4)
Female
2367 (30.8)
2254 (31.1)
113 (25.6)
Race/Ethnicity
0.003
White, non-Hispanic
4468 (58.1)
4218 (58.2)
250 (56.6)
Black, non-Hispanic
1030 (13.4)
971 (13.4)
59 (13.4)
Hispanic
974 (12.7)
895 (12.3)
79 (17.9)
Others, non-Hispanic
1224 (15.9)
1170 (16.1)
54 (12.2)
Insurance Status
0.003
Not insured
245 (3.2)
227 (3.1)
18 (4.1)
Private insurance
3216 (41.8)
3014 (41.6)
202 (45.7)
Medicaid
707 (9.2)
661 (9.1)
46 (10.4)
Medicare or other
3214 (41.8)
3042 (41.9)
172 (38.9)
Unknown
314 (4.1)
310 (4.3)
4 (0.9)
Percentage of residents not
0.917
graduated from high school
29% or more
1547 (20.1)
1454 (20.0)
93 (21.0)
20%-28.9%
1729 (22.5)
1630 (22.5)
99 (22.4)
14%-19.9%
1620 (21.0)
1526 (21.0)
94 (21.3)
Less than 14%
2478 (32.2)
2342 (32.3)
136 (30.8)
Missing
322 (4.2)
302 (4.2)
20 (4.5)
Annual median household income
0.091
Less than $30,000
1156 (15.0)
1083 (14.9)
73 (16.5)
$30,000-$34,999
1290 (16.8)
1228 (16.9)
62 (14.0)
$35,000-$45,999
2039 (26.5)
1905 (26.3)
134 (30.3)
$46,000 or more
2891 (37.6)
2738 (37.7)
153 (34.6)
Missing
320 (4.2)
300 (4.1)
20 (4.5)
Urban or rural residence
0.333
Metro
6283 (81.6)
5920 (81.6)
363 (86.1)
Urban
991 (12.9)
942 (13.0)
49 (11.1)
Rural
113 (1.5)
104 (1.4)
9 (2.0)
Missing
309 (4.0)
288 (4.0)
21 (4.8)
Distance to facility
0.206
Less than 12.5 miles
3390 (44.0)
3192 (44.0)
198 (44.8)
12.5 to 49.9 miles
2334 (30.3)
2188 (30.2)
146 (33.0)
50 miles or more
1810 (23.5)
1720 (23.7)
90 (20.4)
Missing
162 (2.1)
154 (2.1)
8 (1.8)
Facility type
0.060
Community
230 (3.0)
223 (3.1)
7 (1.6)
Comprehensive
1616 (21.0)
1540 (21.2)
76 (17.2)
Academic/research
4986 (64.8)
4683 (64.6)
303 (68.6)
Other
436 (5.7)
410 (5.7)
26 (5.9)
Missing
428 (5.6)
398 (5.5)
30 (6.8)
Annual hospital hepatectomy volume
0.013
<4/year
2633 (34.2)
2492 (34.4)
141 (31.9)
4-15/year
2383 (31.0)
2264 (31.2)
119 (26.9)
>15/year
2680 (34.8)
2498 (34.4)
182 (41.2)
a SD, standard deviation
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Table 3. 1b. Clinical characteristics of patients undergoing partial hepatectomy (2004-2012), stratified by 30day unplanned readmission
Variable
All, n (%)
30-Day Unplanned Readmission, n (%)
p-value

Total
aAFP tumor marker
Negative/normal
Positive/elevated
Unknown
Fibrosis score
0-4 (none-moderate fibrosis)
5-6 (severe fibrosis/cirrhosis)
Unknown
Charlson-Deyo score
0
1
2
NCDB analytic stage group
I
II
III
IV
Unknown
Tumor grade
I
II
III
IV
Not determined
Tumor size
≤30 mm
>30mm and ≤50 mm
>50 mm
Unknown
Surgical procedure
Wedge or segmental resection
Lobectomy
Extended lobectomy
Unknown type
aAFP: alpha-fetoprotein

7696

No
7254

Yes
442

1914 (24.9)
3315 (43.1)
2467 (32.1)

1818 (25.1)
3124 (43.1)
2312 (31.9)

96 (21.7)
191 (43.2)
155 (35.1)

1099 (14.3)
706 (9.2)
5891 (76.5)

1024 (14.1)
652 (9.0)
5578 (76.9)

75 (17.0)
54 (12.2)
313 (70.8)

4236 (55.0)
2203 (28.6)
1257 (16.3)

4031 (55.6)
2067 (28.5)
1156 (15.9)

205 (46.4)
136 (30.8)
101 (22.9)

3268 (42.5)
1821 (23.7)
1576 (20.5)
291 (3.8)
740 (9.6)

3102 (42.8)
1706 (23.5)
1469 (20.3)
276 (3.8)
701 (9.7)

166 (37.6)
115 (26.0)
107 (24.2)
15 (3.4)
39 (8.8)

1547 (20.1)
3378 (43.9)
1408 (18.3)
251 (3.3)
1112 (14.4)

1467 (20.2)
3163 (43.6)
1323 (18.2)
246 (3.4)
1055 (14.5)

80 (18.1)
215 (48.6)
85 (19.2)
5 (1.1)
57 (12.9)

1410 (18.3)
1816 (23.6)
4202 (54.6)
268 (3.5)

1317 (18.2)
1712 (23.6)
3969 (54.7)
256 (3.5)

93 (21.0)
104 (23.5)
233 (52.7)
12 (2.7)

4099 (53.3)
2434 (31.6)
551 (7.2)
612 (8.0)

3863 (53.3)
2298 (31.7)
518 (7.1)
575 (7.9)

236 (53.4)
136 (30.8)
33 (7.5)
37 (8.4)

0.202

0.011

<0.001

0.115

0.028

0.392

0.965
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Table 3. 2. Multivariate logistic regression analysis of the risk factors for 30-day unplanned readmission after
partial hepatectomy
Variable
Total
Readmission
Adjusted ORa (95% CIb) p-value
n (%)
Total
7696
442 (5.7)
Age
0.992 (0.980 – 1.004)
0.213
Gender
Female
2367
113 (4.8)
Reference
Male
5329
327 (6.1)
1.294 (1.025 – 1.649)
0.033
Race/Ethnicity
White, non-Hispanic
4468
250 (5.6)
Reference
Black, non-Hispanic
1030
59 (5.7)
0.953 (0.682 – 1.311)
0.774
Hispanic
974
79 (8.1)
1.394 (1.037 – 1.851)
0.025
Others, non-Hispanic
1224
54 (4.4)
0.746 (0.532 – 1.026)
0.080
Insurance Status
Private insurance
3216
202 (6.3)
Reference
Not insured
245
18 (7.3)
0.901 (0.465 – 1.592)
0.738
Medicaid
707
46 (6.5)
0.821 (0.549 – 1.196)
0.320
Medicare or other
3214
172 (5.4)
0.861 (0.663 – 1.119)
0.264
Unknown
314
4 (1.3)
0.216 (0.062 – 0.572)
0.006
Annual median household income
$46,000 or more
2891
153 (5.3)
Reference
$35,000-$45,999
2039
134 (6.6)
1.187 (0.923 – 1.525)
0.181
$30,000-$34,999
1290
62 (4.8)
0.770 (0.553 – 1.059)
0.114
Less than $30,000
1156
73 (6.3)
1.152 (0.841 – 1.566)
0.372
Facility type
Academic/research
4986
303 (6.1)
Reference
Community
230
7 (3.0)
0.567 (0.234 – 1.172)
0.162
Comprehensive
1616
76 (4.7)
0.831 (0.611 – 1.120)
0.229
Other
436
26 (6.0)
1.035 (0.657 – 1.564)
0.876
Annual hospital hepatectomy volume
>15/year
2680
182 (6.8)
Reference
4-15/year
2383
119 (5.0)
0.619 (0.477 – 0.799)
<0.001
<4/year
2633
141 (5.4)
0.765 (0.575 – 1.015)
0.065
Charlson-Deyo score
0
4236
205 (4.8)
Reference
1
2203
136 (6.2)
1.309 (1.032 – 1.658)
0.026
2
1257
101 (8.0)
1.550 (1.179 – 2.025)
0.002
Tumor grade
I
1547
80 (5.2)
Reference
II
3378
215 (6.4)
1.180 (0.896 – 1.569)
0.248
III
1408
85 (6.0)
1.192 (0.855 – 1.664)
0.299
IV
251
5 (2.0)
0.834 (0.271 – 2.066)
0.722
Not determined
1112
57 (5.1)
0.943 (0.644 – 1.369)
0.760
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Table 3. 3. Association between 30-day unplanned readmission and 90-day mortality after partial
hepatectomy
Predictor
Unadjusted ORa (95% CIb) p-value
Adjustedc ORa (95% CIb) p-value
30-day unplanned
readmission
No
Reference
Reference
Yes
2.342 (1.663-3.225)
<0.001
2.325 (1.643-3.219)
<0.001
a OR: odds ratios; b CI: confidence interval
c Adjusted for age, sex, race/ethnicity, insurance status, annual hospital volume and Charlson-Deyo score.
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Table 3. 4. Impact of 30-day unplanned readmission on conditional 90-day mortality in selected subgroups
Unadjusted
Adjusted
Factor
ORa
95% CIb
p value ORa
95% CIb
p value
Age
18-49
1.442 0.423-3.730
0.499 1.440 0.413-3.871
0.512
50-64
2.736 1.578-4.493
<0.001 2.846 1.626-4.728
<0.001
65-74
1.993 0.983-3.677
0.039 1.947 0.953-3.628
0.049
75 and above
3.190 1.525-6.155
0.001 3.081 1.453-6.044
0.002
Sex
Male
1.960 1.303-2.854
<0.001 1.985 1.314-2.903
<0.001
Female
3.777 1.946-6.818
<0.001 3.809 1.909-7.114
<0.001
Race/Ethnicity
White, non-Hispanic
3.334 2.213-4.887
<0.001 3.287 2.164-4.862
<0.001
Black, non-Hispanic
1.369 0.403-3.512
0.559 1.165 0.336-3.080
0.781
Hispanic
1.095 0.373-2.582
0.851 1.186 0.396-2.880
0.731
Others, non-Hispanic
1.033 0.166-3.485
0.964 1.374 0.214-4.945
0.677
Insurance Status
Private
2.521 1.432-4.187
<0.001 2.391 1.347-4.012
0.002
Not insured
7.367 1.446-31.021
0.008 11.247 1.666-77.316
0.011
Medicaid
1.653 0.478-4.381
0.361 1.692 0.471-4.766
0.362
Medicare or others
2.180 1.281-3.516
0.002 2.140 1.252-3.472
0.003
AFPc tumor marker
Negative/normal
2.264 0.853-5.021
0.066 2.716 0.805-4.952
0.088
Positive/elevated
2.545 1.548-4.005
<0.001 2.149 1.245-3.529
0.004
Fibrosis score
0-4 (none-moderate)
2.146 0.717-5.212
0.123 2.511 0.820-6.342
0.072
5-6 (severe fibrosis/cirrhosis)
3.606 1.471-7.987
0.003 3.768 1.478-8.815
0.003
Charlson-Deyo score
0
2.067 1.187-3.379
0.006 2.002 1.139-3.312
0.010
1
2.270 1.182-4.032
0.008 2.435 1.257-4.383
0.005
2
2.658 1.385-4.795
0.002 2.741 1.410-5.029
0.002
Annual Hospital Volume
<4/year
1.881 1.012-3.244
0.032 1.667 0.888-2.910
0.089
4-15/year
1.682 0.774-3.238
0.149 1.633 0.743-3.191
0.182
>15/year
3.749 2.231-6.095
<0.001 3.969 2.312-6.561
<0.001
a OR: odds ratios; b CI: confidence interval; c AFP: alpha-fetoprotein
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CHAPTER 4
NAFLD DOES NOT INCREASE THE RISK OF POSTOPERATIVE ADVERSE
OUTCOMES FOLLOWING HEPATIC RESECTION FOR HEPATOCELLULAR
CARCINOMA
ABSTRACT
Background Non-alcoholic fatty liver disease (NAFLD) is increasingly found in patients
with hepatocellular carcinoma (HCC). The aim of this study was to analyze the impact of
NAFLD on postoperative outcomes following hepatectomy for HCC by using a national
database representative of the US population.
Methods Hospitalizations of HCC patients with NAFLD were identified in the National
Inpatient Sample (NIS) from 2005 through 2014 using ICD-9-CM codes. The prevalence
of NAFLD in patients with HCC and trends over the 10-year period were determined.
Univariate and multivariable regression analyses were performed to evaluate the impact
of NAFLD and other risk factors on postoperative outcomes including frequencies of
complications, in-hospital mortality and length of stay (LOS).
Results Among 31,015 hospitalizations with primary diagnosis of HCC, prevalence of
NAFLD and hospital admissions with NAFLD increased 24.5% and 35.2% respectively
over the course of the study . From this cohort, 283 NAFLD and 3,081 non-NAFLD patients
who underwent either partial hepatectomy or hepatic lobectomy were further identified. In
multivariable analyses, factors associated with increased occurrence of postoperative
complications included comorbidity index and hepatic lobectomy. Risk factors of inhospital mortality were morbidity index, hepatic lobectomy, and five postoperative
complications. Risk factors associated with increased odds of longer LOS comprised
female gender, comorbidity index, and hepatic lobectomy. Postoperative complications
associated with increased odds of longer LOS included cardiovascular complications,
bleeding, pulmonary complications, infection, digestive system complications, wound
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complications, DVT, and acute renal failure. NAFLD was not predictive of increased
occurrence of postoperative complications and in-hospital mortality. NAFLD was
associated with 9% reduced hospital length of stay.
Conclusion HCC with NAFLD may not carry higher surgical risks of postoperative
complications, in-hospital mortality and prolonged hospital LOS when compared to HCC
occurring on classical liver diseases.

INTRODUCTION
In the United States, the age-adjusted mortality rate of liver cancer increased by 43%
between 2000 and 2016 (Xu, 2018). Hepatocellular carcinoma (HCC) is the most
prevalent primary liver cancer accounting for 80-90% of all primary liver cancers (Chacko
& Samanta, 2016). Surgical resection or transplantation are the only potentially curative
treatment options for HCC. (Tsim et al., 2010). Historically, liver resection has been
associated with high mortality of 10-20% and morbidity of 20-40% (Martínez-Mier et al.,
2016). Due to the substantial improvement of perioperative management and advances
in surgical techniques, the mortality and morbidity rates after liver resection have dropped
significantly (Yamazaki & Takayama, 2017).
The global rise in the prevalence of obesity has significantly contributed to the increase
of non-alcoholic fatty liver disease (NAFLD), the most common cause of chronic liver
disease since first described approximately 30 years ago (Mikolasevic et al., 2016; Pais
et al., 2016). NAFLD is believed to affect 20-30% of the general population in Europe
(Armstrong et al., 2012; Bedogni et al., 2005) and 25-46% in the United States (Chalasani
et al., 2012; Rinella, 2015; Williams et al., 2011). NAFLD represents a range of conditions
characterized by fat accumulation in ≥ 5% of hepatocytes without evidence of significant
alcohol consumption (<30g/day for men and <20g/day for women) (Puri & Sanyal, 2012).
The histologic spectrum of NAFLD ranges from simple hepatic steatosis and nonalcoholic
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steatohepatitis (NASH) to fibrosis and cirrhosis (Alkhouri & McCullough, 2012). It has been
reported that 10%-40% of all individuals diagnosed with NAFLD are at risk for advanced
liver disease including hepatic fibrosis, cirrhosis with an increased risk of HCC (Younossi
et al., 2012), 10%-20% of patients with NAFLD progress to NASH, of which 8.3% develop
cirrhosis. Up to 50% of NASH with cirrhosis advance to HCC (Kew, 2015). Previous
studies have reported the rise in the prevalence of NAFLD, which were documented by
an increased prevalence from 15% in 2005 to 25% in 2010 worldwide (Younossi et al.,
2016), a doubled increase of prevalence in the U.S. from 1988 to 2008 (Younossi et al.,
2011), and a tripled admission of patients with NAFLD to hospitals in the U.S. from 20072014 (Adejumo et al., 2019). However, reports on the prevalence and temporal trend of
NAFLD in hospitalized patients with HCC are limited. Furthermore, the impact of NAFLD
on surgical outcomes following hepatic resection for HCC is not well delineated. Therefore,
the purpose of this study was to describe a 10-year (2005-2014) national trend and pattern
of NAFLD prevalence among patients with HCC and investigate the impact of NAFLD on
adverse outcomes in patients undergoing liver resection for HCC.

METHODS

Data Source and Data Extraction
For this retrospective analysis of preexisting deidentified data, we used the
Nationwide Inpatient Sample (NIS) database, the largest publicly accessible all-payer
inpatient database created and operated by the Agency for Health Research and Quality
(AHRQ). The database represents approximately 20% of all discharges for over 4500 nonfederal community hospitals in the United States. The NIS database contains clinical
variables on source and type of admissions, diagnosis-related groups (DRGs), 25-30
diagnosis codes from the International Classification of Disease, 9th Revision, Clinical
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Modification (ICD-9-CM), 15 ICD-9-CM procedure codes, procedure days from admission,
length of stay (LOS) and discharge status. Demographic characteristics (gender, age,
race/ethnicity) and nonclinical variables including median household income in the
patients’ zip code area and rural/urban residence and expected payment source are also
included. NIS is widely considered the most valid and reliable source of epidemiological
data on inpatient care and outcomes in the United States. On average, NIS dataset
contains about 7 million discharges each year. In this study we extracted data from 2005
– 2014 using standard SAS code provided by HCUP-NIS to ensure the right coding and
labeling for all variables.

Study Population and Variables of Interest
We identified all patients 18 years and older with the primary diagnosis of HCC using
ICD-9-CM codes of 155.0 (Malignant neoplasm of liver, primary) between 2005 and 2014.
This cohort was used as the denominator for the prevalence of NAFLD. NAFLD was
identified from any of the 14 secondary diagnoses using ICD-9-CM codes of 571.5
(cirrhosis of the liver without mention of alcohol), 571.8 (other nonalcoholic liver disease),
and 571.9 (unspecified chronic liver disease without mention of alcohol), excluding
patients with any ICD-9-CM codes that were related to alcoholic use and other etiologies
of Hepatitis A, B and C, and patients with comorbidity of alcohol abuse. We expected 85%
accuracy of identifying NAFLD by using this algorithm (Allen et al., 2018). We then
selected patients who underwent either partial hepatectomy or hepatic lobectomy with
ICD-9-CM procedure codes of 50.22 and 50.3 respectively. Patients who underwent a
liver resection were divided into two groups based on NAFLD status.
There were three primary outcome variables: increased occurrence of postoperative
complications, in-hospital mortality, and hospital length of stay. Postoperative
complications included cardiovascular complications, bleeding/transfusion, pulmonary
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complications, infection/sepsis, wound complications, deep vein thrombosis/pulmonary
embolism, device (Wong & Devereaux, 2019) complications, acute renal failure, acute
liver failure, and other complications.
We extracted demographic information on age, gender (male and female),
race/ethnicity (White, Black, Hispanic and other), insurance status (Medicare, Medicaid,
private, self-pay and no charge), and household income of residence zip-code (1st, 2nd, 3rd,
and 4th quartile). We also collected hospital and procedure related information which
included hospital region (Northeast, Midwest, South, and West), hospital location/teaching
status (rural, urban/nonteaching, and urban teaching), hospital bed size (small, medium,
and large), and surgical procedure (partial hepatectomy and hepatic lobectomy). Finally,
we extracted 29 comorbidities that covered both physical and psychological types of
comorbidities.

Statistical Analysis
To describe the national trend and pattern of NAFLD prevalence in hospitalized HCC
patients, we calculated the prevalence for each year by dividing the number of patients
with a diagnosis of NAFLD by the total number of patients with HCC. Multivariable logbinomial regression model was used to analyze trends in prevalence of NAFLD over time.
The dependent variable in this model was the diagnosis of NAFLD (NAFLD=1; nonNAFLD=0) and the predictor variables were entered for the year, age group, gender, and
race/ethnicity. We compared the differences of demographic characteristics, hospital,
procedure information, comorbidities, and postoperative outcomes between NAFLD and
non-NAFLD cohorts using Chi-square test for categorical variables, independent t-test for
age, and Mann-Whitney U test for LOS. To examine the association between NAFLD and
in-hospital mortality, we fit univariate and multivariable logistic regression models. We also
performed negative binomial regression analysis to address the impact of NAFLD on
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increased occurrence of postoperative complications and LOS. Instead of using 29
individual comorbidities for adjustment in multivariable models, we adopted the
comorbidity index score as one score for all comorbidities. This score was calculated as
a weighted sum of each binary comorbidity variable and has been validated and proved
effective in assessing the influence of comorbidity in models evaluating the risk of inhospital mortality and readmissions using administrative data (Moore et al., 2017). The
final multivariable models included predictors with a p≤0.1 in univariate analysis. We
reported odds ratios and 95% confidence intervals (95% CI) for all regression models.
All statistical analyses were performed using SAS 9.4 (SAS Institute, Inc., Cary, NC)
and IBM SPSS Statistics for Windows, version 25 (IBM Corp., Armonk, N.Y., USA). All
statistical tests are two-sided and a p-value less than 0.05 is considered statistically
significant.

RESULTS

Trends in NAFLD prevalence
We identified 31,015 patients with a primary diagnosis of HCC between 2005 and
2014, of which 2,995 were also diagnosed with NAFLD. Admissions with NAFLD among
hospitalized HCC patients increased approximately 1.4-fold over the 10 years of study
(264 in 2005 and 357 in 2014). The prevalence of NAFLD was 9.4% in 2005 and 11.7%
in 2014 (Table 4.1), representing an increase of 24.5%. Patients 65 and older had
approximately twice the prevalence than those younger than 65 years of age across all
study years. Female patients showed consistently higher prevalence rates over the 10year period. Hispanics had the highest and black had the lowest prevalence rates of
NAFLD, whereas the prevalence among whites fell in between. Each advancing calendar
year was associated with a 3.6% increased prevalence of NAFLD (PR, 1.036, 95% CI,
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1.022-1.049). Prevalence trend over the 10-year period is shown in Figure 4.1. Statistically
significant increases in trend were observed for almost all age, gender, and race/ethnicity
subgroups except for black race and other races. The greatest increase in annual
prevalence of NAFLD was found in females (PR, 1.044, 95% CI, 1.023-1.066, p<0.001),
followed by Hispanic patients (PR, 1.043, 95% CI, 1.015-1.072, p<0.001).

Demographics and clinical characteristics
Among 31,015 patients, 3,364 underwent either partial hepatectomy (n=2,105,
62.6%) or hepatic lobectomy (n=1,259, 37.4%). In patients undergoing liver resection, a
little over half were younger than 65 years (n=1,761, 52.3%) and male patients accounted
for 65.8% (n=2,212). Approximately 51.8% of the study population were white, followed
by other races (16.8%), black (9.8%), and Hispanics (9.7%). Nearly half (45.6%) were
covered by Medicare insurance and 37.4% had private insurance. In addition, nearly one
third (31.9%) of patients were hospitalized in hospitals located in the South and one fourth
(25.6%) in Northeast. Patients were mostly (89.9%) admitted to teaching hospitals in
urban areas and hospitals with a large bed size (80.2%).
When stratified by NAFLD status, patients with NAFLD were older compared to
those without NAFLD (67±11 vs. 62±13, p<0.001) (Table 4.2). Higher proportion of white
and Hispanics were in the NAFLD group (59.0% vs 51.2% and 12.4% vs. 8.3%,
respectively) while a higher proportion of black and other races was observed in the nonNAFLD group (10.2% vs. 6.0% and 17.3 vs. 10.6%, respectively). More patients with
NAFLD were covered by Medicare (60.8% vs. 44.2%, p<0.001) and underwent partial
hepatectomy (70.3% vs. 61.9%, p=0.005). Household income, hospital region and bed
size had similar distributions between the NAFLD and non-NAFLD groups (Table 4.2).
Comorbidities associated with NAFLD were coagulopathy (18.4% vs. 11.9%,
p=0.002), chronic pulmonary disease (13.4% vs. 10.3%, p=0.015), coagulopathy (11.9%
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vs. 8.3%, p=0.002),uncomplicated diabetes (37.5% vs. 23.5%, p<0.001), liver disease
(100.0% vs. 40.8%, p<0.001), obesity (18.7% vs. 6.3%, p<0.001), peripheral vascular
disorders (8.1% vs.3.7%, p<0.001), and renal failure (7.8% vs. 4.9%, p=0.036). On the
other hand, patients without NAFLD were more likely to have alcohol abuse (8.9% vs. 0%,
p<0.001), drug abuse (2.5% vs. 0.4%, p=0.023), and metastatic cancer (9.3% vs. 4.9%,
p=0.014). In addition, NAFLD group had higher proportion of patients with cirrhosis (79.5%
vs. 31.4%, p<0.001) (Table 4.3).

Postoperative complications
At least one postoperative complication was reported in approximately 33% of
patients with HCC undergoing liver resection. One hundred sixty-five patients (4.9%) died
during hospitalization. The most common complication was bleeding/transfusion (15.7%)
followed by pulmonary complications (10.8%) and acute renal failure (10.1%). Incidence
of other complications is shown in Table 4.4. Univariate analysis indicated that acute renal
failure was significantly higher in NAFLD group compared to non-NAFLD group (14.1%
vs. 9.7%, p=0.019).
Factors associated with increased occurrence of complications in multivariable
negative binomial regression were comorbidity index (OR, 1.049, 95% CI, 1.044-1.055,
p<0.001) and hepatic lobectomy (vs. partial hepatectomy) (OR, 1.338, 95% CI, 1.1911.504, p<0.001) (Table 4.5). NAFLD was not associated with increased occurrence of
complications (p=0.952).

Mortality
In the univariate analysis, patients with NAFLD were more likely to die during
hospitalization (8.1% vs. 4.6%, p=0.009) (Table 4.4), though these results were not
supported after adjustment for covariates (p=0.625).
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Factors associated with in-hospital mortality included hepatic lobectomy (vs. partial
hepatectomy) (OR, 1.770, 95% CI, 1.164-2.694, p=0.008), comorbidity index (OR, 1.049,
95% CI, 1.030-1.069, p<0.001), and cirrhosis (OR, 1.870, 95% CI, 1.193-2.932, p=0.006)
(Table 4.6).
We found that five complications were associated with 2.8 to 8.2-fold higher odds of
in-hospital mortality (Table 4.6). They were pulmonary complications/ pneumonia (OR,
5.695, 95% CI, 3.698-8.771, p<0.001), infection/sepsis (OR, 2.805, 95% CI, 1.668-4.718,
p<0.001), acute renal failure (OR, 4.449, 95% CI, 2.855-6.932, p<0.001), acute liver failure
(OR, 8.195, 95% CI, 3.998-16.797, p<0.001), and device complications (OR, 6.087, 95%
CI, 1.315-28.176, p=0.021).

Length of stay (LOS)
Demographic factors associated with higher odds of longer LOS were Medicaid
insurance (vs. private) (OR, 1.192, 95% CI, 1.114-1.276, p<0.001), other insurance
programs (vs. private) (OR, 1.129, 95% CI, 1.032-1.235, p=0.008), household income first
quartile (vs. fourth quartile) (OR, 1.083, 95% CI, 1.024-1.145, p=0.005). In addition,
comorbidity index (OR, 1.014, 95% CI, 1.011-1.016, p<0.001), and hepatic lobectomy (vs.
partial hepatectomy) (OR, 1.062, 95% CI, 1.020-1.105, p=0.004) were also associated
with increased odds of longer LOS. Postoperative complications associated with longer
LOS included cardiovascular complications (OR, 1.132, 95% CI, 1.027-1.248, p=0.013),
bleeding complications/transfusion (OR, 1.063, 95% CI, 1.005-1.124, p=0.033),
pulmonary complications/pneumonia (OR, 1.442, 95% CI, 1.354-1.535, p<0.001),
infection/sepsis (OR, 1.728, 95% CI, 1.598-1.868, p<0.001), digestive system
complications (OR, 1.314, 95% CI, 1.216-1.419, p<0.001), wound complications (OR,
1.220, 95% CI, 1.051-1.416, p=0.009), deep vein thrombosis/pulmonary embolism (OR,
1.756, 95% CI, 1.542-2.000, p<0.001), and acute renal failure (OR, 1.366, 95% CI, 1.280-
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1.457, p<0.001). NAFLD and male gender were associated with decreased length of stay
(OR, 0.907, 95% CI, 0.842-0.976, p=0.009 and OR, 0.946, 95% CI, 0.908-0.986, p=0.008
respectively) (Table 4.7).

DISCUSSION
Using the Nationwide Inpatient database, we estimated the annual prevalence of
NAFLD in hospitalized patients with HCC from 2005 to 2014, described prevalence trends
during the 10-year period, and investigated the impact of NAFLD on postoperative
outcomes including increased occurrence of complications, in-hospital mortality and
length of hospital stay. In the cohort of 31,015 patients who were diagnosed with HCC,
depending on specific subgroups, up to 18.0% of patients had coexisting NAFLD. Overall,
the prevalence of NAFLD increased at an average rate of 3.6% per year from 2005 to
2014. This continuous rise in the prevalence of NAFLD in hospitalized patients with HCC
throughout the entire study period is consistent with a recent study focusing on economic
burden of NAFLD among hospitalized adults (Hirode et al., 2019). In addition, we found
that prevalence of NAFLD increased more in patients 65 years and older than younger
patients where an annual increase of 4.2% was observed in the older groups compared
to the annual increase of 2.4% in the younger group. NAFLD prevalence increased 4.4%
annually in females while it only increased 3.1% annually in males. Moreover, prevalence
increased by 121% in male patients 45 years and older compared to patients 45 and
younger. Meanwhile, prevalence jumped 206% between the same age groups in women
indicating higher NAFLD prevalence in postmenopausal women. This might be related to
the loss of protective effect of estrogen in women after menopause. Risk factors of NAFLD
such as insulin resistance, hyperlipidemia and visceral fat accumulation increase in
women after menopause (Lovejoy et al., 2008). Our data showed that the highest
prevalence rate of NAFLD was among Hispanics followed by non-Hispanic white. Non-
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Hispanic black had the lowest prevalence rate. Noticing this race disparities in NAFLD
prevalence, researchers have focused on epigenetic and genome-wide association
studies and proposed that PNPLA3 I148M rs738409 variant might be a major determinant
of race-related differences in hepatic fat accumulation (Xu et al., 2015). Similar to
NAFLD/NASH incidence rates, the highest rate of I148M presence of 49% was among
Hispanics followed by non-Hispanic white (23%) and non-Hispanic black (17%) (Romeo
et al., 2008).
Parallel to the epidemic of obesity and type 2 diabetes, the prevalence of NAFLD in
both children and adults is rapidly rising (Tanaka et al., 2019) and has become the most
common cause of chronic liver disease worldwide. Prior research indicated that NAFLDrelated HCC is increasing gradually, accounting for approximately 35% of HCC cases in
2010 (Dyson et al., 2014). Although there is a lot of ongoing NAFLD research, few studies
have been conducted to compare the surgical outcomes in HCC patients with coexisting
NAFLD and those without NAFLD. Our study revealed that despite being older and having
more comorbidities, only postoperative complication of acute renal failure was higher in
NAFLD group than non-NAFLD group. This may be related to the significant higher
proportions of obesity and diabetes in NAFLD patients. Diabetes is a major cause of
chronic kidney disease and obesity is associated with aggravated course and poor
outcomes of chronic kidney disease (Eknoyan, 2011). Acute kidney disease is a risk factor
of chronic kidney disease and vice versa (Chawla, Eggers, Star, & Kimmel, 2014).
Moreover, in multivariable analysis, NAFLD was not associated with increased occurrence
of postoperative complications. Although mortality was higher in NAFLD group, NAFLD
itself was not an independent risk factor of mortality. Interestingly, NAFLD was found to
be associated with shortened hospital LOS in the present study. Similar findings were
reported in a study using the same NIS database, which indicated a shorter length of stay
in NAFLD patients undergoing bariatric surgery (Mavilia, Wakefield, & Karagozian, 2019).
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Although the study did not explain why NAFLD was associated with a shorter length of
stay, we believe that this might reflect the impact of obesity. Hauck and Hollingsworth
have showed that for surgical patients, obese was associated with shorter hospital stay
and the researchers postulated that obesity seemed to have a protective effect on a range
of medical conditions that could improve health outcomes resulting in shorter hospital stay
(Hauck & Hollingsworth, 2010).
Our data showed that NAFLD was neither associated with increased odds of the
occurrence of postoperative complications nor risks of in-hospital mortality. Furthermore,
NAFLD was associated with 9% reduced hospital LOS. Conflicting findings of the impact
of NAFLD on postoperative outcomes have been reported. Results from a previous single
center-based study showed that steatosis was an independent predictor of complications
(Kooby et al., 2003). However, another study evaluated perioperative risk in 437
sequential patients undergoing bariatric surgery and found that NAFLD was not predictive
of postoperative complications (Ribeireiro et al., 2011). A similar retrospective study
comparing postoperative outcomes in patients with and without NAFLD reported no
significant differences in postoperative complication and mortality (Wu et al., 2011).
Comparable perioperative and long-term outcomes were also reported between HCC
patients with NAFLD and patients with other etiologies following liver resection (Yang et
al., 2020). Moreover, studies have reported better overall outcomes in HCC patients with
NAFLD following liver resection. In a prospective study that followed 247 NAFLD-cirrhosis
patients and 267 hepatitis C-cirrhosis patients, lower cumulative incidence of liver-related
complications was observed in patients with NAFLD-cirrhosis (Bhala et al., 2011). In a
separate study, Reddy and research team (Reddy et al., 2012) compared the long-term
survival outcomes after curative therapy between HCC patients with NASH and patients
with HCV and/or alcoholic liver disease. Results from the study indicated that HCC
patients with NASH had less severe liver dysfunction at the time when the HCC was
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diagnosed. The study further revealed that HCC patients with NASH had better overall
survival than patients with HCV and/or alcoholic liver disease. Although, no prior study
had reported what we have found in our study that NAFLD was associated with a reduced
LOS, Ma and colleagues had reported that prolonged LOS was significantly associated
with reduced rates of overall survival (Ma et al., 2015). This may indicate that a reduced
LOS was associated with favorable long-term survival, which had been proved in patients
following elective colorectal cancer resection (Curtis et al., 2016). Therefore, we believe
in patients with either HCC or cirrhosis, coexistence of NAFLD is not a negative factor in
terms of its impact on postoperative outcomes.
Literature has highlighted that NAFLD is strongly associated with features of the
metabolic syndrome (MS), particularly abdominal obesity and type 2 diabetes (Anstee et
al., 2013). In our study approximately 19% of patients with NAFLD were obese compared
to only 6% of patients in non-NAFLD group. Prior studies have reported different scenarios
of the impact of obesity on postoperative complications. Wong and colleagues have
reported that patients with NAFLD-related HCC were less likely to receive grafts because
of the higher proportion of noncirrhotic patients or compensated cirrhotic patients with low
Model for End-Stage Liver Disease (MELD) score below thresholds required to receive
prioritization for liver transplantation (Wong et al., 2017). The decreased occurrence of
postoperative complication in HCC patients with NAFLD may be partially explained by
obesity paradox where obese patients with prevalent chronic disease show lower mortality
and survival benefit (Curcic et al., 2019; Karagozian et al., 2016). It was postulated that
obese individuals may have good nutritional and physiological reserves and demonstrate
enhanced inflammatory response to injury, which may offset comorbidity and mortality
among obese patients undergoing hepatectomy (Guo et al., 2015).
Our study showed that comorbidity index and surgical procedure were independent
predictors of increased occurrence of postoperative complications, in-hospital mortality,
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and hospital LOS. Cirrhosis was only associated with in-hospital mortality. Similar findings
were reported in a retrospective study reviewing HCC patients undergoing liver resection
between 1983 and 2015, which indicated that major surgical procedures were significantly
associated with major complications and early mortality after liver resection (Lee et al.,
2016). An earlier study also showed that the number of comorbid factors and cirrhosis
were the significant predictors of 30-day mortality after hepatic resection (Bolder et al.,
1999). Our study also identified acute liver failure as the most significant risk factor of inhospital mortality followed by device and pulmonary complications. Eight postoperative
complications showed significant impact on hospital LOS. Prior reviews have summarized
available literature regarding the occurrence of postresection liver failure and exclusively
concluded that liver failure is the major cause of mortality after liver resection (Hammond
et al., 2011; Kauffmann & Fong, 2014). A recent population-based retrospective study with
a large sample size of 2,461 patients undergoing hepatectomy in Sweden also proved that
post-hepatectomy liver failure is the single most important cause of mortality after
hepatectomy (Gilg et al., 2018). Regarding postoperative LOS, Lorenzo and colleagues
believed LOS is most influenced by comorbidities (Lorenza et al., 2005). Another study
estimated the impact of major complications on postresection outcomes and financial
burden and found that the occurrence of a major complication increased mean LOS by
8.7 days and increased risk of death by 9.3% (Idrees et al., 2019).
Our study has several limitations, most of which are related to the use of
administrative database. Incomplete coding (Haut, Pronovost, & Schneider, 2012) and
concerns over the clinical accuracy of ICD-9 diagnosis code (Campbell et al., 2011) are
the major ones. In addition, the database does not provide information on HCC stage,
severity of liver disease, tumor grade, and tumor size which may affect postoperative
outcomes. Despite these limitations, findings from this study provided national level
estimates for the prevalence trends of NAFLD across 10 years and evaluated the impact
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of NAFLD on postoperative complications in HCC patients undergoing liver resection. In
summary, our data indicated the significant increase in the prevalence of NAFLD in
hospitalized HCC patients over the course of the study. However, NAFLD was associated
with neither increased occurrence of postoperative complications nor in-hospital mortality.
Furthermore, NAFLD was found to be associated with 9% reduced hospital LOS. Given
the comparable risk of postoperative adverse outcomes in HCC patients with and without
NAFLD, HCC with NAFLD may not be considered carrying higher surgical risks of
postoperative complications, in-hospital mortality and prolonged hospital LOS when
compared to HCC occurring on classical liver diseases.
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Table 4.1. Prevalence of NAFLD among hospitalized HCC patients from 2005 to 2014
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)
Total hospitalized
2805
2470
2955
3582
3288
3224
3446
3046
3135
3064
Total NAFLD
264 (9.4)
209 (8.5)
249 (8.4)
333 (9.3)
286 (8.7)
313 (9.7)
337 (9.8)
304 (10.0)
343 (10.9)
357 (11.7)
Age group (years)
<65
96 (6.4)
78 (5.5)
106 (6.3)
132 (6.3)
104 (5.4)
109 (5.7)
127 (6.4)
113 (6.3)
127 (7.0)
127 (7.1)
≥65
168 (12.9)
131 (12.6)
143 (11.2)
201 (13.5)
182 (13.4)
204 (15.4)
208 (14.4)
191 (15.2)
216 (16.4)
230 (18.0)
Gender
Male
173 (8.7)
133 (7.3)
161 (7.4)
209 (8.1)
179 (7.5)
191 (8.1)
216 (8.4)
205 (9.3)
219 (9.5)
227 (10.0)
Female
91 (11.3)
75 (11.5)
87 (11.3)
124 (12.5)
107 (11.9)
122 (14.3)
121 (13.8)
99 (11.6)
124 14.7)
130 (16.2)
Race/ethnicity
White
139 (11.9)
87 (9.7)
113 (9.2)
156 (9.6)
155 (10.5)
173 (10.4)
200 (11.3)
184 (11.6)
209 (12.7)
209 (12.8)
Black
16 (5.7)
11 (3.7)
10 (3.1)
20 (5.1)
24 (5.4)
14 (3.2)
28 (5.2)
32 (6.4)
27 (5.2)
25 (5.2)
Hispanic
42 (11.3)
42 (11.5)
41 (10.5)
64 (13.9)
38 (9.0)
60 (13.3)
63 (12.7)
49 (11.3)
63 (14.3)
70 (16.3)
Other
19 (5.5)
20 (6.2)
38 (9.7)
34 (6.1)
27 (5.4)
39 (9.8)
23 (5.6)
27 (6.6)
34 (8.8)
39 (10.0)
Unknown
48 (7.5)
49 (8.3)
47 (7.6)
59 (10.7)
42 (9.5)
27 (10.3)
23 (10.6)
12 (9.8)
10 (6.9)
14 (10.5)
Note: NAFLD=non-alcoholic fatty liver disease, HCC=hepatocellular carcinoma
NAFLD prevalence trends were estimated using multivariate log-binomial regression model with NAFLD as outcome and calendar year as a predictor. Gender, age and race/ethnicity
were added to the model. Adjusted prevalence ratio (PR) of year: 1.036, 95% CI 1.022 – 1.049, p<0.001.
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Figure 4. 1. Prevalence of non-alcoholic fatty liver disease overall and by gender from 2005 to 2014 among
hospitalized patients with hepatocellular carcinoma
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Table 4. 2. Demographic and hospital characteristics associated with NAFLD status in hospitalized patients
with HCC and underwent liver resection, 2005-2014
Total
NAFLD
Non-NAFLD
p-value
n (%)
n (%)
n (%)
Total
283
3081
Mean age, y
63 (±13)
67 (±11)
62 (±13)
<0.001
Gender
0.758
Male
2212 (65.8)
186 (65.7)
2026 (65.8)
Female
1146 (34.1)
97 (34.3)
1049 (34.1)
Unknown
6 (0.2)
0 (0)
6 (0.2)
Race
<0.001
White
1743 (51.8)
167 (59.0)
1576 (51.2)
Black
331 (9.8)
17 (6.0)
314 (10.2)
Hispanic
291 (9.7)
35 (12.4)
256 (8.3)
Other
564 (16.8)
30 (10.6)
534 (17.3)
Unknown
435 (12.9)
34 (12.0)
401 (13.0)
Insurance status
<0.001
Medicare
1533 (45.6)
172 (60.8)
1361 (44.2)
Medicaid
377 (11.2)
19 (6.7)
358 (11.6)
Private
1258 (37.4)
77 (27.2)
1181 (38.3)
Other
191 (5.7)
15 (5.3)
176 (5.7)
Unknown
5 (0.1)
0 (0.0)
5 (0.2)
Household income (quartile)
0.701
Frist
786 (23.4)
75 (26.5)
711 (23.1)
Second
775 (23.0)
64 (22.6)
711 (23.1)
Third
829 (24.6)
70 (24.7)
759 (24.6)
Fourth
861 (25.6)
65 (23.0)
796 (25.8)
Unknown
113 (3.4)
9 (3.2)
104 (3.4)
Hospital region
0.092
Northeast
861 (25.6)
85 (30.0)
776 (25.2)
Midwest
651 (19.4)
55 (19.4)
596 (19.3)
South
1074 (31.9)
93 (32.9)
981 (31.8)
West
778 (23.1)
50 (17.7)
728 (23.6)
Hospital location/ teaching status
0.643
Rural
41 (1.2)
3 (1.1)
38 (1.2)
Urban/nonteaching
286 (8.5)
28 (9.9)
258 (8.4)
Urban/teaching
3024 (89.9)
250 (88.3)
2774 (90.1)
Unknown
13 (0.4)
2 (0.7)
11 (0.4)
Hospital bed size
0.103
Small
176 (5.2)
14 (5.0)
162 (5.3)
Medium
477 (14.2)
53 (18.7)
424 (13.8)
Large
2698 (80.2)
214 (75.6)
2484 (80.6)
Unknown
13 (0.4)
2 (0.7)
11 (0.4)
Surgical procedure
0.005
Partial hepatectomy
2105 (62.6)
199 (70.3)
1906 (61.9)
Hepatic lobectomy
1259 (37.4)
84 (29.7)
1175 (38.1)
NAFLD=non-alcoholic fatty liver disease, HCC=hepatocellular carcinoma
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Table 4. 3. Comorbidities associated with NAFLD status in hospitalized patients with HCC and underwent
liver resection, 2005-2014
Total
NAFLD
Non-NAFLD
p-value
n (%)
n (%)
n (%)
Total
3364
283
3081
AIDS
17 (0.5)
1 (0.4)
16 (0.5)
0.706
Alcohol abuse
274 (8.1)
0 (0)
274 (8.9)
<0.001
Deficiency anemias
398 (11.8)
33 (11.7)
365 (11.8)
0.926
Rheumatoid arthritis/collagen
55 (1.6)
4 (1.4)
51 (1.7)
0.759
vascular diseases
Chronic blood loss anemia
35 (1.0)
6 (2.1)
29 (0.9)
0.061
Congestive heart failure
139 (4.1)
17 (6.0)
122 (4.0)
0.098
Chronic pulmonary disease
517 (15.4)
50 (17.7)
467 (15.2)
0.262
Coagulopathy
420 (12.5)
52 (18.4)
368 (11.9)
0.002
Depression
213 (6.3)
25 (8.8)
188 (6.1)
0.071
Diabetes, uncomplicated
831 (24.7)
106 (37.5)
725 (23.5)
<0.001
Diabetes with chronic
92 (2.7)
12 (4.2)
80 (2.6)
0.105
complications
Drug abuse
77 (2.3)
1 (0.4)
76 (2.5)
0.023
Hypertension
1839 (54.7)
166 (58.7)
1673 (54.3)
0.159
Hypothyroidism
269 (8.0)
30 (10.6)
239 (7.8)
0.091
Liver disease
1540 (45.8)
283 (100.0)
1257 (40.8)
<0.001
Lymphoma
22 (0.7)
2 (0.7)
20 (0.6)
0.908
Fluid and electrolyte disorders
795 (23.6)
71 (25.1)
724 (23.5)
0.547
Metastatic cancer
301 (8.9)
14 (4.9)
287 (9.3)
0.014
Other neurological disorders
102 (3.0)
9 (3.2)
93 (3.0)
0.879
Obesity
246 (7.3)
53 (18.7)
193 (6.3)
<0.001
Paralysis
22 (0.7)
4 (1.4)
18 (0.6)
0.098
Peripheral vascular disorders
136 (4.0)
23 (8.1)
113 (3.7)
<0.001
Psychoses
75 (2.2)
9 (3.2)
66 (2.1)
0.258
Pulmonary circulation disorders
63 (1.9)
5 (1.8)
58 (1.9)
0.891
Renal failure
173 (5.1)
22 (7.8)
151 (4.9)
0.036
Solid tumor without metastasis
135 (4.0)
16 (5.7)
119 (3.9)
0.142
Valvular disease
123 (3.7)
13 (4.6)
110 (3.6)
0.380
Weight loss
247 (7.3)
17 (6.0)
230 (7.5)
0.368
Cirrhosis
1191 (35.4)
225 (79.5)
966 (31.4)
<0.001
NAFLD=non-alcoholic fatty liver disease, HCC=hepatocellular carcinoma, AIDS=acquired immune
deficiency syndrome
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Table 4. 4. Postoperative outcomes by NAFLD status in hospitalized patients with HCC, 2005-2014
Total
NAFLD
Non-NAFLD
p-value
n (%)
n (%)
n (%)
Total
3364
283
3081
Complications
Cardiovascular complications
122 (3.6)
11 (3.9)
111 (3.6)
0.807
Bleeding complications/transfusion
527 (15.7)
49 (17.3)
478 (15.5)
0.425
Pulmonary complications/pneumonia
364 (10.8)
38 (13.4)
326 (10.6)
0.140
Infection/sepsis
206 (6.1)
17 (6.0)
189 (6.1)
0.932
Digestive system complications
199 (5.9)
14 (4.9)
185 (6.0)
0.470
Intra-abdominal abscess
107 (3.2)
9 (3.2)
98 (3.2)
1.000
Wound complications
49 (1.5)
3 (1.1)
46 (1.5)
0.561
Deep vein thrombosis/
57 (1.7)
2 (0.7)
55 (1.8)
0.179
pulmonary embolism
Device complications
85 (2.5)
9 (3.2)
76 (2.5)
0.464
Acute renal failure
340 (10.1)
40 (14.1)
300 (9.7)
0.019
Acute liver failure
72 (2.1)
9 (3.2)
63 (2.0)
0.207
Other complications
72 (2.1)
9 (3.2)
63 (2.0)
0.207
Mortality
165 (4.9)
23 (8.1)
142 (4.6)
0.009
LOS (median day, IQR)
6 (4)
6 (4)
6 (4)
0.473
NAFLD=non-alcoholic fatty liver disease, HCC=hepatocellular carcinoma
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Table 4.5. Negative binomial regression analysis of increased occurrence of complications in hospitalized
patients with HCC and underwent liver resection, 2005-2014
Unadjusted
Adjusted
Variable
OR
95% CI
OR
95% CI
p-value
NAFLD
1.133 0.918-1.399
0.994 0.806 -1.224
0.952
Age
1.008 1.003-1.013
NS
Male
1.102 0.969-1.253
NS
Insurance status
Medicaid vs. private
1.138 0.925-1.398
NS
Medicare vs. private
1.219 1.066-1.395
NS
Other vs. private
1.267 0.972-1.650
NS
Household income (quartile)
First vs. fourth
1.304 1.096-1.551
NS
Second vs. fourth
1.158 0.970-1.382
NS
Third vs. fourth
1.258 1.059-1.494
NS
Hepatic lobectomy vs partial hepatectomy 1.423 1.260-1.607
1.338 1.191-1.504
<0.001
Comorbidity index
1.052 1.046-1.057
1.049 1.044-1.055
<0.001
Cirrhosis
1.220 1.078-1.382
NS
OR = odds ratio; CI = confidence interval; NS = non-significant, NAFLD=non-alcoholic fatty liver disease,
HCC=hepatocellular carcinoma
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Table 4. 6. Risk factors for mortality in hospitalized patients with HCC and underwent liver resection, 20052014
Unadjusted
Adjusted
Variable
OR
95% CI
OR
95% CI
p-value
NAFLD
1.830 1.157-2.892
1.176 0.615-2.249
0.625
Age
1.029 1.015-1.043
1.026 1.007-1.045
0.006
Male
1.318 0.933-1.863
NS
Hepatic lobectomy vs partial hepatectomy 2.372 1.727-3.256
1.770 1.164-2.694
0.008
Comorbidity index
1.107 1.092-1.123
1.049 1.030-1.069
<0.001
Cirrhosis
2.603 1.895-3.575
1.870 1.193-2.932
0.006
Complication
Cardiovascular complications
3.132 1.806-5.433
NS
Bleeding complications/transfusion
2.982 2.129-4.176
NS
Pulmonary complications/ pneumonia
21.199 15.027-29.908
5.695 3.698-8.771
<0.001
Infection/sepsis
16.590 11.652-23.620
2.805 1.668-4.718
<0.001
Device complications
6.176 3.611-10.561
6.087 1.315-28.176
0.021
Acute renal failure
17.404 13.126-25.805
4.449 2.855-6.932
<0.001
Acute liver failure
44.041 26.427-73.396
8.195 3.998-16.797
<0.001
Other complications
5.511 3.049 -9.960
NS
OR = odds ratio; CI = confidence interval; NS = non-significant, NAFLD=non-alcoholic fatty liver disease,
HCC=hepatocellular carcinoma
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Table 4. 7. Negative binomial regression analysis of LOS in hospitalized patients with HCC and underwent
liver resection, 2005-2014
Unadjusted
Adjusted
Variable
OR
95% CI
OR
95% CI
p-value
NAFLD
0.948 0.872-1.031
0.907 0.842-0.976
0.009
Age
1.003 1.001-1.005
NS
Male
1.020 0.971-1.071
0.946 0.908-0.986
0.008
Insurance status
Medicaid vs. private
1.268 1.174-1.369
1.192 1.114-1.276
<0.001
Medicare vs. private
1.133 1.077-1.192
NS
Other vs. private
1.158 1.045-1.283
1.129 1.032-1.235
0.008
Household income (quartile)
Frist vs. fourth
1.193 1.117-1.274
1.083 1.024-1.145
0.005
Second vs. fourth
1.119 1.048-1.196
NS
Third vs. fourth
1.116 1.046-1.191
NS
Hospital bed size
Small vs. large
0.871 0.784-0.968
NS
Medium vs. large
0.932 0.872-0.996
NS
Comorbidity index
1.027 1.025-1.029
1.014 1.011-1.016
<0.001
Hepatic lobectomy vs. partial hepatectomy 1.161 1.108-1.217
1.062 1.020-1.105
0.004
Cirrhosis
1.111 1.060-1.166
NS
Complications
Cardiovascular complications
1.359 1.206-1.530
1.132 1.027-1.248
0.013
Bleeding complications/transfusion
1.310 1.232-1.393
1.063 1.005-1.124
0.033
Pulmonary complications/pneumonia
2.194 2.058-2.338
1.442 1.354-1.535
<0.001
Infection/sepsis
2.721 2.513-2.947
1.728 1.598-1.868
<0.001
Digestive system complications
1.653 1.509-1.811
1.314 1.216-1.419
<0.001
Wound complications
1.807 1.510-2.163
1.220 1.051-1.416
0.009
Deep vein thrombosis/
2.545 2.169-2.987
1.756 1.542-2.000
<0.001
pulmonary embolism
Device complications
1.619 1.409-1.859
NS
Acute renal failure
2.085 1.950-2.230
1.366 1.280-1.457
<0.001
Acute liver failure
2.121 1.833-2.453
NS
Other complications
1.530 1.315-1.780
NS
LOS = length of stay; NS = non-significant, NAFLD=non-alcoholic fatty liver disease, HCC=hepatocellular
carcinoma
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CHAPTER 5 DISCUSSION AND CONCLUSIONS

Hepatectomy, the only curative treatment for HCC, is a major surgery and
associated with increased risks of postoperative early mortality, readmission, and other
adverse outcomes. This dissertation project focused on the adverse outcomes which
included 90-day mortality, 30-day unplanned readmission, complications, and hospital
length of stay in HCC patients undergoing hepatectomies. The dissertation project
included three studies.

Summary of current research
In the first study which was described in chapter 2, we reported the 90-day mortality
rate of 10.2%, which was at the higher end of the mortality range. We identified 10 risk
factors including age, sex, race/ethnicity, insurance status, education, Charlson/Deyo
score, annual hospital volume, and surgical procedure that were significantly associated
with 90-day mortality. We also reported 90-day mortality rates of 2.47%, 5.88%, 12.58%,
and 24.67% in low, medium, high, and excessive risk groups respectively. To test the
discriminatory ability of the risk score model, we used receiver operating characteristic
(ROC) and got the area under the curve (AUC) of 0.69. We compared our model with
several models reported from previous research. Our model had similar discriminatory
ability to a study conducted with the widely used P-POSSUM predictive scoring system
for perioperative care (AUC=0.68) (Knoblich et al., 2020). Our study also was comparable
to two studies that used MELD scores to predict postoperative mortality, which showed
the AUC of 0.71 and 0.69 respectively (Fromer et al., 2016; Ghamarnejad et al., 2020).
Studies that incorporated laboratory test variables showed higher AUC values (Hyder et
al., 2013), however, information for these variables are not available for over 60% of the
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cases in NCDB. Among the ten identified risk factors in our study, eight are available
before the surgery and two are available either before the surgery if a biopsy is conducted
or immediately after the surgery. This risk score can quantify patients’ risks for 90-day
mortality after hepatectomy without acknowledgement of detailed information on
postoperative complications and laboratory test values, which could be a useful tool in
improving 90-day mortality after hepatectomy.
In the second study which was included in chapter 3, we described 30-day
unplanned readmission rate in HCC patients following a hepatectomy, identified
associated risk factors and addressed the impact of 30-day unplanned readmission on
conditional 90-day mortality. We reported the 30-day unplanned readmission of 5.2% and
found male gender, Hispanic ethnicity, facility with high hospital hepatectomy volume, and
higher Charlson-Deyo scores were associated with significant higher odds of 30-day
unplanned readmission. Patients with a history of 30-day readmission was associated with
approximately 2.3-fold increased odds of conditional 90-day mortality. The significant
impact of 30-day unplanned readmission on conditional 90-day mortality had
demonstrated in 15 subgroups. The finding of 30-day unplanned readmission rate of 5.2%
is much lower than reports from prior studies. One of the reasons for the low readmission
rate may be partially due to the way that readmission is captured in NCDB where only
readmissions to the same treatment facility are recorded. Our findings that higher
Charlson-Deyo scores were associated with increased odds of 30-day unplanned
readmission were consistent with all previous study indicating the consensus that higher
comorbidities had negative impact on 30-day unplanned readmission. The major goal of
the current study was to evaluate how 30-day unplanned readmission affects conditional
90-day mortality. In subgroup analysis, in terms of age groups, we found that the impact
of 30-day unplanned readmission on conditional 90-day mortality was only significant in
patients 75 years and older. Another interesting finding was that even though male gender

90
was associated with higher odds of 30-day unplanned readmission, females had higher
odds of 90-day mortality than males once they were readmitted within 30 days of discharge.
For the current study, we were the first to investigate the association between 30-day
unplanned readmission on 90-day mortality by AFP level and extent of fibrosis. AFP is
highly expressed in the fetal yolk sac and liver, but not in normal adults’ tissues (Tilghman,
& Belayew, 1982). The elevation of AFP has been shown to correlate with unfavorable
prognosis (Nomura, & Tanabe, 1989). We found that 30-day unplanned readmission
affected 90-day mortality only in patients with an elevated AFP and in patients with severe
liver fibrosis, which may indicate elevated AFP is an indicator of poor prognosis as
reported previously (Peng et al., 2004). The current study was the first to provide national
level estimate for 30-day unplanned readmission and address the impact of readmission
on conditional 90-day mortality. This study might be helpful in improving 30-day unplanned
readmission and 90-day mortality in HCC patients undergoing hepatectomies.
Consistent with previous reports on NAFLD, we found that from 2005 to 2014, the
prevalence of NAFLD increased by 24.5% and admissions to hospitals with NAFLD
increased approximately 35.2%. Each increasing year was associated with 3.6%
increased prevalence. Patients 65 years and older had twice the prevalence as those
younger than 65 years. Due to multiple age-related physiological mechanisms, elderly
individuals are more likely to develop intra-abdominal obesity and metabolic syndrome
which consist of obesity, insulin resistance, dyslipidemia, and hypertension (Bechtold,
Palmer, Valtos, Lasiello, & Sowers, 2006). The greatest increase in annual prevalence of
NAFLD was among females followed by Hispanics. We noted that proportion of female
HCC patients younger than 55 years of age dropped from 21.9% in 2005 to 16.2% in 2015
while that in female HCC patients 55 years and older increased from 78.1% in 2005 to
83.8% in 2014. Previous study speculated that circulating levels of estrogen might have a
protective effect on the development of hepatic steatosis (Carulli et al., 2006). This may
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imply that women have a relatively lower risk of developing NAFLD before menopause,
but the risk increases in postmenopausal women. In contrast, there are no such risk
changes in men. In addition, literature has reported that prevalence of overall obesity and
class 3 obesity had showed significant increasing linear trends among women but not
among men (Flegal et al., 2016). It is expected that the prevalence of NAFLD increases
more rapidly in women. Prevalence of NAFLD also increases greatly in Hispanics. Overall,
Hispanic population has reached nearly 58 million in 2016 accounting for almost half of
the national population growth since 2000 (Flores, 2017). Hispanics had the greatest
increase in the annual prevalence of obesity from 1999-2000 to 2011-2012 than any other
race/ethnicity groups (An, 2014). Also, the greatest increase in the newly diagnosed
elderly individuals with type 2 diabetes between 1994 and 2010 was found in Hispanic
population (McBean, Li, Gilbertson, & Collins, 2004). Given the increase of obesity and
type 2 diabetes, the two main risk factors of NAFLD, it is likely that the prevalence of
NAFLD would increase significantly among hospitalized Hispanic patients with HCC.
Compared to HCC patients without NAFLD, patients with NAFLD had more comorbidities
including obesity, higher complication of acute renal failure, and higher mortality. On the
other hand, more alcohol abuse, drug abuse and metastatic cancer were observed in nonNAFLD group. As discussed previously, NAFLD is closely associated with metabolic
syndromes which include the manifestations of hypertension, dyslipidemia, obesity and
diabetes. Diabetes is a major cause of chronic kidney disease which is also significantly
associated with acute kidney disease. In multivariable analysis, NAFLD did not show to
be independent predictor of increased occurrence of postoperative complications and inhospital mortality. Regarding the impact of NAFLD on postoperative outcome in HCC
patients, literature has not been consistent. Several studies have reported that NAFLD
especially NASH was associated with worse outcomes. However, comparable amount of
studies indicated that NAFLD was not predictive of postoperative complications and
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mortality (Wu et al., 2011), or the outcome between patients with and without NAFLD were
similar (Yang et al., 2020), or NAFLD even showed favorable impact on incidence of liverrelated complications (Bhala et al., 2011) and better overall survival (Reddy et al., 2012).
It has been reported that HCC patients with NASH had less severe liver dysfunction at the
time when the HCC was diagnosed (Reddy et al., 2012). Lower proportion of cirrhotic
individuals and lower MELD score in compensated cirrhotic individuals were noted in HCC
patients with NAFLD (Wong et al., 2017). Interestingly, in the current study, NAFLD was
found to be associated with 9% reduced hospital length of stay. It was noted that HCC
with NAFLD had a significant higher proportion of obesity than those without NAFLD (19%
vs. 6%). Previous study had postulated that individuals with obesity may have a good
nutritional and physiological reserves and demonstrate enhanced inflammatory response
to injury, which may offset comorbidity and mortality among obese patients undergoing
hepatectomy (Guo et al., 2015). The current study found that comorbidity index and
surgical procedure were independent predictors of increased occurrence of postoperative
complications, in-hospital mortality, and hospital LOS while cirrhosis was only associated
with in-hospital mortality. These findings were in consistent with prior studies.
To further verify the impact of NAFLD on increased occurrence of postoperative
complications, in-hospital mortality as well as hospital LOS, we also performed propensity
score (PS) analysis with 1: 1 matching using the nearest neighbor matching method to
obtain matched sets of non-NAFLD patients to each NAFLD patient based on PS scores.
PS is the probability derived through a logistic regression model in which NAFLD was set
as function of patients’ age, gender, race/ethnicity and comorbidities. The PS matched
dataset was then used in multivariable logistic regression and negative binomial
regression analyses. The results from applying PS methods indicated that NAFLD was
not indicative of increased occurrence of postoperative complications, in-hospital mortality,
and prolonged LOS.
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Research Implications
Findings from this dissertation indicated that 90-day mortality after hepatectomy in
HCC patients undergoing hepatectomies was around 10%, though 30-day unplanned
readmission rate was lower at 5.2%, patients with a history of 30-day unplanned
readmission carried higher risk of conditional 90-day mortality. There is room for
improvement of these two important postoperative outcomes. In the first study, we
developed a useful tool – integer valued risk score model that can be applied to predict
90-day mortality, This model quantified the risks of 90-day mortality for each of the
subgroups within respective risk factors by assigning an integer score derived from the
weighting of β coefficients of a logistic regression model, so that total risk score can be
calculated for each individual. Based on total risk score, patients were grouped into low,
medium, high, and excessive risk groups. The corresponding mortality rate in the low risk
group was 2.47% and each increase in the level of risk was associated with approximately
doubled mortality rate, and the highest risk group reached the mortality rate close to 25%.
Clearly, with this this risk score, clinicians can easily identify those who are at more than
the average risk of 90-day mortality immediately after or even before the surgery, so that
special attention may be payed to focus on these high-risk patients in regard to
perioperative care. This useful tool may also be helpful in facilitating communications
between patients and clinicians where a patient should be aware of his/her risk level of
90-day mortality and be more prepared to and compliant with treatment protocols.

Our second study identified higher Charson/Deyo score as the most important risk
factor of 30-day unplanned readmission. This emphasized the significance of comorbidity
management in the post-discharge period as most of readmissions were not related to the
index hospitalization diagnosis but rather to comorbidities (Donzé et al., 2013). It is
estimated that 5% to 79% (median proportion of 27.1%) of readmissions are potentially
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avoidable although the true proportion remains unclear (Van Walraven et al., 2011).
Therefore, careful management and control of common comorbidities after discharge
could improve patients’ overall health condition and reduce early, unplanned readmission.
The finding that a history of 30-day unplanned readmission was associated with 2.3-fold
increased odds of conditional 90-day mortality strengthened the necessity of control for
comorbidities in the post-discharge period to prevent mortality once readmitted.
Even though NAFLD did not seem to affect the frequencies of postoperative
complications or in-hospital mortality, this finding does not imply that the burdens in public
health resulting from NAFLD should be ignored. Rather, the results may just indicate that
liver resection is as safe in HCC patients with NAFLD as in HCC patients with other
etiologies. Since results regarding the impact of NAFLD on postoperative outcomes are
still under debate, more research is needed to truly understand the mechanism that
NAFLD affects human body.

Future Research
Findings of this dissertation increased the knowledge on 90-day mortality, 30-day
unplanned readmission as well as the role of NAFLD in the occurrence of outcomes after
hepatectomy. Given the growing burden of HCC and NAFLD in the US and around the
world, more research should be conducted to address the knowledge gaps and make the
effort to reduce 90-day mortality, 30-day unplanned readmission, and other adverse
outcomes. We suggest that future research may be focused on improving our prediction
model for 90-day mortality by linking mutually beneficial databases. Specifically, we can
link NCDB database with Midwest multi-institutional CoC accredited hospitals. All these
hospitals provide demographic and clinical information to NCDB. We can test the
accuracy/discriminatory ability of our model first by directly applying model algorithms to
patient population queried from linked hospital database. Then, we can add more
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information including detailed preoperative comorbidities, detailed laboratory test values
and perioperative complications to the model. We will observe if, with additional
information, the model will increase its discriminatory ability of predicting predict 90-day
mortality.
For the second study, we believe any research that could follow up comorbidity
management, patients’ care at home and social/psychological support received would be
beneficial. We have demonstrated comorbidity score was most important indicator of 30day unplanned readmission. By comparing readmission outcome between patients with
better management and control of the comorbidities and those without, we will be able to
understand how many readmissions can be avoided due to the management of
comorbidities.
To examine the impact of NAFLD on postoperative outcomes including occurrence
of complications, in-hospital mortality and hospital LOS, we may consider using casecontrol study to investigate the effect of NAFLD on postoperative outcomes. Specifically,
to evaluate the impact of NAFLD on postoperative complications, we can set up the case
as HCC patients with postoperative complication and control as HCC patients without
postoperative complications and then assess how much case and control have exposure
of NAFLD. The case control study could also apply to evaluate the impact of NAFLD on
in-hospital mortality and prolonged hospital LOS. Another suggestion is to evaluate this
association in cross-sectional, large scale research involving multiple centers to increase
the power to detect the difference since current hospital-based studies on the impact of
NAFLD are single-center-based with limited sample size. Research is also needed to
determine how much the impact of NAFLD is affected by obesity paradox, which can be
addressed by examination of NAFLD separately in obese group and no-obese group.
Although we believe obese information is most accurately described in hospital-based
studies while administrative databases often under code this variable, we performed the
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analyses stratified by obesity status for the current study. The results for increased
occurrence of complications indicated that p values and odds ratios of NAFLD were very
close in obese and non-obese patients (p=0.832 and p=0.827; OR=0.951 and OR=0.975
respectively). For the logistic regression models that evaluated the impact of NAFLD on
mortality, the ORs were 0.629 in obese patients and

1.428 in non-obese patients.

However, both were not significant (p=0.801 and p=0.303 respectively). Regarding
hospital LOS, the OR of 0.901 was significant (p=0.013) in non-obese patients while OR
of 0.922 was not significant (p=0.294) in obese patients. Since the sample size of obese
HCC patients was small, we may not have adequate power to detect the effect of NAFLD
to LOS in obese patients.

Conclusion
In summary, based on the β coefficients of risk factors identified by the logistic
regression model, we developed and tested an integer-valued risk score for predicting 90day mortality in HCC patients undergoing hepatectomies. We found this risk score model
could easily quantify each of the patients’ risk level and its discriminatory ability was
comparable to some previously established models derived from the information not
available in NCDB such as MELD scores. We also identified four risk factors of 30-day
unplanned readmission in HCC patients undergoing hepatectomies. Furthermore, we
demonstrated that patients with a history of 30-day unplanned readmission was
associated with 2.3 times higher odds of conditional 90-day mortality and the extent of this
association varied in different subgroups. Lastly, we showed the significant increase in the
prevalence of NAFLD in hospitalized patients with HCC over the 10-year period between
2005 and 2014. However, we noted the similar postoperative adverse outcomes in HCC
patients with and without NAFLD. This finding does not imply that the burdens of NAFLD
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should be ignored. Rather, the results may just indicate that liver resection is as safe in
HCC patients with NAFLD as in HCC patients with other etiologies.

98
REFERENCES
Adami, H. O., Hunter, D. J., & Trichopoulos, D. (Eds.). (2008). Textbook of cancer
epidemiology. Oxford University Press, USA.
Adams, L. A., & Lindor, K. D. (2007). Nonalcoholic fatty liver disease. Annals of
epidemiology, 17(11), 863-869.
Adejumo, A. C., Samuel, G. O., Adegbala, O. M., Adejumo, K. L., Ojelabi, O., Akanbi,
O., ... & Pani, L. (2019). Prevalence, trends, outcomes, and disparities in
hospitalizations for nonalcoholic fatty liver disease in the United States. Annals of
gastroenterology, 32(5), 504.
Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A., Allen, C., ... & Ayele,
T. A. (2017). The burden of primary liver cancer and underlying etiologies from
1990 to 2015 at the global, regional, and national level: results from the global
burden of disease study 2015. JAMA oncology, 3(12), 1683-1691.
Al-alem, F., Mattar, R. E., Fadl, O. A., Alsharabi, A., Al-Saif, F., & Hassanain, M. (2016).
Morbidity, mortality and predictors of outcome following hepatectomy at a Saudi
tertiary care center. Annals of Saudi medicine, 36(6), 414-421.
Alkhouri, N., & McCullough, A. J. (2012). Noninvasive diagnosis of NASH and liver
fibrosis within the spectrum of NAFLD. Gastroenterology & hepatology, 8(10),
661.
Allen, A. M., Therneau, T. M., Larson, J. J., Coward, A., Somers, V. K., & Kamath, P. S.
(2018). Nonalcoholic fatty liver disease incidence and impact on metabolic
burden and death: a 20 year‐community study. Hepatology, 67(5), 1726-1736.

99
American College of Surgeons, American Cancer Society. National Cancer Database.
Natl Cancer Database. 2017.
Amitrano, L., Guardascione, M. A., Brancaccio, V., & Balzano, A. (2002). Coagulation
disorders in liver disease. In Seminars in liver disease (Vol. 22, No. 01, pp. 083096). Copyright© 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue,
New York, NY 10001, USA. Tel.:+ 1 (212) 584-4662.
An, R. (2014). Prevalence and trends of adult obesity in the US, 1999–2012.
International Scholarly Research Notices, 2014.
Andreou, A., Vauthey, J. N., Cherqui, D., Zimmitti, G., Ribero, D., Truty, M. J., ... &
Belghiti, J. (2013). Improved long-term survival after major resection for
hepatocellular carcinoma: a multicenter analysis based on a new definition of
major hepatectomy. Journal of gastrointestinal surgery, 17(1), 66-77.
Anstee, Q. M., Targher, G., & Day, C. P. (2013). Progression of NAFLD to diabetes
mellitus, cardiovascular disease or cirrhosis. Nature reviews Gastroenterology &
hepatology, 10(6), 330.
Armstrong, M. J., Houlihan, D. D., Bentham, L., Shaw, J. C., Cramb, R., Olliff, S., ... &
Newsome, P. N. (2012). Presence and severity of non-alcoholic fatty liver
disease in a large prospective primary care cohort. Journal of hepatology, 56(1),
234-240.
Asiyanbola, B., Chang, D., Gleisner, A. L., Nathan, H., Choti, M. A., Schulick, R. D., &
Pawlik, T. M. (2008). Operative mortality after hepatic resection: are literaturebased rates broadly applicable?. Journal of Gastrointestinal Surgery, 12(5), 842851.

100
Babadjouni, R., Wen, T., Donoho, D. A., Buchanan, I. A., Cen, S. Y., Friedman, R. A., ...
& Attenello, F. J. (2019). Increased hospital surgical volume reduces rate of 30and 90-day readmission after acoustic neuroma surgery. Neurosurgery, 84(3),
726-732.
Bachellier, P., Rosso, E., Pessaux, P., Oussoultzoglou, E., Nobili, C., Panaro, F., &
Jaeck, D. (2011). Risk factors for liver failure and mortality after hepatectomy
associated with portal vein resection. Annals of surgery, 253(1), 173-179.
Bagnardi, V., Blangiardo, M., La Vecchia, C., & Corrao, G. (2001). A meta-analysis of
alcohol drinking and cancer risk. British journal of cancer, 85(11), 1700-1705.
Balzan, S., Belghiti, J., Farges, O., Ogata, S., Sauvanet, A., Delefosse, D., & Durand, F.
(2005). The “50-50 criteria” on postoperative day 5: an accurate predictor of liver
failure and death after hepatectomy. Annals of surgery, 242(6), 824.
Baydar, T., Engin, A. B., Girgin, G., Aydin, S., & Sahin, G. (2005). Aflatoxin and
ochratoxin in various types of commonly consumed retail ground samples in
Ankara, Turkey. Annals of agricultural and environmental medicine, 12(2), 193197.
Bechtold, M., Palmer, J., Valtos, J., Iasiello, C., & Sowers, J. (2006). Metabolic
syndrome in the elderly. Current diabetes reports, 6(1), 64-71.
Becker's Healthcare. Average hospital readmission costs for 18 diagnoses. Retrieved
November 27, 2019, from https://www.beckershospitalreview.com/rankings-andratings/average-hospital-readmission-costs-for-18-diagnoses.html
Bedogni, G., Miglioli, L., Masutti, F., Tiribelli, C., Marchesini, G., & Bellentani, S. (2005).
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos
nutrition and liver study. Hepatology, 42(1), 44-52.

101
Bennett, J. W., & Klich, M. Mycotoxins.(2003). Clin Microbiol Rev, 16(497.516).
Berman, K., Tandra, S., Forssell, K., Vuppalanchi, R., Burton Jr, J. R., Nguyen, J., ... &
Chalasani, N. (2011). Incidence and predictors of 30-day readmission among
patients hospitalized for advanced liver disease. Clinical Gastroenterology and
Hepatology, 9(3), 254-259.
Bhala, N., Angulo, P., van der Poorten, D., Lee, E., Hui, J. M., Saracco, G., ... & Day, C.
P. (2011). The natural history of nonalcoholic fatty liver disease with advanced
fibrosis or cirrhosis: an international collaborative study. Hepatology, 54(4), 12081216.
Boffa, D. J., Rosen, J. E., Mallin, K., Loomis, A., Gay, G., Palis, B., ... & Facktor, M. A.
(2017). Using the National Cancer Database for outcomes research: a review.
JAMA oncology, 3(12), 1722-1728.
Boffetta, P., Boccia, S., & La Vecchia, C. (2014). A quick guide to cancer epidemiology.
Bolder, U., Brune, A., Schmidt, S., Tacke, J., Jauch, K. W., & Löhlein, D. (1999).
Preoperative assessment of mortality risk in hepatic resection by clinical
variables: a multivariate analysis. Liver Transplantation and Surgery, 5(3), 227237.
Bosch, F. X., Ribes, J., Díaz, M., & Cléries, R. (2004). Primary liver cancer: worldwide
incidence and trends. Gastroenterology, 127(5), S5-S16.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018).
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians,
68(6), 394-424.

102
Bressac, B., Kew, M., Wands, J., & Ozturk, M. (1991). Selective G to T mutations of p53
gene in hepatocellular carcinoma from southern Africa. Nature, 350(6317), 429431.
Brudvik, K. W., Mise, Y., Conrad, C., Zimmitti, G., Aloia, T. A., & Vauthey, J. (2015).
Definition of Readmission in 3,041 Patients Undergoing Hepatectomy. Journal of
the American College of Surgeons, 221(1), 38-46.
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y. H., Bodoky, G., ... & Gerolami, R.
(2017). Regorafenib for patients with hepatocellular carcinoma who progressed
on sorafenib treatment (RESORCE): a randomised, double-blind, placebocontrolled, phase 3 trial. The Lancet, 389(10064), 56-66.
Campbell, P. G., Malone, J., Yadla, S., Chitale, R., Nasser, R., Maltenfort, M. G., ... &
Ratliff, J. K. (2011). Comparison of ICD-9–based, retrospective, and prospective
assessments of perioperative complications: assessment of accuracy in
reporting. Journal of Neurosurgery: Spine, 14(1), 16-22.
Carulli, L., Lonardo, A., Lombardini, S., Marchesini, G., & Loria, P. (2006). Gender, fatty
liver and GGT. Hepatology, 44(1), 278-279.
Chacko, S., & Samanta, S. (2016). Hepatocellular carcinoma: A life-threatening disease.
Biomedicine & Pharmacotherapy, 84, 1679-1688.
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., ... &
Sanyal, A. J. (2012). The diagnosis and management of non‐alcoholic fatty liver
disease: Practice Guideline by the American Association for the Study of Liver
Diseases, American College of Gastroenterology, and the American
Gastroenterological Association. Hepatology, 55(6), 2005-2023.

103
Chang, C. M., Yin, W. Y., Su, Y. C., Wei, C. K., Lee, C. H., Juang, S. Y., ... & Lee, C. C.
(2014). Preoperative risk score predicting 90-day mortality after liver resection in
a population-based study. Medicine, 93(12).
Chirapongsathorn, S., Poovorawan, K., Soonthornworasiri, N., Pan‐ngum, W.,
Phaosawasdi, K., & Treeprasertsuk, S. (2020). Thirty‐Day Readmission and Cost
Analysis in Patients With Cirrhosis: A Nationwide Population‐Based Data.
Hepatology Communications, 4(3), 453-460.
Clavien, P. A., Lesurtel, M., Bossuyt, P. M., Gores, G. J., Langer, B., & Perrier, A.
(2012). Recommendations for liver transplantation for hepatocellular carcinoma:
an international consensus conference report. The lancet oncology, 13(1), e11e22.
Couto, O. F. M., Dvorchik, I., & Carr, B. I. (2007). Causes of death in patients with
unresectable hepatocellular carcinoma. Digestive diseases and sciences, 52(11),
3285-3289.
Curcic, I. B., Berkovic, M. C., Kuna, L., Roguljic, H., Smolic, R., Varzic, S. C., ... &
Smolic, M. (2019). Obesity Paradox in Chronic Liver Diseases: Product of Bias or
a Real Thing?. Journal of clinical and translational hepatology, 7(3), 275.
Curtis, N., Noble, E., Salib, E., Awad, M., Hipkiss, R., Dalton, R., ... & Francis, N. (2016).
Impact of laparoscopic surgery and length of stay on long term survival following
colorectal cancer resection within an Enhanced Recovery Programme. Clinical
nutrition ESPEN, 12, e51-e51.
Davila, J. A., Duan, Z., McGlynn, K. A., & El-Serag, H. B. (2012). Utilization and
outcomes of palliative therapy for hepatocellular carcinoma: a population-based
study in the United States. Journal of clinical gastroenterology, 46(1).

104
Davis, G. L., Alter, M. J., El–Serag, H., Poynard, T., & Jennings, L. W. (2010). Aging of
hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort
model of HCV prevalence and disease progression. Gastroenterology, 138(2),
513-521.
Delis, S. G., & Dervenis, C. (2008). Selection criteria for liver resection in patients with
hepatocellular carcinoma and chronic liver disease. World Journal of
Gastroenterology: WJG, 14(22), 3452.
Dhir, M., Melin, A. A., Douaiher, J., Lin, C., Zhen, W. K., Hussain, S. M., ... & Are, C.
(2016). A review and update of treatment options and controversies in the
management of hepatocellular carcinoma. Annals of surgery, 263(6), 1112-1125.
Dimick, J. B., Wainess, R. M., Cowan, J. A., Upchurch Jr, G. R., Knol, J. A., & Colletti, L.
M. (2004). National trends in the use and outcomes of hepatic resection. Journal
of the American College of Surgeons, 199(1), 31-38.
Donato, F., Tagger, A., Gelatti, U., Parrinello, G., Boffetta, P., Albertini, A., ... & Porru, S.
(2002). Alcohol and hepatocellular carcinoma: the effect of lifetime intake and
hepatitis virus infections in men and women. American journal of epidemiology,
155(4), 323-331.
Donzé, J., Lipsitz, S., Bates, D. W., & Schnipper, J. L. (2013). Causes and patterns of
readmissions in patients with common comorbidities: retrospective cohort study.
Bmj, 347.
Dyson, J., Jaques, B., Chattopadyhay, D., Lochan, R., Graham, J., Das, D., ... &
Sumpter, K. (2014). Hepatocellular cancer: the impact of obesity, type 2 diabetes
and a multidisciplinary team. Journal of hepatology, 60(1), 110-117.

105
Egal, S., Hounsa, A., Gong, Y. Y., Turner, P. C., Wild, C. P., Hall, A. J., ... & Cardwell, K.
F. (2005). Dietary exposure to aflatoxin from maize and groundnut in young
children from Benin and Togo, West Africa. International Journal of Food
Microbiology, 104(2), 215-224.
Egger, M. E., Squires III, M. H., Kooby, D. A., Maithel, S. K., Cho, C. S., Weber, S. M., ...
& Scoggins, C. R. (2015). Risk stratification for readmission after major
hepatectomy: development of a readmission risk score. Journal of the American
College of Surgeons, 220(4), 640-648.
Eguchi, S., Kanematsu, T., Arii, S., Omata, M., Kudo, M., Sakamoto, M., ... & Liver
Cancer Study Group of Japan. (2011). Recurrence‐free survival more than 10
years after liver resection for hepatocellular carcinoma. British journal of surgery,
98(4), 552-557.
Eknoyan, G. (2011). Obesity and chronic kidney disease. Nefrología (English Edition),
31(4), 397-403.
El-Serag, H. B. (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma.
Gastroenterology, 142(6), 1264-1273.
El-serag, H. B., Tran, T., & Everhart, J. E. (2004). Diabetes increases the risk of chronic
liver disease and hepatocellular carcinoma. Gastroenterology, 126(2), 460-468.
Ertle, J., Dechêne, A., Sowa, J. P., Penndorf, V., Herzer, K., Kaiser, G., ... & Canbay, A.
(2011). Non‐alcoholic fatty liver disease progresses to hepatocellular carcinoma
in the absence of apparent cirrhosis. International Journal of Cancer, 128(10),
2436-2443.
Etra, J. W., Squires III, M. H., Fisher, S. B., Rutz, D. R., Martin, B. M., Kooby, D. A., ... &
Russell, M. C. (2014). Early identification of patients at increased risk for hepatic

106
insufficiency, complications and mortality after major hepatectomy. HPB, 16(10),
875-883.
Fan, S. T., Lai, E. C., Lo, C. M., Ng, I. O., & Wong, J. (1995). Hospital mortality of major
hepatectomy for hepatocellular carcinoma associated with cirrhosis. Archives of
surgery, 130(2), 198-203.
Fink‐Grernmels, J. (1999). Mycotoxins: their implications for human and animal health.
Veterinary Quarterly, 21(4), 115-120.
Flegal, K. M., Kruszon-Moran, D., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2016).
Trends in obesity among adults in the United States, 2005 to 2014. Jama,
315(21), 2284-2291.
Flores, A. (2017). How the US Hispanic population is changing. Pew Research Center,
18.
Forner A., Reig M., & Bruix J. (2018). Hepatocellular carcinoma. The Lancet, 391, 13011314.
Fromer, M. W., Aloia, T. A., Gaughan, J. P., Atabek, U. M., & Spitz, F. R. (2016). The
utility of the MELD score in predicting mortality following liver resection for
metastasis. European Journal of Surgical Oncology (EJSO), 42(10), 1568-1575.
Ghamarnejad, O., Khajeh, E., Rezaei, N., Afshari, K., Adelian, A., Nikdad, M., ... &
Mehrabi, A. (2020). Comparative Analysis of the Discriminatory Performance of
Different Well-Known Risk Assessment Scores for Extended Hepatectomy.
Scientific Reports, 10(1), 1-9.
Gilg, S., Sandström, P., Rizell, M., Lindell, G., Ardnor, B., Strömberg, C., & Isaksson, B.
(2018). The impact of post-hepatectomy liver failure on mortality: a populationbased study. Scandinavian journal of gastroenterology, 53(10-11), 1335-1339.

107
Giuliante, F., Ardito, F., Pinna, A. D., Sarno, G., Giulini, S. M., Ercolani, G., ... & Pulitanò,
C. (2012). Liver resection for hepatocellular carcinoma≤ 3 cm: results of an
Italian multicenter study on 588 patients. Journal of the American College of
Surgeons, 215(2), 244-254.
Global Burden of Disease Cancer Collaboration. (2019). Global, regional, and national
cancer incidence, mortality, years of life lost, years lived with disability, and
disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic
analysis for the global burden of disease study. JAMA oncology, 5(12), 17491768.
Greenblatt, D. Y., Weber, S. M., O’Connor, E. S., LoConte, N. K., Liou, J. I., & Smith, M.
A. (2010). Readmission after colectomy for cancer predicts one-year mortality.
Annals of surgery, 251(4), 659
Groopman, J. D., Kensler, T. W., & Wild, C. P. (2008). Protective interventions to
prevent aflatoxin-induced carcinogenesis in developing countries. Annu. Rev.
Public Health, 29, 187-203.
Guo, Z., Zhang, J., Jiang, J. H., Li, L. Q., & Xiang, B. D. (2015). Obesity does not
influence outcomes in hepatocellular carcinoma patients following curative
hepatectomy. PLoS One, 10(5).
Guzman, N. J. (2012). Epidemiology and management of hypertension in the hispanic
population. American Journal of Cardiovascular Drugs, 12(3), 165-178.
Hammond, J. S., Guha, I. N., Beckingham, I. J., & Lobo, D. N. (2011). Prediction,
prevention and management of postresection liver failure. British journal of
surgery, 98(9), 1188-1200.

108
Hasan, O., Meltzer, D. O., Shaykevich, S. A., Bell, C. M., Kaboli, P. J., Auerbach, A.
D., ... & Schnipper, J. L. (2010). Hospital readmission in general medicine
patients: a prediction model. Journal of general internal medicine, 25(3), 211219.
Hauck, K., & Hollingsworth, B. (2010). The impact of severe obesity on hospital length of
stay. Medical care, 335-340.
Haut, E. R., Pronovost, P. J., & Schneider, E. B. (2012). Limitations of administrative
databases. Jama, 307(24), 2589-2590.
Hernandez-Meza, G., McKee, S., Carlton, D., Yang, A., Govindaraj, S., & Iloreta, A.
(2019). Association of Surgical and Hospital Volume and Patient Characteristics
With 30-Day Readmission Rates. JAMA Otolaryngology–Head & Neck Surgery,
145(4), 328-337.
Hirode, G., Vittinghoff, E., & Wong, R. J. (2019). Increasing clinical and economic
burden of nonalcoholic fatty liver disease among hospitalized adults in the United
States. Journal of clinical gastroenterology, 53(10), 765-771.
Horwitz, L. I., Lin, Z., Herrin, J., Bernheim, S., Drye, E. E., Krumholz, H. M., & Ross, J.
S. (2015). Association of hospital volume with readmission rates: a retrospective
cross-sectional study. bmj, 350, h447.
Hu, Y., McMurry, T. L., Isbell, J. M., Stukenborg, G. J., & Kozower, B. D. (2014).
Readmission after lung cancer resection is associated with a 6-fold increase in
90-day postoperative mortality. The Journal of Thoracic and Cardiovascular
Surgery, 148(5), 2261-2267.e1.
Hucke, F., Sieghart, W., Schöniger-Hekele, M., Peck-Radosavljevic, M., & Müller, C.
(2011). Clinical characteristics of patients with hepatocellular carcinoma in

109
Austria–is there a need for a structured screening program?. Wiener klinische
Wochenschrift, 123(17-18), 542-551.
Hyder, O., Pulitano, C., Firoozmand, A., Dodson, R., Wolfgang, C. L., Choti, M. A., ... &
Pawlik, T. M. (2013). A risk model to predict 90-day mortality among patients
undergoing hepatic resection. Journal of the American College of Surgeons,
216(6), 1049-1056.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. (2010).
Alcohol consumption and ethyl carbamate. IARC Monographs on the Evaluation
of Carcinogenic Risks to Humans, 96, 3.
Idrees, J. J., Johnston, F. M., Canner, J. K., Dillhoff, M., Schmidt, C., Haut, E. R., &
Pawlik, T. M. (2019). Cost of major complications after liver resection in the
United States: are high-volume centers cost-effective?. Annals of surgery,
269(3), 503-510.
Inokuchi, M., Kato, K., Sugita, H., Otsuki, S., & Kojima, K. (2014). Impact of
comorbidities on postoperative complications in patients undergoing
laparoscopy-assisted gastrectomy for gastric cancer. BMC surgery, 14(1), 97.
Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., ... & Phillips, M.
J. (1995). Histological grading and staging of chronic hepatitis. Journal of
hepatology, 22(6), 696-699.
Ishizawa, T., Hasegawa, K., Aoki, T., Takahashi, M., Inoue, Y., Sano, K., ... & Makuuchi,
M. (2008). Neither multiple tumors nor portal hypertension are surgical
contraindications for hepatocellular carcinoma. Gastroenterology, 134(7), 19081916.

110
Kalogeridi, M. A., Zygogianni, A., Kyrgias, G., Kouvaris, J., Chatziioannou, S., Kelekis,
N., & Kouloulias, V. (2015). Role of radiotherapy in the management of
hepatocellular carcinoma: A systematic review. World journal of hepatology, 7(1),
101.
Kamiyama, T., Nakanishi, K., Yokoo, H., Kamachi, H., Tahara, M., Yamashita, K., ... &
Todo, S. (2010). Perioperative management of hepatic resection toward zero
mortality and morbidity: analysis of 793 consecutive cases in a single institution.
Journal of the American College of Surgeons, 211(4), 443-449.
Kansagara, D., Papak, J., Pasha, A. S., O’Neil, M., Freeman, M., Relevo, R., ... & Jou, J.
H. (2014). Screening for hepatocellular carcinoma in chronic liver disease: a
systematic review. Annals of internal medicine, 161(4), 261-269.
Kanwal, F., Kramer, J. R., Ilyas, J., Duan, Z., & El‐Serag, H. B. (2014). HCV genotype 3
is associated with an increased risk of cirrhosis and hepatocellular cancer in a
national sample of US Veterans with HCV. Hepatology, 60(1), 98-105.
Kanwal, F., Kramer, J. R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson,
P. A., ... & Chu, J. (2018). Risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Gastroenterology, 155(6), 1828-1837.
Karagozian, R., Bhardwaj, G., Wakefield, D. B., & Baffy, G. (2016). Obesity paradox in
advanced liver disease: obesity is associated with lower mortality in hospitalized
patients with cirrhosis. Liver international, 36(10), 1450-1456.
Kattakuzhy, S., Levy, R., Rosenthal, E., Tang, L., Wilson, E., & Kottilil, S. (2016).
Hepatitis C genotype 3 disease. Hepatology international, 10(6), 861-870.

111
Kauffmann, R., & Fong, Y. (2014). Post-hepatectomy liver failure. Hepatobiliary surgery
and nutrition, 3(5), 238.
Kew, M. C. (2013). Aflatoxins as a cause of hepatocellular carcinoma. Journal of
Gastrointestinal & Liver Diseases, 22(3).
Kew, M. C. (2015). Obesity as a cause of hepatocellular carcinoma. Annals of
Hepatology, 14(3), 299-303.
Kim, S., Maynard, E. C., Shah, M. B., Daily, M. F., Tzeng, C. W. D., Davenport, D. L., &
Gedaly, R. (2015). Risk factors for 30-day readmissions after hepatectomy:
analysis of 2444 patients from the ACS-NSQIP database. Journal of
Gastrointestinal Surgery, 19(2), 266-271.
Kimbrough, C. W., Agle, S. C., Scoggins, C. R., Martin, R. C., Marvin, M. R., Davis, E.
G., ... & Jones, C. M. (2014). Factors predictive of readmission after hepatic
resection for hepatocellular carcinoma. Surgery, 156(4), 1039-1048.
Knoblich, T., Hinz, U., Stravodimos, C., Schön, M. R., Mehrabi, A., Büchler, M. W., &
Hoffmann, K. (2020). Comparison of score-based prediction of 90-day mortality
after liver resection. BMC surgery, 20(1), 19.
Kooby, D. A., Fong, Y., Suriawinata, A., Gonen, M., Allen, P. J., Klimstra, D. S., ... &
Jarnagin, W. R. (2003). Impact of steatosis on perioperative outcome following
hepatic resection. Journal of Gastrointestinal Surgery, 7(8), 1034-1044.
Krumholz, H. M. (2013). Post-hospital syndrome–a condition of generalized risk. The
New England journal of medicine, 368(2), 100.
Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., ... & Blanc, J. F.
(2018). Lenvatinib versus sorafenib in first-line treatment of patients with

112
unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority
trial. The Lancet, 391(10126), 1163-1173.
Kwok, J., Langevin, S. M., Argiris, A., Grandis, J. R., Gooding, W. E., & Taioli, E. (2010).
The impact of health insurance status on the survival of patients with head and
neck cancer. Cancer, 116(2), 476-485.
Lawson, D. H., Gray, J. M. B., McKillop, C., Clarke, J., Lee, F. D., & Patrick, R. S.
(1986). Diabetes mellitus and primary hepatocellular carcinoma. QJM: An
International Journal of Medicine, 61(1), 945-955.
Ledda, C., Loreto, C., Zammit, C., Marconi, A., Fago, L., Matera, S., ... & Costa, C.
(2017). Non‐infective occupational risk factors for hepatocellular carcinoma: A
review. Molecular medicine reports, 15(2), 511-533.
Lee, C. W., Tsai, H. I., Sung, C. M., Chen, C. W., Huang, S. W., Jeng, W. J., ... & Chen,
M. F. (2016). Risk factors for early mortality after hepatectomy for hepatocellular
carcinoma. Medicine, 95(39).
Lee, H. Y., Shin, J. Y., Lee, S. A., Ju, Y. J., & Park, E. C. (2019). The 30-day unplanned
readmission rate and hospital volume: a national population-based study in
South Korea. International Journal for Quality in Health Care.
Liu, Y., & Wu, F. (2010). Global burden of aflatoxin-induced hepatocellular carcinoma: a
risk assessment. Environmental health perspectives, 118(6), 818-824.
Llovet, J. M., & Bruix, J. (2003). Systematic review of randomized trials for unresectable
hepatocellular carcinoma: chemoembolization improves survival. Hepatology,
37(2), 429-442.

113
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., ... & Rodés, J.
(2002). Arterial embolisation or chemoembolisation versus symptomatic
treatment in patients with unresectable hepatocellular carcinoma: a randomised
controlled trial. The Lancet, 359(9319), 1734-1739.
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., ... & Schwartz,
M. (2008). Sorafenib in advanced hepatocellular carcinoma. New England journal
of medicine, 359(4), 378-390.
Lok, A. S., Everhart, J. E., Wright, E. C., Di Bisceglie, A. M., Kim, H. Y., Sterling, R.
K., ... & Dienstag, J. L. (2011). Maintenance peginterferon therapy and other
factors associated with hepatocellular carcinoma in patients with advanced
hepatitis C. Gastroenterology, 140(3), 840-849.
Lopez, C., Ramos, L., Bulacio, L., Ramadan, S., & Rodriguez, F. (2002). Aflatoxin B1
content in patients with hepatic diseases. MEDICINA-BUENOS AIRES-, 62(4),
313-316.
Lorenzo, C. S., Whitney, M. L., Lurie, F., & Wong, L. L. (2005). Factors affecting
outcome in liver resection. HPB, 7(3), 226-230.
Lovejoy, J. C., Champagne, C. M., De Jonge, L., Xie, H., & Smith, S. R. (2008).
Increased visceral fat and decreased energy expenditure during the menopausal
transition. International journal of obesity, 32(6), 949-958.
Lucas, D. J., Sweeney, J. F., & Pawlik, T. M. (2014). The timing of complications impacts
risk of readmission after hepatopancreatobiliary surgery. Surgery, 155(5), 945953.

114
Ma, L., Li, J., Shao, L., Lin, D., & Xiang, J. (2015). Prolonged postoperative length of
stay is associated with poor overall survival after an esophagectomy for
esophageal cancer. Journal of thoracic disease, 7(11), 2018.
Maluccio, M., & Covey, A. (2012). Recent progress in understanding, diagnosing, and
treating hepatocellular carcinoma. CA: a cancer journal for clinicians, 62(6), 394399.
Margonis, G. A., Sasaki, K., Andreatos, N., Nishioka, Y., Sugawara, T., Amini, N., ... &
Pawlik, T. M. (2017). Prognostic impact of complications after resection of early
stage hepatocellular carcinoma. Journal of surgical oncology, 115(7), 791-804.
Martinez, B. A. F., Leotti, V. B., Nunes, L. N., Machado, G., & Corbellini, L. G. (2017).
Odds ratio or prevalence ratio? an overview of reported statistical methods and
appropriateness of interpretations in cross-sectional studies with dichotomous
outcomes in veterinary medicine. Frontiers in veterinary science, 4, 193.
Martínez-Mier, G., Esquivel-Torres, S., Alvarado-Arenas, R. A., Ortiz-Bayliss, A. B.,
Lajud-Barquín, F. A., & Zilli-Hernandez, S. (2016). Liver resection morbidity,
mortality, and risk factors at the departments of hepatobiliary surgery in
Veracruz, Mexico. Revista de Gastroenterología de México (English Edition),
81(4), 195-201.
Mavilia, M. G., Wakefield, D., & Karagozian, R. (2019). Nonalcoholic fatty liver disease
does not predict worse perioperative outcomes in bariatric surgery. Obesity
research & clinical practice, 13(4), 416-418.
Mayo, S. C., Shore, A. D., Nathan, H., Edil, B. H., Hirose, K., Anders, R. A., ... & Pawlik,
T. M. (2011). Refining the definition of perioperative mortality following

115
hepatectomy using death within 90 days as the standard criterion. HPB, 13(7),
473-482.
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., ... &
Gennari, L. (1996). Liver transplantation for the treatment of small hepatocellular
carcinomas in patients with cirrhosis. New England Journal of Medicine, 334(11),
693-700.
McBean, A. M., Li, S., Gilbertson, D. T., & Collins, A. J. (2004). Differences in diabetes
prevalence, incidence, and mortality among the elderly of four racial/ethnic
groups: whites, blacks, Hispanics, and Asians. Diabetes care, 27(10), 23172324.
Mikolasevic, I., Milic, S., Wensveen, T. T., Grgic, I., Jakopcic, I., Stimac, D., ... & Orlic, L.
(2016). Nonalcoholic fatty liver disease-A multisystem disease?. World journal of
gastroenterology, 22(43), 9488.
Mittal, S., & El-Serag, H. B. (2013). Epidemiology of HCC: consider the population.
Journal of clinical gastroenterology, 47, S2.
Mochari-Greenberger, H., Cohen, L. P., Liao, M., & Mosca, L. (2015). Racial and Ethnic
Differences in 30-Day Readmission and 1-Year Mortality among Patients
Hospitalized for Heart Failure. J Clin Exp Cardiolog, 6(3)
Montero, A. J., Stevenson, J., Guthrie, A. E., Best, C., Goodman, L. M., Shrotriya, S., ...
& Kalaycio, M. E. (2016). Reducing unplanned medical oncology readmissions
by improving outpatient care transitions: A process improvement project at the
Cleveland Clinic. Journal of oncology practice, 12(5), e594-e602.

116
Moore, B. J., White, S., Washington, R., Coenen, N., & Elixhauser, A. (2017). Identifying
increased risk of readmission and in-hospital mortality using hospital
administrative data. Medical care, 55(7), 698-705.
Mullen, J. T., Ribero, D., Reddy, S. K., Donadon, M., Zorzi, D., Gautam, S., ... &
Vauthey, J. N. (2007). Hepatic insufficiency and mortality in 1,059 noncirrhotic
patients undergoing major hepatectomy. Journal of the American College of
Surgeons, 204(5), 854-862.
Nagasue, N., Kohno, H., Chang, Y. C., Taniura, H., Yamanoi, A., Uchida, M., ... &
Yukaya, H. (1993). Liver resection for hepatocellular carcinoma. Results of 229
consecutive patients during 11 years. Annals of surgery, 217(4), 375.
Namasivayam, S., Martin, D. R., & Saini, S. (2007). Imaging of liver metastases: MRI.
Cancer Imaging, 7(1), 2.
Narula, N., Kim, B. J., Davis, C. H., Dewhurst, W. L., Samp, L. A., & Aloia, T. A. (2018).
A proactive outreach intervention that decreases readmission after hepatectomy.
Surgery, 163(4), 703-708.
Nomura, F., Ohnishi, K., & Tanabe, Y. (1989). Clinical features and prognosis of
hepatocellular carcinoma with reference to serum alpha‐fetoprotein levels.
Analysis of 606 patients. Cancer, 64(8), 1700-1707.
Ostrovsky, A., O'Connor, L., Marshall, O., Angelo, A., Barrett, K., Majeski, E., ... & Levy,
J. (2016). Predicting 30-to 120-day readmission risk among Medicare fee-forservice patients using nonmedical workers and mobile technology. Perspectives
in health information management, 13(Winter).

117
Pais, R., Barritt 4th, A. S., Calmus, Y., Scatton, O., Runge, T., Lebray, P., ... & Conti, F.
(2016). NAFLD and liver transplantation: current burden and expected
challenges. Journal of hepatology, 65(6), 1245-1257.
Parkin, D. M. (2006). The global health burden of infection‐associated cancers in the
year 2002. International journal of cancer, 118(12), 3030-3044.
Pekow, J. R., Bhan, A. K., Zheng, H., & Chung, R. T. (2007). Hepatic steatosis is
associated with increased frequency of hepatocellular carcinoma in patients with
hepatitis C‐related cirrhosis. Cancer, 109(12), 2490-2496.
Peng, S. Y., Chen, W. J., Lai, P. L., Jeng, Y. M., Sheu, J. C., & Hsu, H. C. (2004). High
α‐fetoprotein level correlates with high stage, early recurrence and poor
prognosis of hepatocellular carcinoma: significance of hepatitis virus infection,
age, p53 and β‐catenin mutations. International journal of cancer, 112(1), 44-50.
Peng, Y., Qi, X., & Guo, X. (2016). Child–Pugh versus MELD score for the assessment
of prognosis in liver cirrhosis: a systematic review and meta-analysis of
observational studies. Medicine, 95(8).
Persson, E. C., Schwartz, L. M., Park, Y., Trabert, B., Hollenbeck, A. R., Graubard, B.
I., ... & McGlynn, K. A. (2013). Alcohol consumption, folate intake, hepatocellular
carcinoma, and liver disease mortality. Cancer Epidemiology and Prevention
Biomarkers, 22(3), 415-421.
Piscaglia, F., Svegliati‐Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., ...
& HCC‐NAFLD Italian Study Group. (2016). Clinical patterns of hepatocellular
carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study.
Hepatology, 63(3), 827-838.

118
Poon, R. T. P., Fan, S. T., Lo, C. M., Liu, C. L., & Wong, J. (2002). Long-term survival
and pattern of recurrence after resection of small hepatocellular carcinoma in
patients with preserved liver function: implications for a strategy of salvage
transplantation. Annals of surgery, 235(3), 373
Puri, P., & Sanyal, A. J. (2012). Nonalcoholic fatty liver disease: definitions, risk factors,
and workup. Clinical Liver Disease, 1(4), 99.
Raimondi, S., Bruno, S., Mondelli, M. U., & Maisonneuve, P. (2009). Hepatitis C virus
genotype 1b as a risk factor for hepatocellular carcinoma development: a metaanalysis. Journal of hepatology, 50(6), 1142-1154.
Ramacciato, G., D'angelo, F., Baldini, R., Petrucciani, N., Antolino, L., Aurello, P., ... &
Cucchetti, A. (2012). Hepatocellular carcinomas and primary liver tumors as
predictive factors for postoperative mortality after liver resection: a meta-analysis
of more than 35,000 hepatic resections. The American Surgeon, 78(4), 456-467.
Rau J. Kaiser Health News. New round of Medicare readmission penalties hits 2,583
hospitals. 2019. https://khn.org/news/hospital-readmission-penalties-medicare2583-hospitals/. Accessed November 29, 2019.
Reddy, S. K., Steel, J. L., Chen, H. W., DeMateo, D. J., Cardinal, J., Behari, J., ... &
Tsung, A. (2012). Outcomes of curative treatment for hepatocellular cancer in
nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.
Hepatology, 55(6), 1809-1819.
Resende, V., Rezende-Neto, J. B. D., Fernandes, J. S., & Cunha-Melo, J. R. D. (2011).
Assessment of morbidity and mortality after hepatic resections. Revista do
Colegio Brasileiro de Cirurgioes, 38(5), 323-326.

119
Ribeireiro, T., Swain, J., Sarr, M., Kendrick, M., Que, F., Sanderson, S., ... & Charlton,
M. (2011). NAFLD and insulin resistance do not increase the risk of
postoperative complications among patients undergoing bariatric surgery—a
prospective analysis. Obesity surgery, 21(3), 310-315.
Rinella, M. E. (2015). Nonalcoholic fatty liver disease: a systematic review. Jama,
313(22), 2263-2273.
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., ... &
Hobbs, H. H. (2008). Genetic variation in PNPLA3 confers susceptibility to
nonalcoholic fatty liver disease. Nature genetics, 40(12), 1461-1465.
Sangro, B., Carpanese, L., Cianni, R., Golfieri, R., Gasparini, D., Ezziddin, S., ... & Maria
Ettorre, G. (2011). Survival after yttrium‐90 resin microsphere radioembolization
of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a
European evaluation. Hepatology, 54(3), 868-878.
Sapisochin, G., & Bruix, J. (2017). Liver transplantation for hepatocellular carcinoma:
outcomes and novel surgical approaches. Nature Reviews Gastroenterology &
Hepatology, 14(4), 203.
Saunders, R. S., Fernandes-Taylor, S., Kind, A. J., Engelbert, T. L., Greenberg, C. C.,
Smith, M. A., ... & Kent, K. C. (2014). Rehospitalization to primary versus
different facilities following abdominal aortic aneurysm repair. Journal of vascular
surgery, 59(6), 1502-1510.
Schiergens, T. S., Dörsch, M., Mittermeier, L., Brand, K., Küchenhoff, H., Lee, S. M., ...
& Thasler, W. E. (2015). Thirty-day mortality leads to underestimation of
postoperative death after liver resection: a novel method to define the acute
postoperative period. Surgery, 158(6), 1530-1537.

120
Schneider, E. B., Hyder, O., Wolfgang, C. L., Hirose, K., Choti, M. A., Makary, M. A., ...
& Pawlik, T. M. (2012). Patient readmission and mortality after surgery for
hepato-pancreato-biliary malignancies. Journal of the American College of
Surgeons, 215(5), 607-615
Schwartz, M., Roayaie, S., & Konstadoulakis, M. (2007). Strategies for the management
of hepatocellular carcinoma. Nature clinical practice Oncology, 4(7), 424-432.
Shi, J., Zhu, L., Liu, S., & Xie, W. F. (2005). A meta-analysis of case–control studies on
the combined effect of hepatitis B and C virus infections in causing hepatocellular
carcinoma in China. British journal of cancer, 92(3), 607-612.
Shi, M., Guo, R. P., Lin, X. J., Zhang, Y. Q., Chen, M. S., Zhang, C. Q., ... & Li, J. Q.
(2007). Partial hepatectomy with wide versus narrow resection margin for solitary
hepatocellular carcinoma: a prospective randomized trial. Annals of surgery,
245(1), 36.
Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: a cancer
journal for clinicians, 69(1), 7-34.
Simmons, O. L., Feng, Y., Parikh, N. D., & Singal, A. G. (2019). Primary care provider
practice patterns and barriers to hepatocellular carcinoma surveillance. Clinical
Gastroenterology and Hepatology, 17(4), 766-773.
Simon, T. G., King, L. Y., Chong, D. Q., Nguyen, L. H., Ma, Y., VoPham, T., ... & Khalili,
H. (2018). Diabetes, metabolic comorbidities, and risk of hepatocellular
carcinoma: results from two prospective cohort studies. Hepatology, 67(5), 17971806.

121
Simons, J. P., Hill, J. S., Ng, S. C., Shah, S. A., Zhou, Z., Whalen, G. F., & Tseng, J. F.
(2009). Perioperative mortality for management of hepatic neoplasm: a simple
risk score. Annals of surgery, 250(6), 929-934.
Simons, J. P., Ng, S. C., Hill, J. S., Shah, S. A., Zhou, Z., & Tseng, J. F. (2010). In‐
hospital mortality from liver resection for hepatocellular carcinoma: a simple risk
score. Cancer, 116(7), 1733-1738.
Slatore, C. G., Au, D. H., & Gould, M. K. (2010). An official American Thoracic Society
systematic review: insurance status and disparities in lung cancer practices and
outcomes. American journal of respiratory and critical care medicine, 182(9),
1195-1205.
Spolverato, G., Ejaz, A., Kim, Y., Weiss, M., Wolfgang, C. L., Hirose, K., & Pawlik, T. M.
(2014). Readmission incidence and associated factors after a hepatic resection
at a major hepato-pancreatico-biliary academic centre. HPB, 16(11), 972-978.
Starley, B. Q., Calcagno, C. J., & Harrison, S. A. (2010). Nonalcoholic fatty liver disease
and hepatocellular carcinoma: a weighty connection. Hepatology, 51(5), 18201832.
Strosnider, H., Azziz-Baumgartner, E., Banziger, M., Bhat, R. V., Breiman, R., Brune, M.
N., ... & Henry, S. H. (2006). Workgroup report: public health strategies for
reducing aflatoxin exposure in developing countries. Environmental health
perspectives, 114(12), 1898-1903.
Stuver, S. H. E. R. R. I., & Trichopoulos, D. I. M. I. T. R. I. O. S. (2008). Cancer of the
liver and biliary tract. Cancer epidemiology, 2, 308-332.

122
Tamandl, D., Butte, J. M., Allen, P. J., D'Angelica, M. I., DeMatteo, R. P., Groeger, J.
S., ... & Fong, Y. (2015). Hospital readmissions after liver surgery for metastatic
colorectal cancer. Surgery, 157(2), 231-238.
Tanaka, A., Uegaki, S., Kurihara, H., Aida, K., Mikami, M., Nagashima, I., ... & Takikawa,
H. (2007). Hepatic steatosis as a possible risk factor for the development of
hepatocellular carcinoma after eradication of hepatitis C virus with antiviral
therapy in patients with chronic hepatitis C. World Journal of Gastroenterology:
WJG, 13(39), 5180.
Tanaka, N., Kimura, T., Fujimori, N., Nagaya, T., Komatsu, M., & Tanaka, E. (2019).
Current status, problems, and perspectives of non-alcoholic fatty liver disease
research. World journal of gastroenterology, 25(2), 163.
Tang, N., Maselli, J. H., & Gonzales, R. (2014). Variations in 30‐day hospital
readmission rates across primary care clinics within a tertiary referral center.
Journal of hospital medicine, 9(11), 688-694.
Tapper, E. B., Halbert, B., & Mellinger, J. (2016). Rates of and reasons for hospital
readmissions in patients with cirrhosis: a multistate population-based cohort
study. Clinical Gastroenterology and Hepatology, 14(8), 1181-1188.
Testino, G., Leone, S., & Borro, P. (2014). Alcohol and hepatocellular carcinoma: a
review and a point of view. World journal of gastroenterology: WJG, 20(43),
15943.
Thalheimer, U., Triantos, C. K., Samonakis, D. N., Patch, D., & Burroughs, A. K. (2005).
Infection, coagulation, and variceal bleeding in cirrhosis. Gut, 54(4), 556-563.

123
Thompson, H. H., Tompkins, R. K., & Longmire Jr, W. P. (1983). Major hepatic
resection. A 25-year experience. Annals of surgery, 197(4), 375.
Tilghman, S. M., & Belayew, A. (1982). Transcriptional control of the murine
albumin/alpha-fetoprotein locus during development. Proceedings of the National
Academy of Sciences, 79(17), 5254-5257.
Torzilli, G., Belghiti, J., Kokudo, N., Takayama, T., Capussotti, L., Nuzzo, G., ... &
Morenghi, E. (2013). A snapshot of the effective indications and results of
surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to
the EASL/AASLD recommendations? An observational study of the HCC EastWest study group. Annals of surgery, 257(5), 929-937.
Tsai, T. C., Joynt, K. E., Orav, E. J., Gawande, A. A., & Jha, A. K. (2013). Variation in
surgical-readmission rates and quality of hospital care. New England Journal of
Medicine, 369(12), 1134-1142.
Tsim, N. C., Frampton, A. E., Habib, N. A., & Jiao, L. R. (2010). Surgical treatment for
liver cancer. World Journal of Gastroenterology: WJG, 16(8), 927.
Tzeng, C. W. D., Cooper, A. B., Vauthey, J. N., Curley, S. A., & Aloia, T. A. (2014).
Predictors of morbidity and mortality after hepatectomy in elderly patients:
analysis of 7621 NSQIP patients. HPB, 16(5), 459-468.
Van Walraven, C., Bennett, C., Jennings, A., Austin, P. C., & Forster, A. J. (2011).
Proportion of hospital readmissions deemed avoidable: a systematic review.
Cmaj, 183(7), E391-E402.
Vauthey, J. N., Chaoui, A., Do, K. A., Bilimoria, M. M., Fenstermacher, M. J.,
Charnsangavej, C., ... & Caridi, J. (2000). Standardized measurement of the

124
future liver remnant prior to extended liver resection: methodology and clinical
associations. Surgery, 127(5), 512-519.
Verloh, N., Haimerl, M., Rennert, J., Müller-Wille, R., Nießen, C., Kirchner, G., ... &
Wiggermann, P. (2013). Impact of liver cirrhosis on liver enhancement at GdEOB-DTPA enhanced MRI at 3 Tesla. European journal of radiology, 82(10),
1710-1715.
Viganò, L., Conci, S., Cescon, M., Fava, C., Capelli, P., D’Errico, A., ... & Salizzoni, M.
(2015). Liver resection for hepatocellular carcinoma in patients with metabolic
syndrome: A multicenter matched analysis with HCV-related HCC. Journal of
hepatology, 63(1), 93-101.
Virani, S., Michaelson, J. S., Hutter, M. M., Lancaster, R. T., Warshaw, A. L.,
Henderson, W. G., ... & Tanabe, K. K. (2007). Morbidity and mortality after liver
resection: results of the patient safety in surgery study. Journal of the American
College of Surgeons, 204(6), 1284-1292.
Wakai, T., Shirai, Y., Sakata, J., Korita, P. V., Ajioka, Y., & Hatakeyama, K. (2011).
Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver
disease. Journal of Gastrointestinal Surgery, 15(8), 1450-1458.
Wang, P., Kang, D., Cao, W., Wang, Y., & Liu, Z. (2012). Diabetes mellitus and risk of
hepatocellular carcinoma: a systematic review and meta‐analysis.
Diabetes/metabolism research and reviews, 28(2), 109-122.
Wang, Q., Fiel, M. I., Blank, S., Luan, W., Kadri, H., Kim, K. W., ... & Hiotis, S. P. (2013).
Impact of liver fibrosis on prognosis following liver resection for hepatitis Bassociated hepatocellular carcinoma. British journal of cancer, 109(3), 573.

125
Weaver, C., Schiech, L., Held-Warmkessel, J., Kedziera, P., Haney, E., DiLullo, G., ... &
Barsevick, A. (2006, May). Risk for unplanned hospital readmission of patients
with cancer: results of a retrospective medical record review. In Oncology
Nursing Forum (Vol. 33).
Weller, W. E., Rosati, C., & Hannan, E. L. (2007). Relationship between surgeon and
hospital volume and readmission after bariatric operation. Journal of the
American College of Surgeons, 204(3), 383-391.
Welzel, T. M., Graubard, B. I., Quraishi, S., Zeuzem, S., Davila, J. A., El-Serag, H. B., &
McGlynn, K. A. (2013). Population-attributable fractions of risk factors for
hepatocellular carcinoma in the United States. The American journal of
gastroenterology, 108(8), 1314.
White, D. L., Kanwal, F., & El–Serag, H. B. (2012). Association between nonalcoholic
fatty liver disease and risk for hepatocellular cancer, based on systematic review.
Clinical gastroenterology and hepatology, 10(12), 1342-1359.
White, D. L., Thrift, A. P., Kanwal, F., Davila, J., & El-Serag, H. B. (2017). Incidence of
hepatocellular carcinoma in all 50 United States, from 2000 through 2012.
Gastroenterology, 152(4), 812-820.
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., ... &
Harrison, S. A. (2011). Prevalence of nonalcoholic fatty liver disease and
nonalcoholic steatohepatitis among a largely middle-aged population utilizing
ultrasound and liver biopsy: a prospective study. Gastroenterology, 140(1), 124131.
Williams, J. H., Phillips, T. D., Jolly, P. E., Stiles, J. K., Jolly, C. M., & Aggarwal, D.
(2004). Human aflatoxicosis in developing countries: a review of toxicology,

126
exposure, potential health consequences, and interventions. The American
journal of clinical nutrition, 80(5), 1106-1122.
Wong, C. R., Njei, B., Nguyen, M. H., Nguyen, A., & Lim, J. K. (2017). Survival after
treatment with curative intent for hepatocellular carcinoma among patients with
vs without non‐alcoholic fatty liver disease. Alimentary pharmacology &
therapeutics, 46(11-12), 1061-1069.
Wong, J. A., & Devereaux, P. J. (2019). Cardiac Device Implantation Complications: A
Gap in the Quality of Care?. Annals of internal medicine, 171(5), 368-369.
Wong, R. J., Cheung, R., & Ahmed, A. (2014). Nonalcoholic steatohepatitis is the most
rapidly growing indication for liver transplantation in patients with hepatocellular
carcinoma in the US. Hepatology, 59(6), 2188-2195.
World Health Organization. (2014). GLOBOCAN 2012: Estimated cancer incidence,
mortality and prevalence worldwide in 2012.
Woz, S., Mitchell, S., Hesko, C., Paasche-Orlow, M., Greenwald, J., Chetty, V. K., ... &
Jack, B. (2012). Gender as risk factor for 30 days post-discharge hospital
utilisation: a secondary data analysis. BMJ open, 2(2), e000428.
Wu, T. H., Yu, M. C., Chan, K. M., Lee, C. F., Chen, T. C., Chang, H. C., ... & Lee, W. C.
(2011). Prognostic effect of steatosis on hepatocellular carcinoma patients after
liver resection. European Journal of Surgical Oncology (EJSO), 37(7), 618-622.
Xu, J. (2018). Trends in liver cancer mortality among adults aged 25 and over in the
United States, 2000-2016. US Department of Health & Human Services, Centers
for Disease Control and Prevention, National Center for Health Statistics.
Xu, R., Tao, A., Zhang, S., Deng, Y., & Chen, G. (2015). Association between patatinlike phospholipase domain containing 3 gene (PNPLA3) polymorphisms and

127
nonalcoholic fatty liver disease: a HuGE review and meta-analysis. Scientific
reports, 5, 9284.
Yamazaki, S., & Takayama, T. (2017). Management strategies to minimize mortality in
liver resection for hepatocellular carcinoma. Japanese journal of clinical
oncology, 47(10), 899-908.
Yang, B., Liu, J. B., So, S. K., Han, S. S., Wang, S. S., Hertz, A., ... & Hsing, A. W.
(2018). Disparities in hepatocellular carcinoma incidence by race/ethnicity and
geographic area in C alifornia: Implications for prevention. Cancer, 124(17),
3551-3559.
Yang, J. D., Kim, B., Sanderson, S. O., Sauver, J. L. S., Yawn, B. P., Pedersen, R. A., ...
& Kim, W. R. (2012, January). Hepatocellular carcinoma in olmsted county,
Minnesota, 1976-2008. In Mayo Clinic Proceedings (Vol. 87, No. 1, pp. 9-16).
Elsevier.
Yang, T., Hu, L. Y., Li, Z. L., Liu, K., Wu, H., Xing, H., ... & Gu, W. M. (2020). Liver
resection for hepatocellular carcinoma in non-alcoholic fatty liver disease: A
multicenter propensity matching analysis with HBV-HCC. Journal of
Gastrointestinal Surgery, 24(2), 320-329.
Yao, F. Y., Ferrell, L., Bass, N. M., Watson, J. J., Bacchetti, P., Venook, A., ... &
Roberts, J. P. (2001). Liver transplantation for hepatocellular carcinoma:
expansion of the tumor size limits does not adversely impact survival.
Hepatology, 33(6), 1394-1403.
Yi, S. W., Choi, J. S., Yi, J. J., Lee, Y. H., & Han, K. J. (2018). Risk factors for
hepatocellular carcinoma by age, sex, and liver disorder status: A prospective
cohort study in Korea. Cancer, 124(13), 2748-2757.

128
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016).
Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic
assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73-84.
Younossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., & Srishord,
M. (2011). Changes in the prevalence of the most common causes of chronic
liver diseases in the United States from 1988 to 2008. Clinical Gastroenterology
and Hepatology, 9(6), 524-530.
Younossi, Z. M., Stepanova, M., Negro, F., Hallaji, S., Younossi, Y., Lam, B., & Srishord,
M. (2012). Nonalcoholic fatty liver disease in lean individuals in the United
States. Medicine, 91(6), 319-327.
Zhan, K. Y., Graboyes, E. M., Nguyen, S. A., & Day, T. A. (2016). Risk Factors
Associated With Unplanned Readmission in Patients Undergoing Parotid Cancer
Surgery: A Study of the National Cancer Database. JAMA Otolaryngology–Head
& Neck Surgery, 142(6), 544-550.
Zou, H., Tao, Y., & Wang, Z. M. (2017). Integration of Child‐Pugh score with future liver
remnant yields improved prediction of liver dysfunction risk for HBV‐related
hepatocellular carcinoma following hepatic resection. Oncology letters, 13(5),
3631-3637.

